UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________________________________
FORM 10-K
_____________________________________________________________________________________________
(Mark One)
☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the fiscal year ended December 31, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the transition period from __________ to __________
Commission file number 1-4448
_____________________________________________________________________________________________
Baxter International Inc.
(Exact Name of Registrant as Specified in its Charter)
_____________________________________________________________________________________________
Delaware
36-0781620
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
One Baxter Parkway, Deerfield, Illinois
60015
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code 224.948.2000
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $1.00 par value
BAX (NYSE)
New York Stock Exchange
1.3% Global Notes due 2025
BAX 25
New York Stock Exchange
1.3% Global Notes due 2029
BAX 29
New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
_____________________________________________________________________________________________
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☑
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405
of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to
submit such files) Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and
“emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its
internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting
firm that prepared or issued its audit report. ☑
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included
in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based
compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
The aggregate market value of the voting common equity held by non-affiliates of the registrant as of June 30, 2024 (the last business day of the
registrant’s most recently completed second fiscal quarter), based on the assumption for the purpose of this computation only that all of the
registrant’s directors and executive officers are affiliates, was approximately $17 billion. The number of shares of the registrant’s common stock,
$1.00 par value, outstanding as of February 13, 2025 was 511,624,996.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive 2024 proxy statement for use in connection with its Annual Meeting of Stockholders expected to be held on
May 6, 2025 are incorporated by reference into Part III of this report.
TABLE OF CONTENTS
Page
Number
Item 1.
Business
1
Item 1A. Risk Factors
8
Item 1B. Unresolved Staff Comments
30
Item 1C. Cybersecurity
30
Item 2.
Properties
32
Item 3.
Legal Proceedings
33
Item 4.
Mine Safety Disclosures
33
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities
35
Item 6.
Reserved
35
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
35
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
64
Item 8.
Financial Statements and Supplementary Data
65
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
131
Item 9A. Controls and Procedures
131
Item 9B. Other Information
131
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
131
Item 10.
Directors, Executive Officers and Corporate Governance
132
Item 11.
Executive Compensation
132
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
132
Item 13.
Certain Relationships and Related Transactions, and Director Independence
133
Item 14.
Principal Accountant Fees and Services
133
Item 15.
Exhibits and Financial Statement Schedules
133
Item 16.
Form 10-K Summary
133
PART I
Item 1.
Business.
Company Overview
Baxter International Inc., through its subsidiaries, provides a broad portfolio of essential healthcare products,
including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled
anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical
equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health
devices. These products are used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers,
doctors’ offices, kidney dialysis centers and patients at home under physician supervision. Our global footprint and
the critical nature of our products and services play a key role in expanding access to healthcare in emerging and
developed countries. As of December 31, 2024, after giving effect to the recent sale of our Kidney Care business
(as discussed below), we manufactured products in over 20 countries and sold them in over 100 countries.
Baxter International Inc. was incorporated under Delaware law in 1931. As used in this report, “Baxter International”
means Baxter International Inc. and “we", "our” or "us" means Baxter International and its consolidated subsidiaries,
unless the context otherwise requires.
Recent Strategic Actions
In mid-2022, our Board of Directors authorized a strategic review of our business portfolio, with the goal of
increasing stockholder value. As part of that review process, we identified and evaluated a range of potential
strategic actions, including opportunities for sales and other separation transactions. In January 2023, following the
completion of that review, we announced a number of planned strategic actions, as discussed below, which are
intended to enhance our operational effectiveness, accelerate innovation and drive additional stockholder value. We
completed the last of these strategic actions on January 31, 2025 in connection with the sale of our Kidney Care
business.
Sale of Kidney Care Business
On August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group
Inc. (Carlyle) to sell our Kidney Care business. That business, which is now known as Vantive Health LLC (Vantive)
is comprised of our former Kidney Care segment and provides chronic and acute dialysis therapies and services,
including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support
therapies. On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate
purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After
giving effect to certain adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the
transaction with the net after tax proceeds currently estimated to be approximately $3.4 billion, subject to certain
post-closing adjustments. We determined that our Kidney Care business met the criteria to be classified as held-for-
sale in August 2024, and we also concluded that it met the conditions to be reported as a discontinued operation at
that time. Accordingly, our Kidney Care business is reported in discontinued operations in the accompanying
consolidated financial systems, and our prior period results have been adjusted to reflect discontinued operations
presentation.
Implementation of New Operating Model and Resulting Segment Change
Our reportable segments were previously comprised of the following geographic segments related to our legacy
Baxter business: Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia
Pacific), and a global segment for the Hill-Rom Holdings, Inc. (Hillrom) business we acquired in December 2021. In
the third quarter of 2023, we completed the implementation of a new operating model intended to simplify and
streamline our operations and better align our manufacturing and supply chain to our commercial activities. Under
this operating model, our business is currently comprised of three reportable segments: Medical Products &
Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Our segment reporting was changed during
the third quarter of 2023 to align with our new operating model, and all periods presented are under the new
operating model.
1
Sale of BPS Business
On September 29, 2023, we completed the sale of our BioPharma Solutions (BPS) business and received cash
proceeds of $3.96 billion from that transaction. The results of operations and cash flows of our BPS business,
including the $2.88 billion pre-tax gain ($2.59 billion net of tax) from the sale of that business and the related cash
proceeds received, are reported as discontinued operations in the accompanying consolidated financial statements.
We used substantially all of the after-tax proceeds from this transaction to repay certain of our debt obligations,
including $514 million of commercial paper borrowings and $2.28 billion of long-term debt that we repaid during the
fourth quarter of 2023, as well as €750 million of senior notes that we repaid during the second quarter of 2024.
Business Segments and Products
We currently manage our global operations based on three reportable segments: Medical Products & Therapies,
Healthcare Systems & Technologies and Pharmaceuticals.
The Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems,
administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products.
The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration
tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health
devices and advanced equipment for the surgical space, including surgical video technologies, precision positioning
devices and other accessories. The Pharmaceuticals segment includes sales of specialty injectable
pharmaceuticals, inhaled anesthetics and drug compounding services.
For financial information about our segments, see Note 18 in Item 8 of this Annual Report on Form 10-K.
Business Strategy
Our business strategy is focused on driving sustainable growth and innovation aligned with our mission to save and
sustain lives and our vision to transform healthcare with a customer focus to help improve patient outcomes,
enhance workflow efficiency, and enable cost-effective care. Our diversified and broad portfolio of medical products
that treat acute or chronic conditions and our global presence are core components of our strategy as we work to
achieve these objectives. We are focused on key strategic pillars as part of our pursuit of industry leading
performance: innovation; operational efficiency; and capital allocation.
Innovation
Our innovation strategy, which encompasses both organic and inorganic initiatives, is focused on accelerating our
sales growth through the introduction of new connected care and core therapy offerings. Connected care offerings
include devices or software that can digitally connect, communicate and/or analyze data to help transform
healthcare and improve patient outcomes, and we are continuing to build out our connected care portfolio offerings,
which includes smart bed systems, infusion pumps, patient monitoring and diagnostic technologies, respiratory
health devices and advanced equipment for the surgical space. Our core therapy product offerings include
pharmaceuticals and consumable medical products designed to address essential patient and provider needs
across the continuum of care.
As part of this strategy, we are prioritizing investments that drive innovation in product areas where we believe we
have compelling opportunities to better serve patients and healthcare professionals, particularly in markets with
higher growth rates. We are working to accelerate the pace at which we bring these advances to market to support
our future growth. We are in the midst of launching (or have recently launched) several new products, geographic
expansions and line extensions in areas such as smart pump technology, hospital pharmaceuticals and nutritionals,
surgical sealants, smart beds, respiratory vests and more. These comprise a mix of entirely new product offerings
and meaningful improvements to existing technologies.
Portfolio Optimization
Our strategy also involves active portfolio management in the interest of maximizing value for Baxter stockholders
and best positioning Baxter for long-term success. The recent Kidney Care sale has given us enhanced flexibility to
deploy (or in some cases redeploy) capital toward opportunities that seek to accelerate our growth objectives,
2
whether as a result of innovation or expanding our portfolio geographically or as a result of channel expansion or
market development activities.
Operational Excellence
As discussed above under “Recent Strategic Actions,” in the third quarter of 2023, we implemented a new operating
model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our
commercial activities. We believe these changes will allow us to be a more integrated and nimble organization that
can respond more effectively to operational challenges and changes in the macroeconomic environment while
enhancing our ability to drive innovation in our product portfolio. We also continue to focus on increasing efficiencies
through automation and digitization. We intend to continue to actively manage our cost structure and strive to
commit resources to the highest value uses. Such high value activities include supporting innovation, actively
managing the portfolio, expanding patient access and accelerating growth for our stockholders.
Maintaining Disciplined and Balanced Capital Allocation
Subject to market conditions and our investment grade targets, our capital allocation strategies currently include the
following:
•
debt repayments to support our deleveraging commitments;
•
active portfolio management through the identification of attractive acquisition and divestiture
transactions, including the recent divestitures of our BPS and Kidney Care businesses; and
•
returning capital to stockholders through dividends, while balancing any returns with other strategic
actions we take. We also intend to reinstate share repurchases over the longer term.
We paid down $3.65 billion of net debt during 2024 and through February 21, 2025 using proceeds from the sales of
our BPS and Kidney Care businesses, and we are committed to retaining our investment grade rating, including
taking actions toward achieving a net leverage target of approximately 3.0x by the end of 2025 through ongoing
debt repayment and financing activities. During this deleveraging period, we currently intend to continue paying a
dividend (which we reduced in November 2024), not make any share repurchases and be highly selective with
respect to any potential acquisitions.
Sales and Distribution
We have our own direct sales force and also make sales to and through independent distributors, drug wholesalers
acting as sales agents and specialty pharmacy or other alternate site providers. In the United States, third parties,
such as Cardinal Health, Inc., warehouse and ship a significant portion of our products through their distribution
centers. These centers are generally stocked with adequate inventories to facilitate prompt customer service. Sales
and distribution methods include frequent contact by sales and customer service representatives, automated
communications via various electronic purchasing systems, circulation of catalogs and merchandising bulletins,
direct-mail campaigns, trade publication presence and advertising.
Sales are made and products are distributed on a direct basis or through independent distributors or sales agents in
more than 100 countries as of December 31, 2024, giving effect to the sale of our Kidney Care business.
International Operations
A significant portion of our revenues are generated outside of the United States and thoughtful geographic
expansion remains a key component of our strategy. Our international presence includes operations in Europe, the
Middle East, Africa, Asia-Pacific, Latin America and Canada. We are subject to certain risks inherent in conducting
business outside the United States. For more information on these risks, see the information under the captions
“Risks Relating to Our Business—We are subject to risks associated with doing business globally” and “—Changes
in foreign currency exchange rates and interest rates have had, and may in the future have, an adverse effect on
our results of operations, financial condition, cash flows and liquidity” in Item 1A. Risk Factors of this Annual Report
on Form 10-K.
For financial information about our foreign and domestic revenues and segment information, see Note 18, in Item 8
of this Annual Report on Form 10-K. For more information regarding foreign currency exchange risk, refer to the
3
discussion under the caption entitled “Financial Instrument Market Risk” in Item 7. Management's Discussion and
Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K.
Contractual Arrangements
Our products are sold through contracts with customers, both within and outside the United States. Some of these
contracts have terms of more than one year and place limits on our ability to increase prices. In the case of
hospitals, governments and other facilities, these contracts may specify minimum quantities of a particular product
or categories of products to be purchased by the customer.
In keeping with the increased emphasis on cost-effectiveness in healthcare delivery, many hospitals and other
customers of medical products in the United States have joined group purchasing organizations (GPOs), or formed
integrated delivery networks (IDNs), to enhance purchasing power. GPOs and IDNs negotiate pricing arrangements
with manufacturers and distributors and the negotiated prices are made available to members. We have purchasing
agreements with several of the major GPOs in the United States, which are subject to renewal from time to time.
GPOs may have agreements with more than one supplier for certain products. Accordingly, in these cases, we face
competition from other suppliers even where a customer is a member of a GPO under contract with us, which may
constrain our ability to secure negotiated price increases. Purchasing power is similarly consolidated in many other
countries. For example, public contracting authorities often act as the purchasing entities for the hospitals and other
customers of medical products in their region and many hospitals and other customers have joined joint
procurement entities and buying consortia. The result is that demand for healthcare products is increasingly
concentrated across our markets globally. Additionally, our contractual pricing arrangements with GPOs, IDNs and
public contracting authorities can sometimes limit our ability to increase prices in order to offset raw materials or
component price increases or otherwise. Some of these agreements contain failure to supply clauses with varying
remedies, inclusive of limited termination rights.
Raw Materials and Component Parts
Raw materials and component parts essential to our business are purchased from numerous suppliers worldwide in
the ordinary course of business. While many of these materials are generally available, we have experienced and
may in the future experience shortages of supply. Additionally, certain of these materials are secured from single
source suppliers or on a spot basis and not pursuant to a contractual arrangement.
In an effort to manage risk associated with raw materials and component supply, we work closely with our suppliers
to help ensure availability and continuity of supply while maintaining high quality and reliability. We also seek to
develop new and alternative sources of supply where beneficial to our overall raw materials procurement strategy.
Refer to Item 1A. Risk Factors of this Annual Report on Form 10-K for further information regarding risks related to
the supply chain, raw materials and component parts (including with respect to the qualification of any new or
alternative supplier).
We are not always able to recover cost increases for raw materials and component parts through customer pricing
due to contractual limits, where applicable, and market forces. For example, during 2022 and 2023, our profit
margins were adversely impacted because we were unable to fully offset all related cost increases resulting from
the high inflationary environment through customer pricing adjustments or other pricing actions. Additionally, our
profit margins were negatively impacted in the fourth quarter of 2024 (and may continue to be negatively impacted
in the short term) because we were unable to fully offset the increased supply chain costs associated with our
ongoing North Cove recovery efforts (including as a result of importing additional product from outside the United
States to support IV solutions demand). We seek to utilize long-term supply contracts with some suppliers to help
maintain continuity of supply and manage the risk of price increases. Our ability to do so in the face of limited supply
of certain raw materials and component parts and inflationary environment has been and may in the future be
limited.
Competition and Healthcare Cost Containment
Our businesses benefit from a number of competitive advantages, including the breadth and depth of our product
offerings and our strong relationships with customers, including hospitals and clinics, GPOs, IDNs, physicians and
patients, many of whom self-administer home-based therapies that we supply. We also benefit from efficiencies and
cost advantages resulting from shared manufacturing facilities and the technological advantages of our products.
4
Although no single company competes with us in all of our businesses, we face substantial competition in each of
our segments from international and domestic healthcare, medical products and pharmaceutical companies and
providers of all sizes, and these competitors often differ across our businesses. In addition, global and regional
competitors continue to expand their manufacturing capacity and sales and marketing channels. We believe
customer purchasing decisions are primarily focused on cost-effectiveness, price, service, product performance and
technological innovation. There has been consolidation in our customer base and by our competitors, which has
resulted and continues to result in pricing and market pressures.
1.
Global efforts toward healthcare cost containment continue to exert pressure on product pricing.
Governments around the world use various mechanisms to control healthcare expenditures, such as price
controls, the formation of public contracting authorities, product formularies (lists of recommended or
approved products), and competitive tenders which require the submission of a bid to sell products. Sales of
our products are dependent, in part, on the availability of reimbursement by government agencies and
healthcare programs, as well as insurance companies and other private payers. In the United States, the
federal government and many states have adopted or proposed initiatives relating to Medicaid and other
health programs that may limit reimbursement or increase rebates that we and other providers are required
to pay to the state. In addition to government regulation, managed care organizations in the United States,
which include medical insurance companies, medical plan administrators, health-maintenance
organizations, hospital and physician alliances and pharmacy benefit managers, continue to put pressure
on the price and usage of healthcare products. Managed care organizations seek to contain healthcare
expenditures, and their purchasing strength has been increasing due to their consolidation into fewer, larger
organizations and a growing number of enrolled patients. We face similar issues outside of the United
States. In Europe and Latin America, for example, the government provides healthcare at low cost to
patients, and controls its expenditures by purchasing products through public tenders, collective purchasing,
regulating prices, setting reference prices in public tenders or limiting reimbursement or patient access to
certain products. Additionally, China has been implementing volume-based procurement policies and a
series of centralized reforms on both a national and regional basis which have resulted in significant price
cuts for pharmaceuticals and medical consumables. For further discussion, refer to Item 1A. Risk Factors of
this Annual Report on Form 10-K.
Intellectual Property
Patents and other proprietary rights are essential to our business. We rely on patents, trademarks, copyrights, trade
secrets, know-how and confidentiality agreements to develop, maintain and strengthen our competitive position. We
own numerous patents and trademarks throughout the world and have entered into license arrangements relating to
various third-party patents and technologies. Products manufactured by us are sold primarily under our own
trademarks and trade names. Some products distributed by us are sold under our trade names, while others are
sold under trade names owned by our suppliers or partners. Trade secret protection of unpatented confidential and
proprietary information is also important to us. We maintain certain details about our processes, products and
technology as trade secrets and generally require employees, consultants, and business partners to enter into
confidentiality agreements. These agreements may be breached and we may not have adequate remedies for any
breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.
To the extent that our employees, consultants, and business partners use intellectual property owned by others in
their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
Our policy is to protect our products and technology through patents and trademarks on a worldwide basis. This
protection is sought in a manner that balances the cost of such protection against obtaining the greatest value for
us. We also recognize the need to promote the enforcement of our patents and trademarks and take commercially
reasonable steps to enforce our patents and trademarks around the world against potential infringers, including
judicial or administrative action where appropriate.
We operate in an industry susceptible to significant patent litigation. At any given time, we are involved as either a
plaintiff or defendant in a number of patent infringement and other intellectual property-related actions. Such
litigation can result in significant royalty or other payments or result in injunctions that can prevent the sale of
products. For more information on patent and other litigation, see Note 8 in Item 8 of this Annual Report on Form
10-K.
Research and Development
5
We believe our investment in research and development (R&D), consistent with our portfolio optimization and
capital allocation strategies, will help fuel our future growth and our ability to remain competitive. Accordingly, we
continue to focus our investment on select R&D programs to enhance future growth through clinical differentiation.
Expenditures for our R&D activities were $590 million in 2024, $518 million in 2023, and $450 million in 2022. These
expenditures include costs associated with R&D activities performed at our R&D centers located around the world,
which include facilities in Belgium, India, Italy, Malta and the United States, as well as in-licensing, milestone and
reimbursement payments made to partners for R&D work performed at non-Baxter locations. As discussed above in
under "Recent Strategic Actions," in the third quarter of 2023, we implemented a new operating model intended to
simplify and streamline our operations, including with respect to our R&D activities. We are also working to create a
more resilient supply chain and better align our manufacturing footprint and supply chain to our commercial
activities. These activities may result in the consolidation of one or more R&D facilities.
For more information on our R&D activities, refer to the discussion under the caption entitled “Strategic Objectives”
in Item 7. Management's Discussion of Analysis and Financial Condition and Results of Operations of this Annual
Report on Form 10-K.
Quality Management
Our continued success depends upon the quality of our products. Quality management plays an essential role in
determining and meeting customer requirements, helping to prevent defects, facilitating continuing improvement of
our processes, products and services, and helping to assure the safety and efficacy of our products. Our quality
system enables the design, development, manufacturing, packaging, sterilization, handling, distribution and labeling
of our products to help ensure that they conform to customer requirements. In order to consistently improve the
effectiveness and efficiency of our quality system, various measurement, monitoring and analysis methods, such as
management reviews and internal, external and vendor audits, are employed at local and central levels.
Each product that we market is required to meet specific quality standards, both in packaging and in product
integrity and quality. If any of those is determined to be compromised at any time, we endeavor to take corrective
and preventive actions designed to ensure compliance with regulatory requirements and to meet customer
expectations. For more information on corrective actions taken by us, refer to the discussion under the caption
entitled “Certain Regulatory Matters” in Item 7. Management's Discussion of Analysis and Financial Condition and
Results of Operations of this Annual Report on Form 10-K.
Corporate Responsibility
Driven by our mission to save and sustain lives, Baxter's corporate responsibility strategy focuses on addressing
corporate responsibility matters that affect our patients, customers, employees, communities and other critical
stakeholders worldwide. Advancing our corporate responsibility goals contributes to business, social and economic
value, including attraction and retention of employees, enhanced operational efficiency and implementation of
enterprise risk management strategies, among others.
In 2021, we launched our 2030 Corporate Responsibility Commitment featuring strategic goals for focused action.
Our Commitment is anchored by three pillars - Empower our Patients, Protect our Planet and Champion our People
and Communities. The 2030 Corporate Responsibility Commitment and Goals highlight Baxter's corporate
responsibility focus and help to further advance our corporate responsibility performance. We expect to announce a
refreshed Corporate Responsibility commitment and goal set after the issuance of our 2024 Corporate
Responsibility Report (to be issued in June 2025), either in a separate announcement or as part of the 2025
Corporate Responsibility Report. This timing should allow for a new, permanent CEO to have the opportunity to
review and contribute to our commitment and goals and to reflect recent operational and other developments
(including the recent Kidney Care sale). Our progress against our current goals and commitments is published
annually in our Corporate Responsibility Report which is available on our website under "Our Story-Corporate
Responsibility." The Corporate Responsibility Report is not incorporated by reference into this Annual Report on
Form 10-K or any other document filed with the SEC.
Government Regulation
As a medical products company, our operations and many of the products manufactured or sold by us are subject to
extensive regulation by numerous government agencies, both within and outside the United States. The Food and
Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) and the Medicines &
6
Healthcare products Regulatory Agency (MHRA) in Europe, the National Medical Products Administration (NMPA) in
China and other government agencies, inside and outside of the United States, administer requirements covering
the testing, safety, effectiveness, manufacturing, labeling, promotion and advertising, distribution and post-market
surveillance of our products. We must obtain specific clearance, approval or other marketing authorization from FDA
and non-U.S. regulatory authorities before we can market and sell most of our products in a particular country. Even
after we obtain regulatory authorization to market a product, additional regulatory authorization may be necessary to
maintain the product in the market, including additional 501(k) clearances, new drug approval (NDA) supplements,
and other regulatory submissions. In addition, the raw materials, manufacturing facilities, processes and quality
systems used in the manufacture of a product are subject to continued review by FDA and other regulatory
authorities globally. State agencies in the United States also regulate our facilities, operations, employees, products
and services within their respective states. We, along with our facilities, are subject to periodic inspections and
possible administrative and legal actions by FDA and other regulatory agencies inside and outside the United
States. Such actions may include warning letters, product recalls or seizures, monetary sanctions, injunctions to halt
the manufacture and distribution of products, civil or criminal sanctions, refusal of a government to grant approvals
or licenses, restrictions on operations or withdrawal of existing approvals and licenses. As situations require, we
take steps to ensure the safety and efficacy of our products, such as removing products from the market that are
found not to meet applicable requirements and improving the effectiveness of quality systems. For more information
on compliance actions taken by us, refer to the discussion under the caption entitled “Certain Regulatory Matters” in
Item 7. Management's Discussion of Analysis and Financial Condition and Results of Operations of this Annual
Report on Form 10-K.
We are also subject to various laws inside and outside the United States concerning our relationships with
healthcare professionals and government officials, price reporting and regulation, the promotion, sales and
marketing of our products and services, the importation and exportation of products, the operation of our facilities
and the distribution of products. In the United States, we are subject to the oversight of FDA, Office of the Inspector
General within the Department of Health and Human Services (OIG), the Center for Medicare/Medicaid Services
(CMS), the Department of Justice (DOJ), Environmental Protection Agency, Department of Defense and Customs
and Border Protection in addition to others. We supply products and services to healthcare providers that are
reimbursed by federally funded programs such as Medicare. As a result, our activities are subject to regulation by
CMS and enforcement by OIG and DOJ. In each jurisdiction outside the United States, our activities are subject to
regulation by government agencies including the EMA and MHRA in Europe, NMPA in China and other agencies in
other jurisdictions. Many of the agencies enforcing these laws have increased their enforcement activities with
respect to healthcare companies in recent years. These actions appear to be part of a general trend toward
increased enforcement activity globally.
Our operations involve the use of substances regulated under environmental laws, primarily in manufacturing and
sterilization processes. Our environmental policies require compliance with all applicable environmental regulations
and contemplate, among other things, appropriate capital expenditures for environmental protection.
Human Capital Management
As of December 31, 2024, after giving effect to the Kidney Care sale, we employed approximately 38,000 people
globally, with approximately 15,000 employees in the United States and approximately 23,000 employees outside of
the United States. Our employees set the foundation for our ability to achieve our strategic objectives. They
contribute to our success and are instrumental in driving operational execution and our ability to deliver strong
financial performance, advancing innovation and maintaining a strong quality and compliance program across our
organization.
The success and growth of our business depends in large part on our ability to attract, retain and develop talented
and high-performing employees at all levels of our organization with a myriad of backgrounds and experiences,
including the individuals who comprise our global workforce as well as executive officers and other key personnel.
To succeed in a competitive labor market, we have developed recruitment and retention strategies, objectives and
measures that we focus on as part of the overall management of our business. These strategies, objectives and
measures form our human capital management framework and are advanced through the following programs,
policies and initiatives:
•
Competitive Pay and Benefits. Our compensation programs are designed to align the compensation of
our employees with our performance and to provide the proper incentives to attract, retain and motivate
7
employees to achieve superior results. The structure of our compensation programs balances incentive
earnings for both short-term and long-term performance.
•
Health and Safety. Health and safety are firmly rooted across our global footprint. We aim for a zero-harm
workplace and prioritize the elimination of risks and incident precursors to drive improvement. In 2024,
Baxter focused on employee engagement, hazard identification and accelerated technology deployment to
better understand and address top health and safety risk areas. We have continued to mobilize our hazard
identification program for our operational workforce, in concert with a centralized corrective action tracking
tool. These improvements have enabled us to harvest actionable insights, support ergonomic evaluations
and implement safety control technology for improved operation of our powered industrial vehicles.
•
Recruitment, Training and Development. We use recruitment vehicles to attract talent to our organization
and we prioritize learning opportunities that foster a growth mindset. Our formal offerings include a tuition
reimbursement program, an e-learning platform known as BaxU and virtual workshops that support our
culture, strategy and the development of crucial skills. To assess the impact of the investments we make in
our people, and to help us consistently improve our human resources programs, we regularly conduct
anonymous surveys of our global workforce to seek feedback on a variety of topics including confidence in
our leadership, competitiveness of our compensation and benefits packages, career growth opportunities
and improvements on how we can make our company an employer of choice. Administered and analyzed
by an independent third-party, the survey results are reviewed by our senior leaders, which include our
executive officers. Summaries of select surveys are also provided to our Board of Directors. The results of
this engagement survey are also shared with individual managers, who are then tasked with taking action
based on their employees’ anonymous feedback.
Available Information
We make available free of charge on our website at www.baxter.com our Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant
to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (Exchange Act), as soon as
reasonably practicable after electronically filing or furnishing such material with the Securities and Exchange
Commission. These reports are also available free of charge via EDGAR through the Securities and Exchange
Commission website (www.sec.gov). In addition, our Corporate Governance Guidelines, Code of Conduct, and the
charters for the committees of our Board of Directors are available on our website at www.baxter.com under “Our
Story — Our Governance.” All the foregoing materials will be made available to stockholders in print upon request
by writing to: Corporate Secretary, Baxter International Inc., One Baxter Parkway, Deerfield, Illinois 60015.
Information contained on our website shall not be deemed incorporated into, or to be a part of, this Annual Report
on Form 10-K.
Item 1A.
Risk Factors.
In addition to the other information in this Annual Report on Form 10-K, stockholders or prospective investors should
carefully consider the following risk factors for a description of the principal risks that we face. If any of the events
described below occurs, our business, results of operations, financial condition, cash flows, future growth prospects
and stock price could suffer. Further, other unknown or unpredictable factors could also have material adverse
effects on our future results.
Risk Factors Summary
This summary of risks below is intended to provide an overview of the risks we face and should not be considered a
substitute for the more detailed risk factors discussed immediately following this summary.
Risks Relating to Our Strategic Actions
•
We are exposed to risks as a result of our strategic actions, including the recent sale of our Kidney Care
business.
•
We may continue to experience difficulties with our ongoing integration of Hillrom or fail to realize the
anticipated benefits of the Hillrom acquisition.
•
If our business strategy and development activities are unsuccessful, our business, results of operations,
financial condition and cash flows could be adversely affected.
8
Risks Relating to Our Financial Performance and Our Common Stock
•
Global economic conditions, including inflation and supply chain disruptions, have adversely affected, and
could continue to adversely affect, our operations.
•
Our operating results and financial condition have fluctuated and may in the future continue to fluctuate.
•
We may not achieve our financial goals.
•
Our common stock price has fluctuated significantly and may continue to do so.
•
Our significant indebtedness requires us to use a substantial amount of our cash flow for debt service and
could constrain our flexibility in responding to unanticipated or adverse business conditions and adversely
affect our business, results of operations, financial condition and cash flows.
•
Changes in foreign currency exchange rates and interest rates have had, and may in the future have, an
adverse effect on our results of operations, financial condition, cash flows and liquidity.
•
Future material impairments in the value of our goodwill, intangible assets and other long-lived assets,
would negatively affect our operating results.
•
We cannot guarantee that in the future we will not further reduce the amount of dividends we pay.
Risks Relating to Our Business
•
If we are unable to successfully introduce or monetize new and existing products or services, or fail to keep
pace with changing consumer preferences and needs or advances in technology, our business, results of
operations, financial condition and cash flows could be adversely affected.
•
Issues with quality management or product quality could, among other things, have an adverse effect on our
business or cause a loss of customer confidence in us or our products.
•
There is substantial competition in the product markets in which we operate and the risk of declining
demand and pricing pressures could adversely affect our business, results of operations, financial condition
and cash flows.
•
If we fail to attract, develop, retain and engage key employees, including a permanent Chief Executive
Officer (CEO) and other members of our senior management, our business may suffer.
•
Pandemics and other public health emergencies, or the fear thereof, have had, and may in the future have,
a material adverse effect on our business.
Risks Relating to Our Operations
•
Segments of our business are significantly dependent on major contracts with GPOs, IDNs, and certain
other distributors and purchasers.
•
We may not be successful in achieving expected operating efficiencies and sustaining or improving
operating expense reductions and may experience business disruptions and adverse tax consequences
associated with restructuring, realignment and cost reduction activities.
•
If we are unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective
price or if we experience other manufacturing, sterilization, supply or distribution difficulties, our business,
results of operations, financial condition and cash flows may be adversely affected.
•
Breaches and breakdowns affecting our information technology systems or protected information, including
from obsolescence, cyber security breaches and data leakage, could have a material adverse effect on us.
•
Incorporating artificial intelligence, machine learning and other emerging technologies into our products,
services and operations exposes us to legal and regulatory risks and could result in reputational harm or
have other adverse consequences to our business, financial condition or results of operations.
9
•
Climate change, or legal, regulatory or market measures to address climate change, could adversely affect
our business, results of operations, financial condition and cash flows.
•
Our commitments, goals and disclosures related to corporate responsibility matters, and the perception of
our activities in these areas, may adversely impact the company, including through reputational harm.
•
We are subject to risks associated with doing business globally.
•
A portion of our workforce is unionized, and we could face labor disruptions that would interfere with our
operations.
Risks Relating to Legal and Regulatory Matters
•
We are subject to a number of laws and regulations, and we are susceptible to a changing regulatory
environment.
•
Increasing regulatory focus on, and expanding laws relating to, privacy, artificial intelligence and
cybersecurity could impact our business and expose us to increased liability.
•
If reimbursement or other payment for our current or future products is reduced or modified in the United
States or in foreign countries or there are changes to policies with respect to pricing, taxation or rebates,
our business could suffer.
•
We could be subject to fines or damages and possible exclusion from participation in federal or state
healthcare programs if we fail to comply with the laws and regulations applicable to our business.
•
If we are unable to protect or enforce our patents or other proprietary rights, or if we become subject to
claims or litigation alleging infringement of the patents or other proprietary rights of others, our
competitiveness and business prospects may be materially damaged.
•
Changes in tax laws or exposure to additional income tax liabilities may have a negative impact on our
operating results.
•
We are party to a number of pending lawsuits and other disputes which may have an adverse impact on our
business, results of operations, financial condition and cash flows.
•
Our Amended and Restated By-Laws could limit our stockholders’ ability to choose their preferred judicial
forum for disputes with us or our directors, officers, or employees.
Risks Relating to Our Recent and Ongoing Strategic Actions
We are exposed to risks as a result of our strategic actions, including the recent sale of our Kidney Care
business.
Our businesses have begun to face, and will continue to face, material challenges in connection with the sale of our
Kidney Care business and the other strategic actions we have undertaken (including the implementation of a
simplified operating model and the ongoing simplification of our manufacturing footprint). The success of the sale of
our Kidney Care business depends on, among other things, our ability to effectively transition the Kidney Care
business to Carlyle in a manner that: minimizes disruption to our customers, employees, other personnel and
operations; realizes the expected tax benefits; avoids potential liabilities or claims; and enables us to achieve
related cost savings initiatives. The Kidney Care sale may result in challenges such as: the diversion of
management’s attention from our ongoing business concerns and any newly identified strategic initiatives;
attracting, retaining and motivating key management and other employees; retaining existing, or attracting new,
business and operational relationships, including with customers, suppliers, employees and other counterparties;
maintaining our relationships with regulators; the potential for disputes or litigation with Carlyle or Vantive, as
applicable, arising from the transaction, the EPA or the various agreements (including a transition services
agreement and a manufacturing and supply agreement) that we entered into with Vantive in connection with the
Kidney Care closing (as further described below) and liabilities and obligations otherwise related to the transaction,
the EPA or the other agreements described in this paragraph; the potential for exposure related to certain pre-
closing Kidney Care liabilities we retained; the potential for adverse tax consequences or changes in tax laws or
10
regulations that could affect our remaining businesses; the potential for regulatory actions or investigations related
to the transaction or the businesses involved; and potential negative reactions from the financial markets, ratings
agencies, customers, employees, other personnel or other stakeholders.
In addition, in the last few years, we have undertaken other strategic and business transformation actions (including
the divestiture of our BPS business, the acquisition of Hillrom and cost reduction initiatives) that have entailed
changes across our organizational structure, senior leadership, culture, functional alignment, outsourcing and other
areas. These actions pose risks in the form of personnel capacity constraints and institutional knowledge loss that
has led to, and could in the future lead to, missed performance of financial targets (including those related to cost
savings initiatives) and harm to our reputation.
In connection with the closing of the Kidney Care sale, we entered into certain agreements as described above
(including a transition services agreement and a manufacturing and supply agreement). These agreements provide
for the performance of services, and the provision of certain dialysis-related products, other products and product
components, by each company for the benefit of the other for a period of time. If Vantive is unable to satisfy its
obligations under these agreements, including its supply and indemnification obligations, we could incur losses.
Additionally, in the event that Vantive asserts claims for breaches of any of these agreements, our indemnity
obligations and other liabilities to Vantive under these agreements could be significant. These arrangements could
also lead to disputes over rights to certain shared property and rights and over the allocation of costs and revenues
for products and operations. Our inability to effectively manage these activities and related events could adversely
affect our business, financial condition or results of operations.
We have incurred, and will continue to incur, significant expenses in connection with the sale of our Kidney Care
business. For example, we will continue to incur the costs of providing transition services, products and product
components to Vantive under the agreements described above and other stranded costs that we will no longer be
able to share with the Kidney Care business and which we may not be able to fully offset. Such expenses have
been significant, and may continue to grow. In addition, the anticipated benefits of the sale are based on a number
of assumptions, some of which may prove incorrect, and we cannot predict with certainty when the expected
benefits will occur, or the extent to which they will be achieved. As a result, even with the completed sale of the
Kidney Care business, we may not achieve some or all of the anticipated strategic, financial, operational or other
benefits in the expected timeframe, or at all, which could adversely impact our business, results of operations,
financial condition and cash flows. Further, the sale of the Kidney Care business results in a smaller, less diversified
company, with more limited and concentrated businesses than before the transaction, which may leave us more
vulnerable to changing market conditions.
Additionally, until the market has fully analyzed our valuation following the sale of the Kidney Care business, the
price of our common stock may continue to fluctuate even after a sufficient amount of time has passed for the
market to fully analyze our valuation following the sale of the Kidney Care business. Our common stock may not
match some holders’ investment strategies or meet minimum criteria for inclusion in stock market indices or
portfolios, causing certain investors to sell their shares, which could in turn lead to declines in the trading price of
such stock. Furthermore, with the sale having decreased the diversification of our revenues, costs and cash flows,
our operations, cash flows, working capital, effective tax rate and financing requirements may be subject to
increased volatility, and our ability to fund capital expenditures and investments, pay dividends and meet debt
obligations and other liabilities may be diminished.
We may continue to experience difficulties with our ongoing integration of Hillrom or fail to realize the
anticipated benefits of the Hillrom acquisition.
During 2021, we completed the acquisition of Hillrom. The success of this acquisition depends on, among other
things, our ability to complete the integration of Hillrom in a manner that facilitates growth opportunities, realizes
anticipated cost and revenue synergies and achieves certain previously communicated net leverage targets without
adversely affecting current revenues and investments in future growth. If we are not able to successfully achieve
these objectives (including completing the ongoing integration), the anticipated benefits of the Hillrom acquisition
may not be realized fully, or at all, or may take longer to realize than expected.
There is a significant degree of difficulty and management distraction inherent in the process of integrating an
acquisition. The integration of Hillrom into our operations is complex and time-consuming and certain aspects have
taken longer than originally anticipated and have required more effort than was originally planned. Challenges
associated with our integration efforts are also heightened due to the other strategic actions we have recently
completed (including the sale of our Kidney Care business). This has resulted in, and may continue to result in,
additional expenses and other difficulties as we work to complete the integration, including challenges consolidating
certain operations and functions (including regulatory and other corporate functions), integrating technologies
11
(including differing information technology systems and processes), organizations, procedures, policies and
operations and addressing differences in the business cultures of the two companies, any of which could adversely
affect our ability to achieve the anticipated benefits of the acquisition. The integration process and other disruptions
resulting from the Hillrom acquisition and our recently completed strategic initiatives also disrupt our ongoing
businesses and could cause inconsistencies in standards, controls, procedures and policies that adversely affect
our relationships with market participants, employees, regulators and others with whom we have business or other
dealings. Any failure to successfully or cost-effectively integrate Hillrom could have a material adverse effect on our
business and cause reputational harm.
If our business strategy and development activities are unsuccessful, our business, results of operations,
financial condition and cash flows could be adversely affected.
While we remain committed to deleveraging, we expect to engage in significant business development activities
over the longer term in a manner that is consistent with our net leverage targets, including evaluating acquisitions,
joint development opportunities, technology licensing arrangements and other opportunities, such as potential
divestitures and targeted market exits as we look to optimize our product portfolio and improve our operating
margins. These activities may result in substantial investment of our resources. Our success developing products,
expanding into new markets and optimizing our market presence from such activities will depend on a number of
factors, including our ability to find suitable opportunities or partners for acquisition, investment, alliance or
divestiture; competition from other companies in the industries in which we operate that are seeking similar
opportunities; whether we are able to complete an acquisition, investment, alliance or divestiture on terms that are
satisfactory to us or at all; the strength of the underlying technology and products of any of the other parties involved
in a transaction, as well as their ability to execute their business strategies; any intellectual property and litigation
related to any other party’s products or technology; and our ability to successfully integrate the acquired company,
business, product, technology or research into our existing operations (or to divest such company, business,
product, technology or research from our existing operations), including the ability to adequately fund acquired in-
process R&D projects and to maintain adequate controls over the combined operations. Certain of these activities
are subject to antitrust and competition laws, which could impact our ability to pursue strategic transactions and
could result in mandated divestitures in the context of proposed acquisitions. Additionally, certain divestitures could
result in negative market or regulatory reactions. If we are unsuccessful in our business development activities, we
may not realize the intended benefits of such activities, including that acquisition and integration or divestiture costs
may be greater than expected or the possibility that the expected return on investment, synergies and accretion will
not be realized or will not be realized within the expected timeframes. For more information, see Note 3 in Item 8 of
this Annual Report on Form 10-K.
Risks Relating to Our Financial Performance and Our Common Stock
Global economic conditions, including inflation and supply chain disruptions, have adversely affected, and
could continue to adversely affect, our operations.
General global economic downturns and macroeconomic trends, including heightened inflation, capital markets
volatility, interest rate and currency rate fluctuations, changes in monetary policy and economic slowdown or
recession, have resulted in, and may continue to result in, unfavorable conditions that negatively affect demand for
our products and exacerbate other risks described in this “Risk Factors” section that affect our business, results of
operations, financial condition and cash flows. Both domestic and international markets have been experiencing
significant inflationary pressures in recent years and inflation rates in the U.S., as well as in other countries in which
we operate, are currently expected to continue at elevated levels for the near term. In addition, increases in interest
rates and volatility in currency exchange rates have negatively impacted, and may continue to negatively impact,
our results of operations. See “Risks Relating to Our Financial Performance and Our Common Stock – Changes in
foreign currency exchange rates and interest rates have had, and may in the future have, an adverse effect on our
results of operations, financial condition, cash flows and liquidity”.
We have experienced significant challenges to our global supply chain in recent periods, including production
delays and interruptions, increased costs and shortages of raw materials and component parts (including resins and
electromechanical devices), heightened inventory levels to reduce the risk of patient supply disruption and higher
transportation and labor costs, resulting from significant weather events (including Hurricane Helene), elevated
inflation levels, disruptions to certain ports of call around the world, the war in Ukraine, the conflict in the Middle
East and other geopolitical events. Due to the nature of our products, which include dense consumable medical
products such as IV fluids, and the geographic locations of our manufacturing, storage and distribution facilities,
which were further consolidated in anticipation of the recent Kidney Care sale and which often require us to
transport our products long distances, we may be more susceptible to increases in freight costs and other supply
12
chain challenges than certain of our industry peers. We expect to experience some of these and other challenges
related to our supply chain in future periods. These challenges, including the unavailability of certain raw materials
and component parts, have also had a negative impact on our sales for certain product categories due to our
inability to fully satisfy demand and may continue to have a negative impact on our sales in the future. They have
also made it increasingly difficult to model accurately our short-term and long-term financial objectives and may
continue to do so in the future.
Our ability to generate cash flows from operations has been affected, and could continue to be affected, if there is a
material decline in the demand for our products or, in the solvency or planned capital expenditures of our customers
or suppliers, or if there is deterioration in our key financial ratios or credit ratings. Current or worsening economic
conditions may impact the ability of our customers (including governments) to pay for our products and services and
the amount spent on healthcare generally, which could result in decreased demand for our products and services, a
decline in cash flows, longer sales cycles, increased inventory levels, slower adoption of new technologies and
increased price competition. These conditions may also adversely affect certain of our suppliers, which could disrupt
our ability to produce products. We continue to do business with foreign governments in certain countries that have
experienced deterioration in credit and economic conditions. While global economic conditions to date have not
significantly impacted our ability to collect receivables, liquidity issues in certain countries have resulted, and may
continue to result, in delays in the collection of receivables and credit losses and may also impact the stability of the
U.S. Dollar, Euro, Renminbi or other currencies.
Our operating results and financial condition have fluctuated and may in the future continue to fluctuate.
Our operating results and financial condition have, and may in the future, fluctuate from quarter-to-quarter and year-
to-year for a number of reasons. Events, such as changes to our expectations, strategy or forecasts (including as a
result of evolving global macroeconomic conditions, updated expectations regarding the timing of new regulatory
approvals or the impact or timing of our cost savings initiatives) or even a relatively small revenue shortfall or
increase in supply chain or other costs which we are unable to offset have, and may in the future, cause financial
results for a period to be below our expectations or projections. As a result, we believe that period-to-period
comparisons of our results of operations are not necessarily meaningful, nor should they be relied upon as an
indication of future performance. Our operating results and financial condition are also subject to fluctuation from all
of the risks described throughout this section. These fluctuations may adversely affect our results of operations and
financial condition and our stock price.
We may not achieve our financial goals.
We continue to evaluate and refine both our short-term and long-term financial objectives, including our stated
commitment to achieve certain net leverage targets and to fully offset the stranded costs related to the recent sale
of our Kidney Care business. Our ability to achieve these anticipated benefits depends, in part, on our ability to
realize the anticipated benefits of the Hillrom acquisition and Kidney Care sale (and related cost and revenue
synergy targets) while working to execute on our stated portfolio management initiatives. We may fail to achieve our
targeted financial results if we are unsuccessful in implementing our strategies or if our estimates or assumptions
change or for any other reason. Our failure to achieve our financial goals could have a material adverse effect on
our business, results of operations, financial condition and cash flows.
Our common stock price has fluctuated significantly and may continue to do so in the future.
The price of our common stock has fluctuated significantly and may continue to do so in the future for a number of
reasons, including the following:
•
market perceptions of any strategic actions or other developments related to our business including, for
example, the Kidney Care sale;
•
variations in our net sales, earnings or other financial results from investors’ expectations or our previously
issued guidance;
•
departure of key personnel;
•
fluctuations in the results of our operations and general conditions in the economy, our market, and the
markets served by our customers, including with respect to technological advances; and
•
the operating and stock performance of comparable companies or related industries.
13
In addition, prices in the stock market have generally been volatile in recent years, and may continue to be volatile.
In certain cases, the fluctuations have been unrelated to the operating performance of the affected companies. As a
result, the price of our common stock could also fluctuate in the future without regard to our operating performance.
Our significant indebtedness requires us to use a substantial amount of our cash flow for debt service and
could constrain our flexibility in responding to unanticipated or adverse business conditions and adversely
affect our business, results of operations, financial condition and cash flows.
As of December 31, 2024, we had approximately $13.13 billion of indebtedness outstanding and, as of February 21,
2025 have paid down approximately $3.13 billion. Our significant level of indebtedness and our future financial
performance requires us to use a substantial amount of our cash flow for debt service and reduces funds available
(under our credit facilities or otherwise) for investments in product development, capital expenditures, dividend
payments, acquisitions, share repurchases and other activities and may create competitive disadvantages for us
relative to other companies with lower debt levels. Our level of indebtedness can also constrain our flexibility in
responding to unanticipated or adverse business conditions. If we are unable to repay our indebtedness in
accordance with our stated objectives, or at all, or if credit ratings agencies do not believe we are repaying our
indebtedness promptly, they may further reduce our senior debt credit ratings. In addition, until we achieve our
stated commitment regarding the reduction of our indebtedness, our capital allocation activities and operational
flexibility is limited. There can be no assurance that we will be successful in achieving that commitment on a timely
basis or at all. Further, difficulties in, or the inability to, refinance our indebtedness, or to do so upon attractive terms,
could materially and adversely affect our business, prospects, results of operations, financial condition and cash
flows, and make us vulnerable to adverse industry and general economic conditions.
Changes in foreign currency exchange rates and interest rates have had, and may in the future have, an
adverse effect on our results of operations, financial condition, cash flows and liquidity.
We generate a meaningful portion of our net sales and profit outside the United States and currency exchange rates
have been especially volatile in recent years. As a result, currency fluctuations have affected, and may continue to
affect, the reported value of our assets and liabilities, as well as our cash flows and results of operations We cannot
predict with any certainty changes in foreign currency exchange rates or our ability to mitigate these risks. We have
experienced, and may continue to experience, additional volatility as a result of inflation and other macroeconomic
factors, including in emerging market countries. We are also exposed to changes in interest rates, and our ability to
access the money markets and capital markets on terms that are favorable to us, or at all, could be impeded if
market conditions are not favorable. For example, the Federal Reserve in the U.S. and other central banks in
various countries have raised, and may again raise, interest rates in response to concerns about inflation, which,
coupled with reduced government spending and volatility in financial markets, has had, and may continue to have,
the effect of further increasing economic uncertainty and heightening these risks. Interest rate increases or other
government actions taken to reduce inflation have resulted in, and may continue to result in, recessionary pressures
in many parts of the world. For more information see “Financial Instrument Market Risk” in Item 7. Management's
Discussion of Analysis and Financial Condition and Results of Operations of this Annual Report on Form 10-K.
Future material impairments in the value of our goodwill, intangible assets and other long-lived assets
would negatively affect our operating results.
We regularly review our goodwill, intangible assets and property, plant and equipment for potential impairment.
Goodwill and indefinite-lived intangible assets are subject to impairment reviews on an annual basis or whenever
potential impairment indicators are present. Intangible assets subject to amortization and property, plant and
equipment are reviewed for potential impairment when there is an indication that an impairment may have occurred.
Adverse changes to macroeconomic conditions or our earnings forecasts, as well as changes in our strategic goals
or business direction, could lead to impairment charges. In addition, we may, from time to time, pursue the sale of
assets that we determine are not critical to our strategy, including in connection with strategic exits, such as the
Kidney Care sale. Such transactions could result in impairment charges if the estimated fair value of the assets, less
costs to sell, is less than their related carrying amount. Material impairment charges would negatively affect our
results of operations.
For example, as described in more detail in Note 5 of Item 8 of this Annual Report, we recorded a $425 million
goodwill impairment related to our Front Line Care reporting unit within our Healthcare Systems & Technologies
segment and an impairment charge of $50 million to reduce the carrying amount of an in-process research &
development (IPR&D) asset to its fair value during 2024. Previously, as described in more detail in Note 3 of Item 8
of this Annual Report, we recognized $2.81 billion of goodwill impairments and $332 million of indefinite-lived
intangible asset impairments during 2022, both related to Healthcare Systems & Technologies assets acquired in
14
connection with our December 2021 acquisition of Hillrom. Further adverse changes to macroeconomic conditions
or our earnings forecasts could lead to additional goodwill or intangible asset impairment charges in future periods
and such charges could be material to our results of operations. For more information on the valuation of goodwill
and intangible assets, see “Critical Accounting Policies” in Item 7. Management's Discussion of Analysis and
Financial Condition and Results of Operations of this Annual Report on Form 10-K.
We cannot guarantee that in the future we will not further reduce the amount of dividends we pay.
The timing, declaration, amount and payment of any future dividends fall within the discretion of our Board of
Directors and will depend on many factors, including our available cash, estimated cash needs, earnings, financial
condition, operating results, capital requirements, limitations in our contractual agreements, applicable law,
regulatory constraints, industry practice and other business considerations that our Board of Directors considers
relevant. In November 2024, we announced a reduction in our quarterly dividend in anticipation of the sale of our
Kidney Care business and the corresponding reduction to our earnings and cash flows. Any further change in our
dividend program could have an adverse effect on the market price of our common stock.
Risks Relating to Our Business
If we are unable to successfully introduce or monetize new and existing products or services, or fail to keep
pace with changing consumer preferences and needs or advances in technology, our business, results of
operations, financial condition and cash flows could be adversely affected.
We need to successfully introduce or monetize new and existing products and services to achieve our strategic
business objectives. We can provide no assurances that we will be able to develop new products and services, that
our new products and services will achieve commercial acceptance in the marketplace, or that we will be able to
separately bill for new or existing services. In addition, difficulties in manufacturing or in obtaining or maintaining
regulatory approvals have delayed, and may in the future delay or prohibit, the introduction of new or maintenance
of existing products into the marketplace. We may not be able to obtain patent protection on our new products or be
able to defend our intellectual property rights globally. See “Risks Relating to Legal and Regulatory Matters – If we
are unable to protect or enforce our patents or other proprietary rights, or if we become subject to claims or litigation
alleging infringement of the patents or other proprietary rights of others, our competitiveness and business
prospects may be materially damaged.” Warranty claims and service costs relating to our new products might be
greater than anticipated, and we might be required to devote significant resources to address any quality issues
associated with our new products, which could reduce the resources available for further new product development
and other matters. In addition, the introduction of new products and services might also cause customers to defer
purchases of existing products or services. Our future financial performance will also depend in part on our ability to
influence, anticipate, identify and respond to changing consumer preferences and needs. We might not correctly
anticipate or identify trends in customer preferences or needs or might identify or react to them later than
competitors do.
In order to successfully introduce or monetize new and existing products and services, we must commit, and
continue to commit, substantial funds and other resources to R&D and innovation initiatives. Failure to successfully
introduce new products or services in a cost-effective manner, or delays in customer purchasing decisions related to
the evaluation of new products or services, could cause us to lose market share and could materially adversely
affect our business. Furthermore, product development requires substantial investment and there is inherent risk in
the R&D process. A successful product development process further depends on many other factors, including our
ability to adapt to new technologies, demonstrate satisfactory clinical results and differentiate our products from
those of our competitors. If we cannot successfully introduce new competitive products or adapt to changing
technologies, our products may become obsolete and our net sales and profitability could suffer.
Issues with quality management or product quality could have an adverse effect on our business or cause a
loss of customer confidence in us or our products, among other negative consequences.
The development of new or enhanced products involves a lengthy regulatory process and is capital intensive. As a
result, our ability to match our production levels and capacity to market demand is imprecise and may result in a
failure to meet market demand or satisfy customer requirements for our products or, alternatively, an oversupply of
inventory. Increased costs relating to freight, raw materials or component parts and difficulties hiring and retaining
staff have had, and may continue to have, a negative impact on product supply. Failure to meet market demand
may result in customers transitioning to available competitive products, loss of market share, negative publicity,
reputational damage, loss of customer confidence or other negative consequences (including a decline in stock
price).
15
Our success also depends on our ability to maintain and routinely improve product quality and our quality
management program. Quality management plays an essential role in meeting customer requirements, preventing
defects, improving our products and services and assuring the safety and efficacy of our products. While we have a
quality system that covers the lifecycle of our products, quality and safety issues have occurred, and may in the
future occur, with respect to our products. For example, we have experienced certain recalls, including related to our
Novum IQ Syringe and infusion systems, SIGMA Spectrum pump and Life2000 Ventilator. New or unintended uses
of our products (for example, in response to changing clinical practice) may also raise quality or safety issues. In
addition, our customers’ use of third parties to service or repair our products has caused, and may in the future
cause, quality or safety issues, including due to such third parties’ lack of knowledge of or training on our products.
A quality or safety issue may result in negative publicity, product recalls (either voluntary or required by FDA or
similar governmental authorities in other countries), adverse regulatory site inspection reports, voluntary or official
action indicated classifications, warning letters, import bans or seizures, monetary sanctions, injunctions to halt
manufacture and distribution of products, civil or criminal sanctions (which may include corporate integrity
agreements), costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or
withdrawal of existing approvals and licenses. See “Risks Relating to Legal and Regulatory Matters.” An inability to
address a quality or safety issue in an effective and timely manner may also cause negative publicity, potentially
leading to a loss of customer confidence in us or our current or future products, which may result in the loss of sales
and difficulty in successfully launching new products. Additionally, we have made, and could in the future make,
significant investments in assets, including inventory and property, plant and equipment, which relate to potential
new products or modifications to existing products. Product quality or safety issues may restrict us from being able
to realize the expected returns from these investments, potentially resulting in asset impairments in the future.
Unaffiliated third-party suppliers provide a number of goods and services to our R&D, clinical and manufacturing
organizations, many of whom do so on a spot basis and not pursuant to a contractual arrangement. Our ability to
receive goods or services at all, or on reasonable financial terms, from these third parties will be impacted if they
are unable or refuse to supply or service us. Moreover, we may have limited or no recourse if the goods or services
are not subject to contractual terms. If we are unable to identify or secure regulatory approval for an alternative
provider on reasonable terms, our ability to meet our obligations to our customers could be negatively impacted,
which could adversely affect our financial results and our reputation. Additionally, third-party suppliers are required
to comply with our quality standards and those of applicable regulatory bodies. Failure of a third-party supplier to
provide compliant raw materials, component parts or supplies, give us adequate notice of issues or help us secure
all required regulatory approvals for the use of their products or services has resulted in delays, service interruptions
and quality-related issues, and may do so again in the future, and may negatively impact our business results and
results of operations.
There is substantial competition in the product markets in which we operate and the risk of declining
demand and pricing pressures could adversely affect our business, results of operations, financial
condition and cash flows.
We face substantial competition in all of our markets from international and domestic healthcare medical products
and pharmaceutical companies and providers of all sizes, and these competitors often differ across our businesses.
Competition is primarily focused on cost-effectiveness, price, service, product performance and technological
innovation.
Competition may increase further as additional companies begin to enter our markets, launch new products or
modify their existing products to compete directly with ours. If our competitors respond more quickly to new or
emerging technologies and changes in customer requirements, or we do not introduce new versions or upgrades to
our product portfolio in response to those requirements, our products may be rendered obsolete or non-competitive.
If our competitors develop more effective or affordable products or achieve earlier patent protection or product
commercialization than we do, our business, results of operations, financial condition and cash flows will likely be
negatively affected. For example, innovations in technology and care delivery models could materially adversely
affect the demand for and future pricing and sale of our products and services. Furthermore, if we are forced to
reduce our prices due to increased competition, our business could become less profitable.
In addition, many healthcare industry companies, including healthcare systems, distributors, manufacturers,
providers and insurers, are consolidating or have formed strategic alliances. As the healthcare industry consolidates
and new entrants emerge, competition to provide goods and services to industry participants has become, and will
continue to become, more intense. Further, this consolidation creates larger enterprises with greater negotiating
power, which they can use to negotiate price concessions. If we face an increase in costs or are unable to achieve
targeted price increases because of industry consolidation or otherwise, the long-term nature of our customer
16
contracts or for other reasons, or if we lose customers as a result of consolidation, our business, results of
operations, financial condition and cash flows could be adversely affected.
Demand for our products and services, and our overall growth, depend in large part on overall demand and growth
in the healthcare market. With the healthcare market’s increased focus on asset and resource efficiency, as well as
reimbursement constraints and competitive dynamics, we have seen margins for some of our products decline and
they may continue to do so over time. Any decline or lower-than-expected growth in the markets (or portions
thereof) in which we operate or intend to operate could diminish demand for our products and services, which may
adversely affect our financial performance. Further, the competitive pressures in our industry could cause us to lose
market share unless we increase our commercial investments or reduce our prices, which could adversely impact
our operating results. These factors, along with possible legislative, regulatory, macroeconomic and other
developments, might result in significant shifts in market share among the industry’s major participants, which
includes us. Accordingly, if we are unable to effectively differentiate ourselves from our competitors in terms of new
products and diversification of our product portfolio, then our market share, sales and profitability could be adversely
impacted through lower volume or decreased prices.
If we fail to attract, develop, retain and engage key employees, including a permanent CEO and other
members of our senior management, our business may suffer.
Our ability to compete effectively depends on our ability to attract, develop, retain and engage key employees,
including people in senior management, sales, marketing, information technology and R&D positions. Competition
for top talent in the healthcare industry can be intense, especially for experienced management and technical and
professional employees, which could increase costs associated with identifying, attracting and retaining such
individuals. Our ability to recruit, develop, retain and engage such talent depends on a number of factors, including
hiring practices of our competitors, compensation and benefits (as may be impacted by any financial performance
challenges, including any related impact on outstanding equity awards), work location, work environment (including
our competitors’ policies regarding remote or hybrid work arrangements), the market’s perception of our strategic
initiatives, including the recently completed Kidney Care sale, and industry economic conditions. Further, a lack of
employee engagement could lead to loss of productivity and increased employee burnout, turnover, absenteeism,
product quality incidents and decreased customer and patient satisfaction.
In addition, the loss of services of our senior management or other key employees could delay or prevent the
achievement of our financial, operating or strategic objectives. In February 2025, we announced that José Almeida
had ceased serving as Chair, President and CEO and the appointment of Brent Shafer, the former lead independent
director of our Board of Directors, as Chair and interim CEO. We also announced the Board’s initiation of a search
for a permanent CEO. The timeline for identifying, retaining and integrating a new CEO is currently unknown. Any
failure to timely identify and hire a new CEO and successfully integrate and transition that person into their new role
within our company could adversely impact our ability to achieve our long-term financial, operating or strategic
objectives. We have also experienced, and may continue to experience, attrition among our senior management
team and key employees in recent years, including during the CEO search process. These leadership changes may
be difficult to manage and may result in additional costs, uncertainty concerning our future direction, changes to our
corporate culture, lower employee morale or the loss of personnel with deep institutional knowledge and industry
relationships. Further, we have increased our dependency on the remaining members of our executive management
team during the transition process. Our executive officers could terminate their employment with us at any time, and
any such departure could be particularly disruptive in light of the recent leadership changes. The replacement of any
of our senior management or other key employees involves significant time and costs, and any loss of services of
any such key employee for any reason could significantly delay or prevent the achievement of our financial,
operating or strategic objectives. If we are unable to mitigate these or other similar risks, our business, results of
operations and financial condition may be adversely affected.
Pandemics and other public health emergencies, or the fear thereof, have had, and may in the future have, a
material adverse effect on our business. The nature and extent of future impacts are uncertain and
unpredictable.
Our global operations expose us to risks associated with public health emergencies, including epidemics and
pandemics, such as the COVID-19 pandemic. Pandemics or other public health emergencies have adversely
impacted, and may continue to adversely impact, our operations, supply chains and distribution systems, and have
increased, and may continue to increase, our expenses, including due to preventive and precautionary measures
that we, other businesses and governments have taken and may continue to take.
The COVID-19 pandemic adversely affected our business in many ways, including significant reductions and
increases in demand for certain products, increased difficulty in serving customers, disruptions to manufacturing
17
and supply chains, and negative effects on certain of the company’s operations as well as the operations of its
suppliers, distributors, customers, manufacturers and other third-party vendors. Further, pandemics or other public
health emergencies may impact, and during COVID-19 impacted, the global economy, including negatively
impacting economic growth, financial and capital markets, inflation rates, foreign currency exchange rates, interest
rates, and the global supply chain. Any of these and other impacts have had, and could in the future have, a
material adverse effect on our business, results of operations, financial condition and cash flows. The scope and
duration of any future public health emergency will depend on a number of factors, including the potential
emergence of a new or extended pandemic, the pace at which government restrictions are imposed and lifted and
the extent of such restrictions, the scope of additional actions taken to mitigate the spread of disease and the
availability and effectiveness and acceptance of vaccines. The effect of such a health emergency on our business
will also vary based on the speed with and extent to which global markets and utilization rates for our products fully
recover from the disruptions caused by such a public health emergency. The impact of these and other factors on
our business, results of operations, financial condition and cash flows will depend on future developments that are
highly uncertain and cannot be predicted with confidence.
Risks Relating to Our Operations
Segments of our business are significantly dependent on major contracts with GPOs, IDNs and certain
other distributors and purchasers.
A portion of our U.S. hospital sales and rentals are made pursuant to contracts with hospital GPOs. At any given
time, we are typically at various stages of responding to bids, negotiating and renewing expiring GPO agreements,
some of which contain failure to supply clauses with varying remedies, inclusive of limited termination rights. Failure
to be awarded or to maintain certain of these agreements could have a material adverse effect on our business,
including product sales and service and rental revenue. In addition, we have faced and continue to face challenges
related to increasing costs associated with these agreements (associated with ongoing supply chain challenges and
inflation), which have negatively impacted our revenues and may continue to do so in the future.
Our participation in these agreements often requires increased discounting or restrictions on our ability to raise
prices, and failure to participate or to be awarded these agreements might result in a reduction of sales to the
member hospitals. In addition, in recent years, select market participants have shown an increased focus on
individual GPO members negotiating directly with manufacturers on committed contracts. IDNs and health systems,
when negotiating directly with manufacturers, often request additional discounts or other enhancements. Further,
certain other distributors and purchasers have similar processes to the GPOs and IDNs and failure to be included in
agreements with these other purchasers could have a material adverse effect on our business.
We may not be successful in achieving expected operating efficiencies and sustaining or improving
operating expense reductions and may experience business disruptions and adverse tax consequences
associated with restructuring, realignment and cost reduction activities.
Portions of our business have been, and may in the future be, the subject of restructuring, realignment and cost
reduction initiatives. For example, we recently divested our BPS and Kidney Care businesses and have
implemented a simplified operating model. While we are undertaking these actions, as well as any future initiatives,
with the goal of realizing potential efficiencies, we may not be successful in achieving efficiencies and cost reduction
benefits we expect in full or at all. Further, such benefits might be realized later than expected, and the ongoing
costs of implementing these measures might be greater than anticipated. If these measures are not successful or
sustainable, we might undertake additional realignment and cost reduction efforts, which could result in future
charges. Moreover, our ability to achieve our other business plans might be adversely affected, and we could
experience business disruptions, if our restructuring and realignment efforts and our cost reduction activities prove
ineffective. These actions, the resulting costs, and potential delays or potential lower than anticipated benefits might
also impact our foreign tax positions and might require us to record tax reserves against certain deferred tax assets
in our international business.
If we are unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective
price or if we experience other manufacturing, sterilization, supply or distribution difficulties, our business,
results of operations, financial condition and cash flows may be adversely affected.
The manufacture of our products requires, among other things, the timely supply or delivery of sufficient amounts of
quality components and raw materials. We manufacture our products in approximately 40 principal manufacturing
locations. We acquire our components, raw materials and other requirements for manufacturing from many
suppliers and vendors in various countries, including sometimes from ourselves for self-supplied requirements. We
18
endeavor, either alone or working closely with our suppliers, to ensure the continuity of our inputs and supplies, but
these efforts may not always be successful.
Further, while efforts are made to diversify certain of our sources of components and raw materials, in certain
instances we have made a strategic determination to use a single source or supplier or there is only a sole source
or supplier with no acceptable alternatives yet identified and, as applicable, qualified. This reliance on sole or limited
source suppliers exposes us to several risks that could adversely affect our business, financial condition and results
of operations. The disruption or termination of the supply of these components could cause significant production
interruptions, delays and inefficiencies. In the event of a disruption, establishing additional or replacement suppliers
for such materials or components may not be timely or cost-effective due to market constraints or regulatory
requirements. The process of qualifying new suppliers may be lengthy and complex, requiring approval of materials
and components prior to their use in our products from governmental agencies, such as FDA and other worldwide
regulatory agencies. As a result, we may experience lengthy delays in resuming production of affected products,
which could lead to lost sales, loss of market share and harm to our reputation. Our reliance on sole source
suppliers may also lead to increased costs. If we are unable to pass these cost increases on to our customers, our
business and results of operations could be adversely impacted.
Additionally, we obtain certain components and materials on a spot basis from third-party suppliers with whom we
do not have contractual arrangements. A reduction, interruption or suspension in supply, other supply chain issues,
including those due to the revocation of distribution facilities’ licenses or as a result of our recently completed
strategic initiatives (including the recent sale of our Kidney Care business), and our inability to quickly develop
acceptable alternative sources for such supply could adversely affect our ability to manufacture, distribute and sell
our products in a timely or cost-effective manner. Such supply chain issues could also prevent us from satisfying
obligations under one or more of our customer contracts or arrangements, which could result in significant failure to
supply penalties, which in some instances include contract termination rights or may prevent us from participating in
future tenders. We have faced, and may in the future face, difficulties obtaining supplies of key materials, such as
electromechanical components, active ingredients for pharmaceuticals and resins, due to supply chain disruptions
and global pandemics. Moreover, changes in regulation, world trade policies, international taxes and government-to-
government relations and issues with export and import activities could negatively impact our ability to distribute
products within a country and across countries. See “Risks Relating to Legal and Regulatory Matters.”
Additionally, our success depends upon the availability and quality of our products and the underlying raw materials
and component parts. The medical products and pharmaceutical industries are competitive and subject to complex
market dynamics and varying demand levels. These levels vary in response to economic conditions, regulatory
requirements, seasonality, natural disasters, wars, acts of terrorism, pandemics, epidemics and other matters.
Significant increases in the cost of raw materials, sub-assemblies or materials used in the production of our
products that cannot be recovered through increased prices of our products (or the unavailability of those raw
materials, sub-assemblies or production materials) have adversely affected our business, results of operations,
financial condition and cash flows and may continue to do so in the future. There can be no assurance that the
marketplace will support higher prices or that such prices and productivity gains will fully offset any commodity cost
increases in the future. From time to time, we enter into fixed price supply contracts with respect to raw material
purchases. Future decisions not to enter into fixed price supply contracts may result in increased cost volatility,
potentially adversely impacting our profitability. Volatility in the demand for our products or our costs of energy,
transportation, freight, raw materials and component parts and other supply, manufacturing, distribution and
warehousing or storage costs have adversely affected, and could in the future adversely affect, our business, results
of operations, financial condition and cash flows and have prevented, and may continue to prevent, suppliers from
providing goods and services to us on reasonable terms or at all. See also “Risks Relating to Our Financial
Performance and Our Common Stock—Global economic conditions, including inflation and supply chain
disruptions, have adversely affected, and could continue to adversely affect, our operations.”
Many of our products are difficult to manufacture. This is due to the complex nature of manufacturing devices and
pharmaceuticals, including biologics, as well as the strict regulatory regime governing our manufacturing operations.
Variations in the manufacturing process may result in production failures, which could lead to launch delays, product
shortage, unanticipated costs, lost revenues and damage to our reputation. A failure to identify and address
manufacturing problems prior to the release of products to our customers may also result in a quality or safety issue
of the type discussed in the “Risk Factors” section.
We rely heavily on a limited number of providers of transport services for reliable and secure point-to-point transport
of our products to our customers and patients and for tracking of these shipments, and from time to time we require
warehousing for our products. If any of these providers were to encounter delivery performance issues such as loss,
damage or destruction of any systems or machines, it would be costly to replace such systems or machines in a
19
timely manner and such occurrences may damage our reputation and lead to decreased demand for our products
and increased cost and expense to our business.
Some of our products are manufactured at a single manufacturing facility or stored at a single storage site.
Additionally, some of our manufacturing facilities are located in the same geographic area. Loss or damage to, or
closure of, a manufacturing facility or storage site due to a natural disaster, such as we experienced as a result of
Hurricane Helene, war, acts of terrorism or otherwise has adversely affected, and could in the future adversely
affect, our ability to manufacture sufficient quantities of key products or deliver products to meet customer demand
or contractual requirements, which has resulted, and may in the future result, in a loss of revenue and other adverse
business consequences, including those identified in the paragraphs above. We may be unable to transfer
manufacturing of the relevant products to another facility or location in a cost-effective or timely manner, if at all.
This potential inability to transfer production could occur for several reasons, including a lack of necessary relevant
manufacturing capability at another facility, or the regulatory requirements of FDA or other governmental regulatory
bodies. Such an event could materially negatively impact our business, results of operations, financial condition and
cash flows.
In addition, several of our manufacturing facilities are leased and we may not be able to renew leases on favorable
terms or at all. Because of the time required to approve and license a manufacturing facility, a third-party
manufacturer may not be available on a timely basis (if at all) to replace production capacity in the event we lose
manufacturing capacity or products are otherwise unavailable. Any of the foregoing could adversely affect our
business, results of operations, financial condition and cash flows.
Some of our products require sterilization prior to sale or distribution, and we utilize both Baxter-owned and third-
party facilities for this process. If an event occurs that results in damage to or closure, whether temporarily or
permanent, of one or more of these facilities, we may be unable to manufacture or sterilize the relevant products at
prior levels or at all, and a third party may not be available on a timely basis (if at all) to replace sterilization capacity.
For example, in September 2024, Hurricane Helene brought unprecedented rain and extensive flooding to Western
North Carolina, which impacted our North Cove facility. We temporarily closed our North Cove facility to undertake
remediation efforts, some of which remain ongoing. Further, in 2021, our facility in Mountain Home, Arkansas
entered into a Consent Administrative Order with the Arkansas Division of Environmental Quality relating to certain
air emissions control technology used to reduce ethylene oxide emissions from sterilization equipment. These and
other events or disruptions of manufacturing or sterilization processes that we or third parties may experience,
whether due to a lack of capacity, environmental, regulatory or compliance issues (including evolving regulatory
requirements), catastrophic events or otherwise, have resulted in, and could in the future result in, product shortage,
unanticipated costs, loss of revenues, operational restrictions, additional capital expenditure requirements, litigation
and damage to our reputation, all of which could have a material adverse effect on our business, results of
operations, financial condition and cash flows.
Breaches and breakdowns affecting our information technology systems or protected information,
including from obsolescence, cyber security breaches and data leakage, could have a material adverse
effect on our business, results of operations, financial condition, cash flows, reputation and competitive
position.
We rely upon information technology systems and infrastructure, including services provided by our partners and
third parties, to support our business, facilities, products and customers. For example, we routinely rely on
technology systems and infrastructure in the collection, use, storage and transfer, disclosure and other processing
of voluminous amounts of protected information, including personal data, protected health information, and sensitive
data (of patients, employees, customers and third parties) as well as confidential, business, financial, and other
sensitive information (collectively, Protected Information). We also rely on systems for our business model, including
product development, manufacturing, order management, distribution, customer service, regulatory compliance and
various other matters. Certain of our products and systems collect Protected Information regarding patients and
their therapies and some are internet enabled or connect to our systems for maintenance and other purposes. The
acquisition of Hillrom in December 2021 meaningfully increased the number of these products and systems within
our portfolio. Some of our products connect to the internet, hospital networks, electronic medical record systems or
electronic health record systems. Further, we expect that the breadth and complexity of our information and
technology systems and infrastructure will increase as we expand our product offerings to utilize and generate data
analytics and potentially artificial intelligence (AI) (which create emerging enterprise risks, including cybersecurity,
monitoring, and oversight). See “Risks Relating to Our Operations – Incorporating artificial intelligence, machine
learning and other emerging technologies into our products, services and operations may result in legal and
regulatory risks, reputational harm or have other adverse consequences to our business, financial condition or
20
results of operations”. The continuing evolution of technology we use, including cloud-based computing and data
hosting as well as AI, and reliance on third parties and Software as a Service solutions, whom may also use cloud-
based computing and data hosting or AI tools, create additional opportunities for the unintentional, intentional,
unauthorized or unlawful disclosure, exposure, dissemination, loss, alteration, access or destruction of Protected
Information stored or processed in our devices, systems, servers, infrastructure and products (collectively,
Technology). Security threats, including cyber and other attacks, have become very sophisticated, frequent and
adaptive.
Our Technology is vulnerable to breakdown, interruption, cyber and other security attacks, system malfunction,
unauthorized access, inadvertent exposure or disclosure of information, theft and other events and requires at times
requires the manual application of security upgrades or patches on each machine or device that utilizes the
Technology. Third-party systems and solutions that we rely upon are also vulnerable to the same risks and may
contain defects in design or manufacture or other problems that could result in system disruption or compromise the
information security of our own systems and products. Any such vulnerability could compromise our Technology and
could expose Protected Information to unauthorized third parties and/or cause temporary or permanent loss or
unavailability of such Protected Information. In addition, our Technology may cause product functionality issues that
could result in risk to patient safety, field actions or product recalls. We, like other global companies, have
experienced cyber incidents in the past (including ones related to the unauthorized access to or disclosure of data),
and may experience them in the future. These events have exposed and may continue to expose vulnerabilities in
our information technology systems. There is no assurance that our investments in the protection of data and
Technology (i) have prevented or will prevent future breakdowns, attacks or breaches in our Technology, cyber
incidents or other incidents or (ii) ensure compliance with all applicable cybersecurity and privacy laws, regulations
and standards, including with respect to third-party service providers that host or process Protected Information on
our behalf. Any failure to protect against such incidents or non-compliance with applicable security and privacy laws,
regulations and standards could lead to substantial and material regulatory fines and penalties, business disruption,
reputational harm, financial loss or litigation, as well as other damages. Misappropriation or other loss of our
intellectual property from any of the foregoing may have an adverse effect on our competitive position and may
cause us to incur substantial litigation costs. See “Risks Relating to Legal and Regulatory Matters.” As our
customers and FDA and other global regulators, including data protection authorities or supervisory bodies, become
more sensitive to risks related to cybersecurity, our ability to meet certain information technology safety standards or
evolving customer demands could affect our products’ marketability and competitiveness. We could also suffer
strained relationships with customers, business partners, physicians and other healthcare professionals, increased
costs (for security measures, remediation or otherwise), litigation (including class actions and stockholder derivative
actions) or other negative consequences (including a decline in stock price) as a result of breaches, cyber and other
security attacks, industrial espionage, ransomware, phishing scams, malware or other cyber incidents, which could
compromise our system infrastructure and/or lead to data leakage, including at our third-party providers or other
business partners. The insurance we have procured related to cybersecurity risks may not cover a particular cyber
incident or such coverage may be insufficient.
In addition, Technology management issues arise from time-to-time as we continue to consolidate and outsource
certain information technology support activities and certain computer operations and application support activities
as a result of our ongoing business transformation activities and cost saving initiatives.
Additionally, our ongoing integration of Hillrom and the recent sale of our Kidney Care business, as well as a
number of our employees having fully remote or hybrid work arrangements expose us to, among other things,
heightened risks related to our information technology systems and networks, including cyber attacks, computer
viruses, malicious software, security breaches and telecommunication failures, both for systems and networks we
control directly and for those that employees and third-party developers rely on to work remotely. We also face all of
the same risks listed above and other heightened risks when acquiring a company, in particular if we need to
transition or implement certain processes or controls with the acquired company. For example, as we continue to
integrate Hillrom into our business, we have identified certain potential areas of vulnerability as we transition its
information technology systems, products and processes to our processes and controls, including with respect to
cybersecurity and privacy matters. We are also subject to risks associated with Vantive’s information technology
systems, which we will help support during the period of the related transition services agreement. For example,
there may be additional risks during the term of such agreement related to data protection, cyber attacks and
information technology system provisioning relating to Vantive, its customers and its vendors. While we are working
to fully address those vulnerabilities (consistent with our processes and controls), any such vulnerabilities (or any
others) if unidentified or unremediated could have a material adverse effect on our business, results of operations,
financial condition and cash flows.
21
Incorporating artificial intelligence, machine learning and other emerging technologies into our products,
services and operations may result in legal and regulatory risks, reputational harm or have other adverse
consequences to our business, financial condition or results of operations.
We use AI and machine learning (ML) technologies to support our operations and anticipate integrating such
technology in select products and services in the future. We further anticipate that AI and ML will become
increasingly important to our innovation and competitiveness in the future. However, we face risks and uncertainties
related to the development, adoption and use of AI, ML and other emerging technologies, including complying with
an increasingly large amount of complex global regulations related specifically to AI and ML.
We may not be able to successfully develop, integrate or deploy AI or ML technologies in our products and services,
or we may face delays, increased costs or technical difficulties in doing so. We may also encounter difficulties in
obtaining or maintaining the necessary regulatory approvals or clearances for these products and services, or face
increased scrutiny or liability from regulators, customers, or other stakeholders regarding the safety, effectiveness,
accuracy, reliability, security or ethical implications of such technology. We also may have more difficulty protecting
or enforcing our data and intellectual property rights as a result of these technologies, and there may be a risk of
infringing on the intellectual property rights of others which could lead to litigation, arbitration or other disputes over
the ownership, validity, scope or enforcement of our or others’ patents, trademarks, copyrights, trade secrets or
other proprietary rights related to AI and ML technologies. Such disputes could be costly, time-consuming and
disruptive to our business. See “Risks Relating to Legal and Regulatory Matters – If we are unable to protect or
enforce our patents or other proprietary rights, or if we become subject to claims or litigation alleging infringement of
the patents or other proprietary rights of others, our competitiveness and business prospects may be materially
damaged”
We may experience breaches, failures or disruptions of information technology systems or products (whether ours
or those of third parties on which we rely) that use or rely on AI, ML or emerging technologies We have also
experienced and may experience in the future unauthorized or unlawful access, use, disclosure, alteration or
destruction of the data or information that we collect, store, process or transmit for our applications, including data
or information provided to us by third parties. These events could result from cyber attacks, human error, natural
disasters, power outages, sabotage or other causes, and could compromise the confidentiality, integrity or
availability of our or our customers' data or information, or the functionality or performance of our AI and ML-enabled
products and services. These events could result in loss of customer confidence, reputational harm, regulatory
investigations or actions, legal claims or liabilities, remediation costs or other negative consequences.
Climate change, or legal, regulatory or market measures to address climate change, could adversely affect
our business, results of operations, financial condition and cash flows.
The long-term effects of climate change are difficult to predict and may be widespread. The impacts of climate
change may include physical risks (such as water scarcity, rising sea levels or frequency and severity of extreme
weather conditions, including natural disasters such as hurricanes, cyclones and typhoons), social and human
effects (such as population dislocations or harm to health and well-being), compliance costs and transition risks
(including due to regulatory or technology changes), shifts in market trends (for example if customers increasingly
prioritize purchasing products that are sustainably made and that can be reused or recycled) and other adverse
effects. Such impacts, such as damage to manufacturing facilities (including as a result of Hurricane Helene), local
infrastructure and utilities have disrupted, and may in the future disrupt, our supply chain and manufacturing
operations by adversely affecting our ability to procure goods or services required for the operation of our business
at the quantities and levels we require due to impairment of the availability and increases in the cost of certain
products, materials, commodities and energy. For example, material or sustained increases in the price of oil have
had an adverse impact on the cost of many of the plastic materials or resins we use to make and package our
products, as well as our transportation/freight costs. Further, the impacts of climate change, particularly severe
weather events and droughts, may have negatively impacted, and may in the future negatively impact, our ability to
obtain material energy and water sources and other resources, including employee availability and access to
shipping routes. Any of these outcomes may, in turn, result in customers transitioning to available competitive
products, loss of market share, negative publicity, reputational damage, loss of customer confidence or other
negative consequences, such as a decline in stock price. Further, any perceived increase in the potential of severe
weather events and business interruption may put an upward pressure on the cost of our risk insurance premiums,
which could adversely impact our business, results of operations, financial condition and cash flows.
In addition, the increasing concern over climate change has resulted in, and may continue to result in, more local,
state, regional, federal and global legal and regulatory requirements relating to climate change, including regulating
greenhouse gas emissions and related reporting requirements (and the establishment of enhanced internal
22
processes or systems to track them), alternative energy policies and sustainability initiatives. Legislation and
regulations have been, and may continue to be, enacted and promulgated in the United States, United Kingdom, EU
or in any other jurisdictions in which we do business that impose more stringent restrictions and requirements than
our current legal or regulatory obligations (as a result of our publicly disclosed corporate responsibility (CR) goals or
otherwise), we may experience disruptions in, or increases in the costs associated with research, development,
sourcing, manufacturing and distributing our products. Additionally, rising climate change concerns have led to, and
could continue to lead to, additional regulation that could increase our compliance costs. As a result, any such
regulatory changes could have a significant adverse effect on our business, financial condition, result of operations
and cash flows.
Furthermore, companies across all industries are facing increasing scrutiny from investors, regulators, and other
stakeholders related to their CR commitments, performance, and disclosures, including those related to climate
change, social matters, and governance standards. See “Risks Relating to Our Operations – Our commitments,
goals and disclosures related to corporate responsibility matters, and the perception of our activities in these areas,
may adversely impact the company, including reputational harm.”
Our commitments, goals and disclosures related to corporate responsibility matters, and the perception of
our activities in these areas, may adversely impact us, including through reputational harm.
Governmental authorities, investors, customers, employees, certain institutional investors, lenders and other
stakeholders are increasingly focused on CR commitments, practices, performance and disclosures, and in recent
years have placed increasing importance on social costs and related implications of their investments. Our CR
goals, some of which may be reset or reframed or reset in connection with the issuance of our 2024 Corporate
Responsibility Report or otherwise, reflect our current plans and aspirations and are not guarantees that we will be
able to achieve them.
We risk negative stockholder reaction, as well as damage to our brand and reputation and other potential costs, if
we fail to meet our goals and initiatives, if we fail to accurately measure or report our progress with respect to our
goals and initiatives or if we are perceived to not be acting responsibly in key CR areas, including product quality
and safety, environmental stewardship, support for local communities, corporate governance and transparency, and
addressing human capital factors in our operations. Responding to these CR considerations and implementation of
our CR goals and initiatives involves risks and uncertainties, requires investments (some of which still need to be
funded or identified), and depends in part on our relative performance (or perceived performance) against third-
parties that is beyond our control.
Additionally, organizations that provide information to investors on corporate governance and related matters have
developed ratings processes for evaluating companies on their respective approaches to CR matters, which are
increasingly being employed by investors, lenders, and customers to inform their investment, financing, or
purchasing decisions. A failure to adequately meet stakeholder expectations, which may differ or conflict, may result
in the loss of business, reputational impacts, diluted market valuation, an inability to attract customers, and an
inability to attract and retain talent.
In addition, some stakeholders may disagree with our CR goals and initiatives. If we do not meet the evolving and
varied CR expectations of our investors, customers, employees and other stakeholders, we could experience
reduced demand for our products, loss of customers and employees and suffer other negative impacts to our
business and results of operations.
We are subject to risks associated with doing business globally.
Our operations are subject to risks inherent in conducting business globally and under the laws, regulations and
customs of various jurisdictions and geographies. These risks include changes in exchange controls and other
governmental actions, loss of business in government and public tenders that are held annually in many cases,
increasingly complex labor environments, availability of raw materials and component parts, changes in taxation,
tariffs, sanctions, embargos, export control restrictions, changes in or violations of U.S. or local laws, dependence
on a few government entities as customers, pricing restrictions, economic and political instability, monetary or
currency volatility or instability (including as it relates to the U.S. Dollar, the Euro, the Mexican Peso and currencies
in emerging market countries), disputes between countries, trade relationships and conflicts, diminished or
insufficient protection of intellectual property, and disruption or destruction of operations in a significant geographic
region regardless of cause, including natural disaster, pandemic, power loss, cyber attack, data breach, war,
terrorism, riot, labor disruption, civil insurrection or social unrest. Failure to comply with, or material changes to, the
laws and regulations that affect our global operations could have an adverse effect on our business, results of
operations, financial condition and cash flows.
23
The escalating global economic competition and trade tensions among the United States and its trading partners
(including China and Russia) could have an adverse effect on our business, results of operations, financial condition
and cash flows, and there is risk of additional tariffs and other kinds of restrictions, including in connection with the
transition to new political administrations. Tariff exclusions awarded to us by the United States Government require
annual renewal, and policies for granting exclusions could shift. The United States and other countries could impose
other types of restrictions such as limitations on government procurement or technology export restrictions, which
could affect our access to the markets. See also “Risks Relating to Legal and Regulatory Matters—We are subject
to a number of laws and regulations, non-compliance with which could adversely affect our business, results of
operations, financial condition and cash flows, and we are susceptible to a changing regulatory environment.”
More generally, several governments have raised the possibility of policies to induce “re-shoring” of supply chains,
less reliance on imported supplies and greater national production. If such steps triggered retaliation in other
markets, such as by restricting access to foreign products by their government-owned healthcare systems, the
outcomes could have an adverse effect on our business, results of operations, financial condition and cash flows.
A portion of our workforce is unionized, and we could face labor disruptions that would interfere with our
operations.
Some of our employees both in and outside of the United States work under collective bargaining agreements or
national trade union agreements or are subject to works councils. Significant work stoppages as a result of labor
disagreements may occur in the future, including as a result of any failure to maintain the collective bargaining
agreements we have in place for one of our U.S. manufacturing facilities (which are scheduled to expire in January
2027 and January 2029). Our inability to negotiate satisfactory new agreements or a labor disturbance at any of our
manufacturing facilities could have a material adverse effect on our operations.
Risks Relating to Legal and Regulatory Matters
We are subject to a number of laws and regulations, non-compliance with which could adversely affect our
business, results of operations, financial condition and cash flows, and we are susceptible to a changing
regulatory environment.
As a participant in the healthcare industry, our operations and products, and those of our customers, are regulated
by numerous government agencies, both inside and outside the United States.
Laws and regulations, such as the Patient Protection and Affordable Care Act and the Health Care and Education
Reconciliation Act (collectively, the Healthcare Reform Act), aim to decrease costs through comparative
effectiveness research and pilot programs to evaluate alternative payment methodologies. Compliance with these
and similar regulations could result in pricing pressure or negatively impact the demand for our products. In a
number of situations, even though specific laws and regulations may not directly apply to us, our products must be
capable of being used by our customers in a manner that complies with those laws and regulations.
The manufacture, distribution, marketing and use of our products are subject to extensive regulation and scrutiny by
FDA and other regulatory authorities globally, and such regulations require that we obtain specific approval,
clearance, or certifications from FDA or applicable non-U.S. regulatory authorities or notified bodies before we can
market and sell most of our products in a particular country. Failure to obtain or maintain those approvals,
clearances or certifications have had, and could in the future have, an adverse impact on our business, including
with respect to our ability to compete in the product markets in which we currently operate. Specific new products
must undergo lengthy and rigorous testing and other extensive, costly, and time-consuming procedures mandated
by FDA and foreign regulatory authorities. The same testing and procedures sometimes apply to our products that
require authorization or renewal or are subject to changes in laws or regulations. For example, our medical devices
that are sold or distributed in the EU have to comply with the EU Medical Device Regulation that entered into force
in May 2021. This Medical Device Regulation currently provides a staggered phase-in period for manufacturers to
comply with related regulations through December 2028. These regulations require companies that wish to
manufacture and distribute medical devices in EU member states to meet certain quality system and safety
requirements and ongoing product monitoring responsibilities and obtain a “CE” marking (i.e., a mandatory
conformity marking for certain products sold within the European Economic Area) for their products. Various
penalties exist for non-compliance with the laws implementing the European Medical Device Regulations which, if
incurred, could have a material adverse impact on portions of our business, results of operations, financial condition
and cash flows. Changes to current products may be subject to vigorous review, including FDA 510(k) and other
regulatory submissions, and marketing authorization or the time needed to secure approvals are not certain. We
may not be able to obtain such approvals on the timing or conditions we expect, or at all. Our facilities must be
registered, approved and/or licensed prior to production and remain subject to inspection from time to time
24
thereafter. Failure to comply with the requirements of FDA or other regulatory authorities, including requirements
related to good manufacturing practice and adverse event reporting, has resulted in, and could in the future result
in, warning letters, import restrictions, product recalls or seizures, monetary sanctions, reputational damage,
injunctions to halt the manufacture and distribution of products, civil or criminal sanctions, refusal of a government to
grant approvals or licenses, restrictions on operations or withdrawal of existing approvals and licenses. The failure
of our suppliers to comply with applicable regulations could also adversely affect segments of our business as
regulatory actions taken by FDA or other regulatory authorities against those manufacturers, or actions we are
required to take to comply with regulatory requirements with respect to services and goods furnished by our
suppliers, can result in product shortages, recalls or modifications. Any of these actions could cause a loss of
customer confidence in us and our products, which could adversely affect our sales. Further, legislation in the
European Union is being enacted to require companies to conduct risk assessments on the sustainability practices
and procedures of their suppliers and mitigate certain sustainability risks, including the EU Deforestation Regulation
and EU Corporate Sustainability Due Diligence Directive. If our suppliers, including those outside of the European
Union, are unable or unwilling to comply with the sustainability standards under the legislation, or if we fail to comply
with the risk assessment requirements, we may experience an adverse impact on our ability to manufacture or
supply certain products as well as increased costs and interruptions in the supply chain. We could be subject to
litigation, substantial fines and other damages if we fail to comply with the risk assessment requirements, which
could adversely impact our financial condition and results of operations.
Our business is also subject to risks associated with U.S. and foreign legislation, regulations and trade agreements
(including those resulting from the transition to new political administrations) relating to the materials we import,
including quotas, duties, tariffs or taxes, and other charges or restrictions on imports and the nature of materials that
can be used in our products, which could adversely affect our operations and our ability to import materials used in
our products at current or increased levels. For example, the United States has recently enacted and proposed to
enact significant new tariffs, including a 25% tariff on imports from Mexico and Canada into the United States. While
these tariffs are currently suspended while negotiations take place for a long-term agreement, there continues to
exist significant uncertainty about the future relationship between the U.S. and other countries (including China) with
respect to trade policies, treaties and tariffs. These developments, or the perception that they could occur, may have
a material adverse effect on global economic conditions and the stability of global financial markets, and may
significantly reduce global trade and, in particular, trade between the impacted countries. Additionally, as we
currently have manufacturing operations in Mexico in support of our Healthcare Systems & Technologies and
Medical Products & Therapies businesses, a 25% tariff on all imports from Mexico would increase the cost of our
products manufactured in Mexico and adversely impact our business, results of operations, financial condition and
cash flows.
We cannot predict whether additional U.S. and foreign customs quotas, duties (including antidumping or
countervailing duties), tariffs and any retaliatory counter measures, taxes or other charges or restrictions,
requirements as to where raw materials and component parts must be purchased, additional workplace regulations
or other restrictions on our imports will be imposed in the future or adversely modified, or what effect such actions
would have on our costs of operations. Recently imposed or future quotas, duties or tariffs and any retaliatory
counter measures may have a material adverse effect on the cost of our products and the related components and
raw materials and our ability to sell products and services outside the United States. Future trade agreements or
modifications to existing trade agreements could also provide our competitors with an advantage over us, which
could have a material adverse effect on our business, results of operations, financial condition and cash flows. The
ultimate impact of any tariffs and any retaliatory counter measures will depend on various factors, including if any
tariffs are ultimately implemented, the timing of implementation, and the amount, scope and nature of the tariffs. See
also “Risks Relating to Our Operations—We are subject to risks associated with doing business globally.”
The sales, marketing and pricing of products and relationships that medical device and pharmaceutical companies
have with healthcare providers are under increased scrutiny by federal, state and foreign government agencies.
Compliance with the Anti-Kickback Statute, False Claims Act, Food, Drug and Cosmetic Act (including as these laws
relate to off-label promotion of products) and other healthcare-related laws, as well as competition and export and
import laws, is under increased focus by the agencies charged with overseeing such activities. The Department of
Justice and the SEC are focused on the enforcement of the U.S. Foreign Corrupt Practices Act ( FCPA), particularly
as it relates to the conduct of medical product and pharmaceutical companies. The FCPA and similar anti-bribery
laws generally prohibit companies and their employees, contractors or agents from making improper payments to
government officials for the purpose of obtaining or retaining business. Healthcare professionals in many countries
are employed by the government and consequently may be considered government officials. Foreign governments
are also focused on examining medical product and pharmaceutical companies’ sales and marketing activities and
relationships with healthcare providers and competitive practices generally. The laws and standards governing the
25
promotion, pricing, sale and reimbursement of our products and those governing our relationships with healthcare
providers and governments, including the Physician Payments Sunshine Act, are complicated, subject to frequent
change and may be violated unknowingly. Compliance with these and similar laws (or failure to comply with these
laws) could have a material adverse effect on our business, results of operations, financial condition and cash flows.
Additionally, failure to comply with applicable laws or our internal policies has resulted in, and may in the future
result in, the departure or termination of key personnel, which has the potential of disrupting our operations or future
performance. Furthermore, governments have chosen (as in the case of the Chinese government) or may choose to
prioritize anti-corruption efforts in the healthcare sector as part of their law enforcement activities.
We are also subject to environmental laws, which are becoming more stringent throughout the world. For example,
the Environmental Protection Agency regulates the use of ethylene oxide for sterilization of medical devices and is
increasingly focused on reducing emissions from the ethylene oxide sterilization process, which has increased our
costs of operations and necessitated changes to our manufacturing plants and processes. Additionally, the
European Economic Area (EEA) has banned the use of Bis(2-ethylhexyl) phthalate (DEHP) in the immediate
packaging of medicinal products, unless an authorization is granted. There is no guarantee that we will be able to
obtain and maintain such authorization. The EEA is also phasing out the use of DEHP in medical devices by 2030
and is considering imposing restrictions on the use of per- and polyfluoroalkyl substances, and polyvinyl chloride
and its additives. Further, the EEA has prohibited the use of desflurane as an inhalation anesthetic by 2026, except
in instances where alternatives cannot be used for medical grounds, and this legislation also requires fluorinated
gases to be captured. Other governments globally have limited or prohibited, or are considering limiting or
prohibiting, the use of certain chemicals, including polyvinyl chloride, diethyl phthalate and DEHP. These regulatory
changes could materially adversely impact our ability to manufacture or supply certain products. Moreover,
increased regulatory scrutiny around potential impurities, such as nitrosamines, in our products could lead to
regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to
product shortages, import bans or denials of import certifications, delays or denials in new product approvals or line
extensions or supplemental approvals of current products pending resolution of the issues, and reputational harm,
any of which could adversely affect our business. Other environmental laws may have similar consequences for us
or our suppliers, or result in liability to us.
Additionally, the U.S. Department of the Treasury’s Office of Foreign Assets Control and the Bureau of Industry and
Security at the U.S. Department of Commerce administer laws and regulations that restrict U.S. persons and, in
some instances, non- U.S. persons, in conducting activities, transacting business or making investments in certain
countries or regions, or with governments, entities and individuals subject to U.S. economic sanctions. From time to
time, certain of our subsidiaries have limited business dealings with and/or provide humanitarian donations to
jurisdictions subject to sanctions and/or embargoes. These dealings represent an insignificant amount of our
combined net sales and income but expose us to an increased risk of operating in these jurisdictions, including
foreign exchange risks or restrictions or limitations on our ability to access funds generated in these jurisdictions or
the risk of violating applicable sanctions or regulations, which are complex and subject to frequent change.
Our ethics and compliance programs, training, monitoring and policies may not always protect us from conduct by
individual employees that violate these laws. Violations or allegations of violations of these laws may result in large
civil and criminal penalties, debarment or exclusion from participating in government programs, diversion of
management time, attention and resources and may otherwise have an adverse effect on our business, results of
operations, financial condition and cash flows.
The laws and regulations discussed above are broad in scope and subject to evolving interpretations and changes,
which may be violated unknowingly, could require us to incur substantial costs regarding compliance or to alter our
sales and marketing practices and may subject us to enforcement actions or litigation, and of which could adversely
affect our business, results of operations, financial condition and cash flows. We cannot predict with certainty what
laws, regulations and healthcare initiatives, if any, will be implemented, or what the ultimate effect of healthcare
reform or any future legislation or regulation will have on us. For more information related to ongoing government
investigations, see Note 8 in Item 8 of this Annual Report on Form 10-K. For more information on regulatory matters
currently affecting us, including quality-related matters, see “Certain Regulatory Matters” in Item 7. Management’s
Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K.
Increasing regulatory focus on privacy, artificial intelligence and cybersecurity issues and expanding laws
could impact our business and expose us to increased liability.
As a global company, we are subject to global data privacy, AI and cybersecurity laws, regulations and codes of
conduct that apply to our businesses. We are required to comply with increasingly complex and changing legal and
regulatory requirements and frameworks in the United States and in other countries that govern not only the
26
collection, use, storage, security, transfer, disclosure and other processing of protected health information and
personal and sensitive data, but also the development and use of AI, the sharing of certain data and timely
disclosure of cybersecurity incidents. Further, new and emerging digital and technology laws are gradually being
implemented globally and have a strong interplay with data, privacy, AI and cybersecurity rules, which contributes to
the complexity of the regulatory landscape. In the United States, we are subject to the Health Insurance Portability
and Accountability Act, as amended (HIPAA), the Health Information Technology for Economic and Clinical Health
Act and the California Consumer Privacy Act (the CCPA) and California Privacy Rights Act as well as other new and
emerging state laws. HIPAA imposes stringent data privacy and security requirements, and the regulatory authority
has imposed significant fines and penalties on organizations found to be out of compliance. The CCPA provides
consumers with a private right of action against companies that have a security breach due to a lack of appropriate
security measures. In addition, to the U.S. Department of Health and Human Services and the Federal Trade
Commission’s enforcement activity has become more intense, with higher fines, in areas related to heath data that
are out of scope of HIPAA. Further, we are, or will be, subject to the EU’s General Data Protection Regulation (the
GDPR) the EU Data Act, the Artificial Intelligence Act, and the NIS2 Directive, an EU wide cybersecurity legislation,
which became fully in force in 2024. The GDPR imposes stringent EU data protection requirements and provides for
significant penalties for noncompliance, including heightened fines as compared to prior years. The EU Data Act
sets regulatory requirements for data access, sharing, and usage while the AI Act will impose significant obligations
on the development and use of AI systems, both of which will impact how we develop medical devices for the EU
market. Governmental bodies are increasingly imposing AI related regulation as well as cyber incident disclosure
regulations with differing criteria for what incidents must be reported as well as the timelines in which to report them.
We or our third-party providers and business partners may also be subjected to audits or investigations by one or
more domestic or foreign government agencies relating to compliance with information security and privacy laws
and regulations, and noncompliance with such laws and regulations could result in substantial and material fines or
class action litigation.
If reimbursement or other payment for our current or future products is reduced or modified in the United
States or in foreign countries, including through the implementation or repeal of government-sponsored
healthcare reform or other similar actions, cost containment measures, or there are changes to policies
with respect to pricing, taxation or rebates, our business could suffer.
Sales of our products depend, in part, on the extent to which the costs of our products are paid by both public and
private payers. These payers include Medicare, Medicaid, private healthcare insurers in the United States and
foreign governments and third-party payers outside the United States. Our work with government payers carries
various risks inherent in working with government entities and agencies, including government reporting and
auditing, additional regulatory oversight, mandated contractual terms, failure of government appropriations and
other complex procedural requirements.
Public and private payers have challenged, and are expected to continue to challenge, prices charged for medical
products and services. Such downward pricing pressures from any or all of these payers may result in an adverse
effect on our business, results of operations, financial condition and cash flows.
Global efforts toward healthcare cost containment continue to exert pressure on product pricing. Governments
around the world continue to use various mechanisms to control healthcare expenditures, such as price controls,
the formation of public contracting authorities, product formularies, which are lists of recommended or approved
products, and competitive tenders, which require the submission of a bid to sell products. Sales of our products are
dependent, in part, on the availability of reimbursement by government agencies and healthcare programs, as well
as insurance companies and other private payers. In much of Europe, Latin America, Asia and Australia,
governments provide healthcare at low cost to patients and control their expenditures by various means, such as
purchasing products through public tenders, collective purchasing, regulating prices, setting reference prices in
public tenders and limiting reimbursement or patient access to certain products. For example, China has been
implementing volume-based procurement policies, a series of centralized reforms being instituted in China on both
a national and regional basis that has resulted in significant price cuts for pharmaceuticals and medical
consumables. Additionally, austerity measures or other reforms by foreign governments may limit, reduce or
eliminate payments for our products and adversely affect both pricing flexibility and demand for our products. In
addition, operations within our Healthcare Systems & Technologies segment increase our exposure to risks related
to reimbursement as certain portions of that business directly bill various government agencies.
The Healthcare Reform Act includes several provisions which impact our businesses in the United States, including
increased Medicaid rebates and an expansion of the 340B Drug Pricing Program, which provides certain qualified
entities with discounts on the purchase of drugs for outpatient use and an excise tax on the sale of certain drugs.
27
The Healthcare Reform Act reduces Medicare and Medicaid payments to hospitals and other providers, which may
cause us to experience downward pricing pressure. Certain portions of the Healthcare Reform Act could negatively
impact the demand for our products, and therefore our results of operations, financial position and cash flows.
In addition, a substantial portion of our revenues is dependent on federal healthcare program reimbursement, and
any disruptions in federal government operations, including a federal government shutdown or failure of the U.S.
government to enact annual appropriations, could have a material adverse effect on our business, results of
operations, financial condition and cash flows. Additionally, disruptions in federal government operations may
negatively impact regulatory approvals and guidance that are important to our operations and create uncertainty
about the pace of upcoming healthcare regulatory developments or approvals.
As a result of these and other measures, including future measures or reforms that cannot be predicted,
reimbursement may not be available or sufficient to allow us to sell our products on a competitive basis. Legislation
and regulations affecting reimbursement for our products may change at any time and in ways that may be adverse
to us. We cannot predict the impact of these pressures and initiatives, or any negative effects of any additional
regulations that may affect our business.
We could be subject to fines or damages and possible exclusion from participation in federal or state
healthcare programs if we fail to comply with the laws and regulations applicable to our business.
Portions of our business are subject to stringent laws and regulations at the federal or state levels governing the
participation of durable medical equipment suppliers and independent diagnostic testing facilities in federal and
state healthcare programs. From time to time, the U.S. government seeks additional information related to our
claims submissions, and in some instances government contractors perform audits of payments made to us under
Medicare, Medicaid, and other federal healthcare programs. On occasion, these reviews identify overpayments for
which we submit refunds. At other times, our own internal audits identify the need to refund payments. We believe
the frequency and intensity of government audits and review processes has grown, and we expect this will continue,
due to increased resources allocated to these activities at both the federal and state Medicaid level, and greater
sophistication in data review techniques.
In addition, our business contracts with foreign and U.S. federal, state and local government entities are subject to
specific rules, regulations and approvals applicable to government contractors. Our failure to comply with these
could result in contract terminations, suspension or debarment from contracting with these entities, civil fines and
damages, criminal prosecution and possible exclusion from participation in federal healthcare programs, such as
Medicare and Medicaid, as well as possible recoupment of any overpayments related to such violations. While we
believe that our practices materially comply with applicable state, federal and foreign requirements, the
requirements might be interpreted in a manner inconsistent with our interpretation. Failure to comply with applicable
laws and regulations, even if inadvertent, could have a material adverse impact on our business, results of
operations, financial condition and cash flows.
If we are unable to protect or enforce our patents or other proprietary rights, or if we become subject to
claims or litigation alleging infringement of the patents or other proprietary rights of others, our
competitiveness and business prospects may be materially damaged.
Patent and other proprietary rights are essential to our business. Our success depends to a significant degree on
our ability to obtain and enforce patents and licenses to patent rights, both in the United States and in other
countries. Our pending patent applications, and any future patent applications, may not result in issued patents, our
patents issued or licensed may be challenged or circumvented by competitors, our patents may be found to be
invalid or the intellectual property rights of others may prevent us from selling certain products or including key
features in our products.
The patent position of a healthcare company is often uncertain and involves complex legal and factual questions.
Significant litigation concerning patents and products is pervasive in our industry. Patent claims include challenges
to the coverage and validity of our patents on products or processes as well as allegations that our products infringe
patents held by competitors or other third parties. An unfavorable litigation outcome in any of these types of cases
could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of
sales, or otherwise materially affect our business, results of operations, financial condition and cash flows. We also
rely on trademarks, copyrights, trade secrets and know-how to develop, maintain and strengthen our competitive
positions. Third parties may know, discover or independently develop equivalent proprietary information or
techniques, or they may gain access to our trade secrets or publicly disclose our trade secrets.
Our employees, consultants, parties to collaboration agreements and other business partners are generally subject
to confidentiality or similar agreements to protect our confidential and proprietary information. These agreements
28
may be breached, and we may not have adequate remedies for any breach. To the extent that our employees,
consultants, parties to collaboration agreements and other business partners use intellectual property owned by
others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
Furthermore, our intellectual property, proprietary technology and sensitive company data is potentially vulnerable to
loss, damage and misappropriation from system malfunction, computer viruses and unauthorized access to our data
or misappropriation or misuse thereof by those with permitted access and other events, including events connected
with the use of AI and ML technologies. While we have invested to protect our intellectual property, confidential
information and other data, and continue to work diligently in this area, there can be no assurance that our
precautionary measures have prevented or will prevent future breakdowns, breaches, cyber incidents or other
events. See “Risks Relating to Our Operations—Breaches and breakdowns affecting our information technology
systems or protected information, including from cyber security breaches and data leakage, could have a material
adverse effect on our business, results of operations, financial condition, cash flows, reputation and competitive
position” and “Incorporating artificial intelligence, machine learning and other emerging technologies into our
products, services and operations may result in legal and regulatory risks, reputational harm or have other adverse
consequences to our business, financial condition or results of operations.” Any of the events referenced above
could have a material adverse effect on our reputation, business, results of operations, financial condition and cash
flows.
Changes in tax laws or exposure to additional income tax liabilities may have a negative impact on our
operating results.
Changes to the tax laws in the United States or other countries in which we operate could have an adverse effect on
our operating results. For example, the Organization of Economic Co-operation and Development (OECD) and the
G20 Inclusive Framework on Base Erosion and Profit Shifting (the Inclusive Framework) has put forth two proposals
—Pillar One and Pillar Two—that revise the existing profit allocation and nexus rules and ensure a minimal level of
taxation, respectively. On December 12, 2022, the EU member states agreed to implement the Inclusive
Framework’s global corporate minimum tax rate of 15%, and various countries both within and outside the EU have
enacted new laws implementing Pillar Two or have draft legislation proposed for adoption. The OECD continues to
release additional guidance on the two-pillar framework. We are continuing to evaluate the potential impact of the
Inclusive Framework on future periods, which could have an adverse impact on our effective tax rate, income tax
expense and cash flows.
Taxing authorities audit us from time to time and may disagree with certain positions we have taken in respect of our
tax liabilities. Our tax liabilities are affected by many factors, including the amounts we charge in intra-company
transactions for inventory, services, licenses, funding and other items, which are subject to the use of assumptions
and judgment. Because we operate in multiple income tax jurisdictions both inside and outside the United States,
cross border transactions among our affiliates are a significant part of the manner in which we operate. Tax
authorities may disagree with our intra-company charges, cross-jurisdictional transfer pricing or other matters, and
may assess additional taxes as a result.
We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax
provision. However, we may not accurately predict the outcome of these audits and, as a result, the actual outcome
of these audits may have an adverse impact on our financial results. For more information on ongoing audits, see
Note 14 in Item 8 of this Annual Report.
We are party to a number of pending lawsuits and other disputes which may have an adverse impact on our
business, results of operations, financial condition and cash flows.
We are party to a number of pending lawsuits, settlement discussions, mediations, arbitrations and other disputes,
some of which are set forth in Note 8 in Item 8 of this Annual Report on Form 10-K. In addition, in the future we may
be party to additional lawsuits, disputes or other matters, including patent, product liability, commercial,
employment, and other legal matters that arise in the normal course of our business. These current and future
matters may result in a loss of patent protection, reduced net sales, incurrence of significant liabilities and diversion
of our management’s time, attention and resources. Given the uncertain nature of litigation and other disputes
generally, we are not able in all cases to estimate the amount or range of loss that could result from an unfavorable
outcome in our current matters. In view of these uncertainties, the outcome of these current matters may result in
charges in excess of any established reserves, and, to the extent available, liability insurance. We also continue to
be self-insured with respect to product liability claims. The unavailability or inadequacy of third-party insurance
coverage for current or future liability claims could increase our potential exposure to unanticipated claims and
adverse decisions. Protracted litigation and other disputes, including any adverse outcomes, may have an adverse
29
impact on our business, results of operations, financial condition and cash flows. Even claims without merit could
subject us to adverse publicity and require us to incur significant legal fees.
Our Amended and Restated Bylaws could limit our stockholders’ ability to choose their preferred judicial
forum for disputes with us or our directors, officers, or employees.
Our Amended and Restated Bylaws (Bylaws) provide that, unless we consent in writing to the selection of an
alternative forum, the Court of Chancery in the State of Delaware (or, if no state court located in the State of
Delaware has jurisdiction, the federal district court for the District of Delaware) is the sole and exclusive forum, to
the fullest extent permitted by law, to bring (i) any derivative action or proceeding brought on our behalf, (ii) any
action asserting a claim for or based on a breach of a fiduciary duty owed by any current or former director or officer
or other employee of the company to the company or our stockholders, (iii) any action asserting a claim arising
pursuant to any provision of the Delaware General Corporation Law or our Certificate of Incorporation or these
Bylaws, as either may be amended from time to time, or (iv) any action to interpret, apply, enforce or determine the
validity of the Certificate of Incorporation or Bylaws or (v) any other action asserting a claim governed by the internal
affairs doctrine or that is otherwise an “internal corporate claim” as defined in Section 115 of the Delaware General
Corporation Law. Additionally, our Bylaws provide that unless we consent in writing to the selection of an alternative
forum, the federal district courts of the United States shall be the sole and exclusive forum for the resolution of any
complaint asserting a cause of action arising under the Securities Act of 1933, as amended.
Any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to
have received notice of and consented to the foregoing provisions of our Bylaws described above. The choice of
forum provision may result in increased costs for investors to bring a claim. Further, the choice of forum provision
may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our
directors, officers, other employees, or stockholders, which may discourage such lawsuits against us and our
directors, officers, other employees, or stockholders. Alternatively, if a court were to find the exclusive choice of
forum provision contained in our Bylaws to be inapplicable or unenforceable in an action, we may incur additional
costs associated with resolving such action in other jurisdictions.
Item 1B.
Unresolved Staff Comments.
None.
Item 1C.
Cybersecurity.
We assess, identify and manage risks from cybersecurity threats through our Global Cybersecurity and Compliance
Program (Cybersecurity Program). Cybersecurity risks identified in the Cybersecurity Program are integrated into
our Enterprise Risk Management Program. In addition, the Cybersecurity Program seeks to incorporate
consideration of cybersecurity risk into our product development, business strategy, financial planning and capital
allocation decisions.
The Cybersecurity Program is currently overseen by the Board of Directors (Board) and is managed by a dedicated
Chief Information Security Officer (CISO), who in turn reports to the Chief Information Officer (CIO), who currently
reports to the CEO. The CISO's organization has oversight responsibilities for cybersecurity strategy, policy,
standards, architecture and processes for the security of our corporate and manufacturing enterprise network,
information assets and medical device technologies. Our current CISO has over 20 years of experience in
cybersecurity and risk and technology management, and has held numerous positions in the cybersecurity sector,
including serving as Global Cyber Risk Officer at another Fortune 500 medical products and equipment company
and CISO at other healthcare companies and health care delivery organizations. Our current CIO has over 30 years
of experience in information technology and has served in a number of professional services leadership roles,
including as CIO over the past 15 years at three companies. The CISO’s organization monitors and manages, and
works to identify and assess, cybersecurity risk through various technologies, resources, processes and policies
that are updated as necessary to align with the changing threat landscape, our evolving business needs as well as
global regulatory requirements. In addition, from time to time, we also utilize external auditors and assessors to help
evaluate our Cybersecurity Program, including conducting penetration testing and vulnerability, risk and maturity
assessments. We also actively engage with industry experts, regulatory agencies, advocacy groups, industry peers,
intelligence and law enforcement communities as part of our continuing efforts to evaluate and enhance the
effectiveness of our Cybersecurity Program and to stay abreast of the emerging cybersecurity landscape.
We use a range of defenses to help protect against cybersecurity threats and to work to secure our assets, reduce
the time it takes to detect a cybersecurity threat and improve our recoverability capabilities. These defenses include
30
the ongoing monitoring of our systems (including with the assistance of third-party vendors), conducting response
and recovery exercises with employees and senior management (including our executive officers) to promote
awareness of related matters and improve internal processes, and engaging with external cybersecurity rating
agencies that assess our cyber risk. In addition, to help promote privacy and security awareness throughout the
company, the CISO maintains a Cyber Awareness and Engagement Program. As part of this program, all
employees with a Baxter email address receive annual training on the recognition and prevention of cybersecurity
threats as well as training on how to report suspicious activity or potential breaches through the appropriate
channels. Our Cyber Awareness team communicates cybersecurity best practices to our employees through
internal communications, including the company intranet, newsletters and global virtual seminars, and also hosts
ongoing cybersecurity awareness campaigns, including phishing simulations. Further, our Third-Party Risk
Management Program utilizes a managed service that uses a standard framework to help identify, assess and
monitor potential cybersecurity risks posed by third parties. Third-party cybersecurity risks (including reputational
ones) are assessed by evaluating the third party's security practices (including those associated with data
protection), compliance with applicable regulations and planning associated with business continuity and incident
detection and response.
The Cybersecurity Program maintains a cybersecurity governance and oversight framework that seeks to drive
accountability for all levels of employees, including senior management and executive officers. Cybersecurity
matters are generally managed by a combination of working groups that report to the cybersecurity compliance
committee and ultimately the cybersecurity executive oversight committee, as appropriate. Our cross functional
cybersecurity compliance committee, which is led by the CISO, is composed of members of senior management,
including the CIO, and reviews matters such as cybersecurity escalations, critical remediations and disclosure
recommendations. The output from the cybersecurity compliance committee meetings is discussed at meetings of
Baxter’s cybersecurity executive oversight committee, which is led by the CISO and includes the CIO and other
members of management.
In February 2024, we amended the charters of the Audit Committee and Quality and Regulatory Compliance (QRC)
Committee of our Board to provide for the realignment of oversight over the company’s innovation strategy and
cybersecurity to the full Board, as these responsibilities now sit within the vertically integrated segments and are
part of the business strategies themselves. The Board oversees information technology functions generally,
including product related cybersecurity matters (which had previously been subject to the oversight of the QRC
Committee). The Audit Committee is responsible for the oversight of certain significant cybersecurity incidents,
including ones related to our products and services and receives related updates from management on those
incidents. Consistent with this oversight responsibility, the Audit Committee is responsible for reviewing proposed
disclosures in connection with any material cybersecurity incident consistent with our disclosure obligations under
Item 1.05 of Form 8-K. The full Board receives periodic updates on information technology and cybersecurity
matters from company management (including the CIO and CISO) and external advisors from time to time and the
Audit Committee receives periodic updates (including as part of continuing director education) on the evolving
cybersecurity landscape and regulatory reporting requirements.
The CISO maintains and annually updates a Cybersecurity Incident Response Plan which is a guide for our Cyber
Security Incident Response Team and business to respond to cybersecurity incidents in a coordinated manner.
Additionally, the CISO, in partnership with a third-party consultant, facilitates periodic cyber-crisis tabletop exercises
with members of senior management (including our executive officers) to help us prepare for the occurrence of a
significant cybersecurity event and our related response activities. Cybersecurity risks and threats, including any
previous cybersecurity incidents, have not materially impacted us or our operations to date. However, we cannot
provide any assurance that we will not be subject to a material cybersecurity incident in the future. See "Risks
Relating to Our Operations—Breaches and breakdowns affecting our information technology systems or protected
information, including from cyber security breaches and data leakage, could have a material adverse effect on our
business, results of operations, financial condition, cash flows, reputation and competitive position” in Item 1A. Risk
Factors of this Annual Report on Form 10-K for a discussion of cybersecurity-related risks.
31
Item 2.
Properties.
Our corporate offices are owned and located at One Baxter Parkway, Deerfield, Illinois 60015.
We manage our global operations based on three reportable segments: Medical Products & Therapies, Healthcare
Systems & Technologies, and Pharmaceuticals. We own or have long-term leases on all of our manufacturing
facilities and the location of the principal manufacturing facilities of each of our segments are listed below:
Segments
Location
Owned/Leased
Medical Products & Therapies
Aibonito, Puerto Rico
Leased
Alliston, Canada
Owned
Cali, Colombia
Owned
Cartago, Costa Rica
Owned
Haina, Dominican Republic
Leased
Hayward, California
Leased
Cleveland, Mississippi
Leased
Medina, New York
Leased
Jayuya, Puerto Rico
Leased
Sao Paulo, Brazil
Owned
North Cove, North Carolina
Owned
St. Paul, Minnesota
Leased
Irvine, California
Owned
Toongabbie, Australia
Owned
Lessines, Belgium
Owned
Marsa, Malta
Leased
Sabinanigo, Spain
Owned
San Vittore, Switzerland
Leased
Thetford, United Kingdom
Owned
Tel Aviv, Israel
Leased
Elstree, United Kingdom
Leased
Shanghai, China
Owned
Mountain Home, Arkansas
Owned/Leased (1)
Healthcare Systems & Technologies
Batesville, Indiana
Owned
Charleston, South Carolina
Leased
Milwaukee, Wisconsin
Owned
St. Paul, Minnesota
Leased
Skaneateles Falls, New York
Owned
Suzhou, China
Leased
Taicang, China
Leased
Pluvigner, France
Owned
Saalfeld, Germany
Owned
Tijuana, Mexico
Leased
Monterrey, Mexico
Owned
Luleå, Sweden
Owned
Pharmaceuticals
Guayama, Puerto Rico
Owned
Round Lake, Illinois
Owned
Ahmedabad, India
Owned
(1) Includes both owned and leased facilities
We also own or operate shared distribution facilities throughout the world. In the United States and Puerto Rico,
there are five shared distribution facilities with the principal facilities located in Memphis, Tennessee; Cataño, Puerto
32
Rico; and North Cove, North Carolina. Internationally, we have more than 75 shared distribution facilities located in
Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Czech Republic, Ecuador,
France, Germany, Greece, Hong Kong, India, Ireland, Israel, Italy, Japan, Korea, Mexico, New Zealand, Panama,
Poland, Portugal, Russia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, the United Arab
Emirates, and the United Kingdom.
We regularly evaluate our plants and production lines and believe that our current facilities plus any planned
expansions are generally sufficient to meet our expected needs and expected near-term growth. Expansion projects
and facility closings will be undertaken as necessary in response to market needs.
Item 3.
Legal Proceedings.
Incorporated by reference to Note 8 in Item 8 of this Annual Report on Form 10-K.
Item 4.
Mine Safety Disclosures.
Not Applicable.
Information about our Executive Officers
As of February 21, 2025, the following serve as Baxter’s executive officers:
Brent Shafer, age 67, is Chair and Interim Chief Executive Officer. He was appointed to his role on February 3,
2025, in connection with Mr. José Almeida's separation from Baxter. He is the former Chair and Chief Executive
Officer of Cerner Corporation (Cerner), a leading provider of various health information technologies, ranging from
medical devices to electronic health records to hardware, serving in this role from 2018 to 2021. Prior to Cerner, Mr.
Shafer held a number of roles at Philips, including Chief Executive Officer of Philips North America, a leader in
diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health
and home care. Mr. Shafer was also the Chief Executive Officer of Philips Home Healthcare Solution business.
Before joining Philips, Mr. Shafer was Vice President and General Manager of Hillrom’s Patient Care Environment
Division and worked at GE Medical Systems where he served in key positions in sales, marketing, and general
management. Mr. Shafer has also held senior roles at Hewlett Packard’s Medical Products Group and Johnson &
Johnson. Mr. Shafer currently serves as a director of Tactile Systems Technology, Inc. and Veracyte, Inc.
James Borzi, age 62, is Executive Vice President and Chief Supply Chain Officer. He joined Baxter in August 2020
from GE Healthcare, where he served as Vice President, Chief Supply Chain Officer from 2019 to 2020. Prior to
joining GE Healthcare, he served in various manufacturing operations leadership roles at Becton Dickinson,
including Executive Vice President of Global Operations and Chief Supply Chain Officer from 2013 to 2019. Earlier
in his career, he was Senior Vice President of Operations & Technology at Hydro Aluminum and Executive Vice
President of Worldwide Operations at Lennox International. Prior to that, he was the Chief Operating Officer at
AEES Inc. and Senior Vice President of Americas Operations at Alcoa Corporation. Mr. Borzi is a senior advisor to
the NAI Group, a Pritzker Private Capital company.
Joel T. Grade, age 54, is Executive Vice President, Chief Financial Officer and Interim Chief Accounting Officer. Mr.
Grade joined Baxter in 2023 as Executive Vice President, Chief Financial Officer. Additionally, he was elected as our
interim Chief Accounting Officer and Principal Accounting Officer (CAO) in September 2024 and will cease serving
in that interim capacity as of February 21, 2025. Mr. Grade joined Baxter following a 25-year career with Sysco
Corporation (Sysco), the world’s global foodservice leader. He most recently served as Sysco’s Executive Vice
President, Corporate Development from 2020 to 2023. His previous roles at Sysco included Executive Vice
President and Chief Financial Officer from 2015 to 2020, Senior Vice President of Finance and Chief Accounting
Officer, and Senior Vice President of foodservice operations. He currently serves as a member of Northwestern
University-Kellogg School of Business Financial Network Advisory Board and the Dean’s External Advisory Board of
the University of Wisconsin School of Business.
Heather Knight, age 53, is Executive Vice President, Chief Operating Officer and Interim Group President, Medical
Products & Therapies. She was appointed to her role on February 3, 2025. Ms. Knight has led our Medical Products
& Therapies segment since 2023. From 2021 through 2023, she served as president of our former Americas region
and our Acute Therapies, Clinical Nutrition, and Medication Delivery business units. She joined Baxter in 2019 as
general manager, U.S. Hospital Products. Throughout her 30-year career in the healthcare industry, Ms. Knight has
held numerous roles of increasing leadership in general management, global upstream and commercial capacities
at companies including Medtronic plc (Medtronic), Covidien plc, Tyco International plc and Kendall Healthcare
33
Products Company. Prior to joining Baxter, she most recently served as vice president and general manager in
Medtronic's Surgical Innovations business. Ms. Knight earned her bachelor's degree in Biological Sciences from the
University of Buffalo and completed the Executive Sales and Management program from the University of Chicago
Booth School of Management. Ms. Knight currently serves as a director of Waters Corporation.
Jeanne K. Mason, Ph.D., age 69, is Executive Vice President and Chief Human Resources Officer having served in
that capacity since 2006. Ms. Mason joined Baxter in 2006 from GE Insurance Solutions, a primary insurance and
reinsurance business, where she was responsible for global human resource functions. Ms. Mason began her
career with General Electric (GE) in 1988 after serving with the U.S. General Accounting Office in Washington, D.C.
Her GE experience included leadership roles in Europe for GE Information Services and GE Capital Real Estate.
She is a member of the Board of Directors of Family Service of Lake County and is a member of the Executive
Advisory Council for the Chicago Chapter of National Association of African Americans in Human Resources.
Reazur Rasul, age 48, is Executive Vice President and Group President, Healthcare Systems & Technologies. He
was appointed to his current role in 2023 after serving as President of Front Line Care since 2022. Prior to that, Mr.
Rasul served as General Manager for the Acute Therapies & Medication Delivery businesses from 2021 to 2022,
and General Manager, for the Acute Therapies business from 2017 to 2021. Before joining Baxter in 2017, he
worked with Hewlett Packard Enterprise where he was Vice President and General Manager of the Global Cloud
infrastructure business. Previously, he worked with GE Healthcare where he held several roles of increasing
responsibility in business leadership and strategy, including General Manager of the Global Interventional
Cardiology business. Mr. Rasul began his professional career with Toyota Motor Corporation and ultimately held
multiple leadership positions in strategy, product development and operations.
David S. Rosenbloom, age 65, is Executive Vice President and General Counsel. Mr. Rosenbloom joined Baxter
from McDermott Will & Emery (McDermott), where he served as a partner for 24 years and Global Head of the
Litigation Practice Group from 2017 to 2022. Prior to McDermott, he served for eight years in the U.S. Attorney’s
Office for the Northern District of Illinois. Mr. Rosenbloom is a member of the Board of the Digestive Health
Foundation, which supports research at Northwestern Digestive Health Center, which is part of Northwestern
Medicine at Northwestern Memorial Hospital.
Alok Sonig, age 52, is Executive Vice President and Group President, Pharmaceuticals. He was appointed to his
role in 2023 after serving as President since 2022. Mr. Sonig joined Baxter in 2022 from Lupin, Inc. (Lupin), where
he served as U.S. CEO and Global Head of R&D and Biosimilars from 2018 to 2022. He brings more than 25 years
of experience in the life sciences industry. Prior to Lupin, Mr. Sonig served as CEO of Developed Markets (U.S.,
Canada, Europe, and Japan) at Dr. Reddy’s Laboratories. He also spent more than 15 years at Bristol Myers
Squibb, where he held several positions of increasing responsibility in general management, global strategy and
marketing. Mr. Sonig is currently a member of the Advisory Boards for the American University, Kogod School of
Business, and Sentry Sciences, Inc., and is a member of the Board of the Southern Asian Pharmaceutical Council.
All executive officers hold office until the next annual election of officers or until their respective successors are
elected and qualified.
34
PART II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer
Purchases of Equity Securities.
Issuer Purchases of Equity Securities
In July 2012, the Board of Directors authorized a share repurchase program and the related authorization was
subsequently increased a number of times. During the fourth quarter of 2024, we did not repurchase any shares
under this authority. The remaining authorization under this program totaled approximately $1.30 billion at
December 31, 2024. This program does not have an expiration date.
Market Information and Holders of our Common Stock
Our common stock is listed on the New York and Chicago stock exchanges. The New York Stock Exchange is the
principal market on which our common stock is traded under the symbol “BAX”. As of February 13, 2025, there were
18,094 holders of record of our common stock.
Performance Graph
The following graph compares the change in our cumulative total stockholder return (including reinvested dividends)
on our common stock with the Standard & Poor’s 500 Composite Index and the Standard & Poor’s 500 Health Care
Index over the past five years.
1 TSR calculations (as provided by FactSet) include reinvested dividends.
Item 6.
Reserved.
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of
Operations.
The following commentary should be read in conjunction with the consolidated financial statements and
accompanying notes included in Item 8 of this Annual Report on Form 10-K.
35
EXECUTIVE OVERVIEW
Description of the Company, Recent Strategic Actions and Business Segments
Baxter International Inc. is a global medical technology with approximately 38,000 employees worldwide who are
engaged in the development, manufacture and sale of a broad range of products, digital health solutions and
therapies used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices and
patients at home under physician supervision. Our global footprint and the critical nature of our products and
services, which are sold in over 100 countries as of December 31, 2024, after giving effect to the Kidney Care sale,
play a key role in expanding access to healthcare in emerging and developed countries.
In mid-2022, our Board of Directors authorized a strategic review of our business portfolio, with the goal of
increasing stockholder value. As part of that review process, we identified and evaluated a range of potential
strategic actions, including opportunities for sales and other separation transactions. In January 2023, following the
completion of that review, we announced a number of planned strategic actions, as discussed below, which are
intended to enhance our operational effectiveness, accelerate innovation and drive additional stockholder value. We
completed the last of these strategic actions on January 31, 2025 in connection with the sale of our Kidney Care
business.
Sale of Kidney Care Business
On August 12, 2024, we entered into an Equity Purchase Agreement (EPA ) with certain affiliates of Carlyle Group
Inc. (Carlyle) to sell our Kidney Care business, which will be known as Vantive. That business, which is comprised
of our Kidney Care segment, provides chronic and acute dialysis therapies and services, including peritoneal
dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies. On January 31,
2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion
in cash, subject to certain closing cash, working capital and debt adjustments. After giving effect to certain
adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the transaction with the
net after tax proceeds currently estimated to be approximately $3.4 billion, subject to certain post-closing
adjustments. As of February 21, 2025, we repaid $3.13 billion of short- and long-term indebtedness primarily with
the net after-tax cash proceeds from the sale of our Kidney Care business, and we expect to use substantially all of
the remaining net after-tax proceeds to continue to repay indebtedness through the second quarter of 2025.
We determined that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024, and
we also concluded that it met the conditions to be reported as a discontinued operation at that time. Accordingly, our
Kidney Care business is reported in discontinued operations in the accompanying consolidated financial systems,
and our prior period results have been adjusted to reflect discontinued operations presentation. The fair value and
carrying value of assets held for sale are evaluated each period and a loss on sale is recognized when the fair value
less costs to sell are below the carrying value. There has been no loss on sale recognized for the period ending
December 31, 2024. We will recognize a gain or loss upon disposition of the business depending on the carrying
value at that date, including any tax impacts of the sale, which may be material.
We expect to incur dis-synergies following our sale of our Kidney Care business due to the reduced size of our
company and, as a result, we have begun to undertake certain actions (and will need to undertake additional
actions) to ensure that our cost structure is appropriate to support our remaining businesses.
See Notes 2 and 6 in Item 8 of this Annual Report on Form 10-K for additional information.
Implementation of New Operating Model and Resulting Segment Change
In the third quarter of 2023, we completed the implementation of a new operating model intended to simplify and
streamline our operations and better align our manufacturing and supply chain to our commercial activities. Under
this operating model, our business is currently comprised of three reportable segments: Medical Products &
Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Our segments were changed during the third
quarter of 2023 to align with our new operating model.
The Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems,
administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products.
The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration
tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health
36
devices and advanced equipment for the surgical space, including surgical video technologies, precision positioning
devices and other accessories. The Pharmaceuticals segment includes sales of specialty injectable
pharmaceuticals, inhaled anesthetics and drug compounding services. Other sales not allocated to a segment
primarily include sales of products and services provided directly through certain of our manufacturing facilities and
royalty income under a business development arrangement that ended in early 2023 when we acquired the related
product rights.
For financial information about our segments, see Note 18 in Item 8 of this Annual Report on Form 10-K.
Sale of BPS Business
On September 29, 2023, we completed the sale of our BPS business and received cash proceeds of $3.96 billion
from that transaction. The results of operations and cash flows of our BPS business, including the $2.88 billion pre-
tax gain ($2.59 billion net of tax) from the sale of that business and the related cash proceeds received, are reported
as discontinued operations in the accompanying consolidated financial statements. We used substantially all of the
after-tax proceeds from this transaction to repay certain of our debt obligations, including $514 million of commercial
paper borrowings and $2.28 billion of long-term debt that we repaid during the fourth quarter of 2023, as well as
€750 million of senior notes that we repaid during the second quarter of 2024.
See Notes 2 and 6 in Item 8 of this Annual Report on Form 10-K for additional information.
Financial Results
Our global net sales totaled $10.64 billion in 2024, an increase of 3% over 2023 on a reported basis and 3% on a
constant currency basis. International sales totaled $4.79 billion in 2024, an increase of 5% compared to 2023 on a
reported basis and 6% on a constant currency basis. Sales in the United States totaled $5.85 billion in 2024, an
increase of 1% compared to 2023. Refer to the Net Sales discussion in the Results of Operations section below for
more information related to changes in net sales on a constant currency basis.
Net income (loss) attributable to Baxter stockholders totaled $(649) million, or $(1.27) per diluted share, in 2024.
Net income (loss) attributable to Baxter stockholders in 2024 included special items which adversely impacted net
income (loss) by $2.13 billion, or $4.17 per diluted share. See our special items subsection, in the Results of
Operations section below, for information about special items for all periods present.
Net income (loss) from continuing operations totaled $(326) million, or $(0.64) per diluted share, in 2024. Net
income (loss) from continuing operations in 2024 included special items which adversely impacted our results by
$1.29 billion, or $2.53 per diluted share.
Our financial results included research and development (R&D) expenses totaling $590 million in 2024, which
reflects our focus on balancing investments to support our new product pipeline with efforts to optimize overall R&D
spending (including with respect to the maintenance of our portfolio).
While have faced and may continue to face operational and global macroeconomic challenges, our financial position
remains strong, with operating cash flows from continuing operations totaling $819 million in 2024. We have
continued to execute on our disciplined capital allocation framework, as discussed in the "Business Strategy"
section in Item 1. Business of this Annual Report on Form 10-K, which is designed to optimize stockholder value
creation through reinvestment in our businesses, dividends and share repurchases, as well as acquisitions and
other business development initiatives and debt repayments, consistent with our previously stated commitment to
achieve our net leverage targets.
Capital expenditures totaled $446 million in 2024 as we continued to invest across our businesses to support future
growth, including additional investments in support of new and existing product capacity expansions. Our
investments in capital expenditures in 2024 were focused on projects that improve production efficiency, enhance
our quality systems and optimize manufacturing capabilities to support our business growth.
We also continued to return value to our stockholders. During 2024, we paid cash dividends to our stockholders
totaling $590 million.
37
FACTORS AFFECTING OUR RESULTS OF OPERATIONS
Hurricane Helene
In September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North
Carolina, caused damage to certain of our assets at our North Cove facility in Marion, N.C. and disrupted operations
at that facility. As we work to fully remediate the facility, we currently expect to incur an estimated $50 million of
charges in the first quarter of 2025 primarily consisting of remediation costs, air freight (as we transfer product
across our global network in the interest of increasing the availability of intravenous solutions for our customers) and
other charges. See Note 1 for further discussion of insurance recoveries related to Hurricane Helene.
Supply Constraints and Global Economic Conditions
In recent years, we have experienced significant challenges to our global supply chain, including production delays
and interruptions, increased costs and shortages of raw materials and component parts (including resins and
electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including
Hurricane Helene and the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions
to certain ports of call and access to shipping ports around the world, the war in Ukraine, the conflict in the Middle
East, and other geopolitical events. While we have seen improvements in the availability of component parts and
improved pricing in raw materials and on transportation costs, some of these challenges (including certain of those
set forth above as we work to fully remediate our North Cove facility) are expected to have a negative impact on our
results of operations in the future.
Our results of operations are also affected by macroeconomic conditions and levels of business confidence. The
war in Ukraine, the conflict in the Middle East, other geopolitical events, the sanctions and other measures being
imposed in response to these conflicts (and the potential for escalation of these conflicts), recently imposed or
future quotas, duties or tariffs and any retaliatory counter measures, and recent political changes to trade policies,
have increased the levels of economic and political uncertainty and we continue to closely monitor the developing
situations. While we have substantially completed our wind down efforts related to our business in Russia, a
significant escalation or expansion of economic disruption or the current scope of the war in Ukraine could have an
adverse effect on our operations (including our supply chain) in the region.
The existence of high inflation rates in the United States and in many of the countries where we conduct business
has resulted in, and may in the future result in, higher interest rates, shipping costs, labor costs, and other costs and
expenses. Additionally, adverse changes in foreign currency exchange rates have increased, and could continue to
increase, our costs of sourcing certain raw materials in some jurisdictions. We have experienced and may in the
future experience inflationary increases in manufacturing costs and operating expenses and we may not be able to
pass these cost increases on to our customers in a timely manner or at all, which could have a material adverse
impact on our profitability and results of operations. Inflation and general macroeconomic factors have caused
certain of our customers to reduce or delay orders for our products and services and could cause them to do so in
the future, which could have a material adverse impact on our sales and results of operations.
As a medical products company, our operations and many of the products manufactured or sold by us are subject to
extensive regulation by numerous government agencies, both within and outside the United States. These
regulations (as described in Item 1, Government Regulation, of this Annual Report on Form 10-K) require that we
obtain specific approval from FDA or applicable non-U.S. regulatory authorities before we can market and sell most
of our products in a particular country. Failure to obtain or maintain those approvals or clearances (including
temporary importation authorizations) could have a material adverse impact on our business (including with respect
to our ability to compete in the product markets in which we currently operate). Furthermore, FDA in the United
States, the EMA and MHRA in Europe, the NMPA in China, and other government agencies, inside and outside of
the United States, administer requirements covering the testing, safety, effectiveness, manufacturing, labeling,
promotion and advertising, pricing, distribution, and post-market surveillance of our products. Our failure to comply
with these requirements may subject us to various actions, including warning letters, product recalls or seizures,
monetary sanctions, injunctions to halt the manufacture and distribution of products, civil or criminal sanctions,
refusal of a government to grant approvals or licenses, restrictions on operations or withdrawal of existing approvals
and licenses, and may have a material adverse impact on our results of operations.
For further discussion, please refer to Item 1A. Risk Factors of this Annual Report on Form 10-K.
38
RECENT BUSINESS COMBINATIONS AND ASSET ACQUISITIONS
Zosyn
On March 22, 2022, we entered into an agreement with a subsidiary of Pfizer Inc. to acquire the rights to Zosyn, a
premixed frozen piperacillin-tazobactam product, in the U.S. and Canada. Zosyn is used for the treatment of intra-
abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections and
community-acquired pneumonia. Under the terms of the acquisition, we paid the acquisition price of $122 million
and received specified intellectual property, including patent rights, in the first quarter of 2022 and received
additional intellectual property, including the product rights to Zosyn, in the first quarter of 2023. Under the
arrangement, we received profit sharing payments from sales of Zosyn until the product rights transferred to us in
March 2023. Refer to Note 3 in Item 8 of this Annual Report on Form 10-K for additional information regarding our
acquisition of the rights to Zosyn.
Hillrom
In 2021, we acquired Hillrom. In 2024, 2023 and 2022 our Healthcare Systems & Technologies segment (formerly
referred to as our Hillrom segment) generated net sales of $2.95 billion, $3.01 billion, and $2.94 billion, respectively.
During 2024, we recorded a $425 million goodwill impairment related to our Front Line Care reporting unit within our
Healthcare Systems & Technologies segment. During 2022, we also recognized $2.81 billion of goodwill
impairments and $332 million of indefinite-lived intangible asset impairments related to goodwill and trade name
intangible assets that arose from the Hillrom acquisition. See Notes 3, 5 and 18 in Item 8 of this Annual Report on
Form 10-K for additional information about the Hillrom acquisition, goodwill and intangible asset impairments, and
our Healthcare Systems & Technologies segment results, respectively.
NON-GAAP FINANCIAL MEASURES
Our presentation of percentage changes in net sales at constant currency rates, which is computed using current
period local currency sales at the prior period’s foreign exchange rates, is a non-GAAP financial measure. This
measure provides information about growth (or declines) in our net sales as if foreign currency exchange rates had
not changed between the prior period and the current period. We believe that the non-GAAP measure of percent
change in net sales at constant currency rates, when used in conjunction with the U.S. GAAP measure of percent
change in net sales at actual currency rates, may provide a more complete understanding and facilitate a fuller
analysis of our results of operations, particularly in evaluating performance from one period to another.
RESULTS OF OPERATIONS
CONSOLIDATED NET SALES
Percent change
At actual
currency rates
At constant
currency rates 3
years ended December 31 (in
millions)
2024
2023
2022
2024
2023
2024
2023
United States
$
5,850 $
5,802 $
5,769
1 %
1 %
1 %
1 %
Emerging markets 1
1,350
1,343
1,253
1 %
7 %
3 %
8 %
Rest of world 2
3,436
3,215
3,035
7 %
6 %
7 %
6 %
Total net sales
$
10,636 $
10,360 $
10,057
3 %
3 %
3 %
3 %
1 Emerging markets include sales from our operations in Eastern Europe, the Middle East, Africa, Latin America and Asia (except for Japan).
2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia and New Zealand.
3 Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial
Measures” for additional information about our use of that measure.
39
As set forth above, foreign currency had no material impact on net sales during the year ended December 31, 2024,
as compared to the prior year period, primarily due to the strengthening of the U.S. Dollar relative to the Turkish
Lira, Japanese Yen, Brazilian Real, Mexican Peso, and the Canadian Dollar, offset by the weakening of the U.S.
Dollar relative to the British Pound and Colombian Peso. Foreign currency had no material impact on net sales
during the year ended December 31, 2023, as compared to the prior year period, primarily due to the strengthening
of the U.S. Dollar relative to the Euro, Turkish Lira, Australian Dollar, Japanese Yen and Chinese Renminbi offset by
the weakening of the U.S. Dollar relative to the Mexican Peso and Brazilian Real.
NET SALES BY SEGMENT
Medical Products & Therapies
Our Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems,
administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products.
Percent change
years ended December 31 (in millions)
2024
2023
At actual
currency rates
At constant
currency rates 1
Infusion Therapies & Technologies
$
4,103 $
3,960
4 %
4 %
Advanced Surgery
1,104
1,051
5 %
6 %
Total Medical Product & Therapies net sales
$
5,207 $
5,011
4 %
5 %
1 Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial
Measures” for additional information about our use of that measure.
Medical Product & Therapies segment net sales increased 4% for the year ended December 31, 2024, as
compared to the prior year period.
Infusion Therapies & Technologies net sales increased 4% for the year ended December 31, 2024, as compared to
the prior year period. Sales performance in 2024 primarily reflected growth in Infusion Systems as a result of sales
of our Novum IQ large volume infusion and syringe pump in the U.S., and sales of Nutrition product offerings, which
was attributable to both pricing initiatives and increased sales volume. In September 2024, Hurricane Helene, which
brought significant rain and extensive flooding to Western North Carolina, caused damage to certain of our assets at
our North Cove facility in Marion, N.C. and disrupted operations at that facility. This facility, which manufactures IV
Solutions primarily for the U.S. market, was not fully operational for most of the fourth quarter. As a consequence,
Hurricane Helene had an estimated $110 million adverse impact on sales, which offset price and underlying volume
gains during the year.
Advanced Surgery net sales increased 5% for the year ended December 31, 2024, as compared to the prior year
period, driven by growth in hemostats and sealants and was primarily attributable to increased sales volume.
Foreign currency exchange rates adversely impacted net sales by 1% for the year ended December 31, 2024, as
compared to the prior year period.
Percent change
years ended December 31 (in millions)
2023
2022
At actual
currency rates
At constant
currency rates 1
Infusion Therapies & Technologies
$
3,960 $
3,817
4 %
4 %
Advanced Surgery
1,051
998
5 %
6 %
Total Medical Product & Therapies net sales
$
5,011 $
4,815
4 %
4 %
1 Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial
Measures” for additional information about our use of that measure.
Medical Product & Therapies segment net sales increased 4% for the year ended December 31, 2023, as
compared to the prior year period.
Infusion Therapies & Technologies net sales increased 4% for the year ended December 31, 2023, as compared to
the prior year period. Sales performance in 2023 reflected strong demand for our infusion systems and
40
administration sets, as well as growth in IV solutions and international nutrition compounding, partially offset by
lower sales of parenteral nutrition products in the U.S. as compared to the prior year.
Advanced Surgery net sales increased 5% for the year ended December 31, 2023, as compared to the prior year
period, driven by continued recovery in surgical procedures, partially offset by temporary supply constraints, the exit
of a product distribution arrangement and a comparison against prior year periods that benefited from competitor
supply constraints. Foreign currency exchange rates adversely impacted net sales by 1% for the year ended
December 31, 2023, as compared to the prior year period.
Healthcare Systems & Technologies
Our Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration
tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health
devices and advanced equipment for the surgical space, including surgical video technologies, precision positioning
devices and other accessories.
Percent change
years ended December 31 (in millions)
2024
2023
At actual
currency rates
At constant
currency rates 1
Care and Connectivity Solutions
$
1,814 $
1,800
1 %
1 %
Front Line Care
1,137
1,213
(6) %
(6) %
Total Healthcare Systems & Technologies net sales
$
2,951 $
3,013
(2) %
(2) %
1 Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial
Measures” for additional information about our use of that measure.
Healthcare Systems & Technologies segment net sales decreased 2% for the year ended December 31, 2024, as
compared to the prior year period.
Care and Connectivity Solutions net sales increased 1% for the year ended December 31, 2024, driven by
increased order volume associated with capital spending in the U.S. as compared to the prior year, partially offset
by declines in care communication products driven by the shifting of installations to future periods and lower sales
outside of the U.S.
Front Line Care net sales decreased 6% for the year ended December 31, 2024, as compared to the prior year
period, primarily driven by a backlog reduction in the prior year period which increased sales in the prior year,
reduced demand in the primary care market, lower government orders, certain product exits and select supply
constraints impacting product availability. These declines were partially offset by growth in our cardiology products.
Percent change
years ended December 31 (in millions)
2023
2022
At actual
currency rates
At constant
currency rates 1
Care and Connectivity Solutions
$
1,800 $
1,791
1 %
1 %
Front Line Care
1,213
1,148
6 %
6 %
Total Healthcare Systems & Technologies net sales
$
3,013 $
2,939
3 %
3 %
1 Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial
Measures” for additional information about our use of that measure.
Healthcare Systems & Technologies segment net sales increased 3% for the year ended December 31, 2023, as
compared to the prior year period.
Care and Connectivity Solutions net sales increased 1% for the year ended December 31, 2023, as compared to
the prior year period, driven by international demand and sales generated from recent product launches in the U.S.,
partially offset by lower rental revenues and lower capital spending in the U.S. reflecting the macroeconomic
environment in 2023.
Front Line Care net sales increased 6% for the year ended December 31, 2023, as compared to the prior year
period, primarily driven by increased demand for our cardiology products, patient monitoring systems and physical
assessment tools. Performance in the current year benefited from backlog reductions due to improved availability of
component parts used in certain of our products.
41
Pharmaceuticals
Our Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthetics and drug
compounding services.
Percent change
years ended December 31 (in millions)
2024
2023
At actual
currency rates
At constant
currency rates 1
Injectables and Anesthesia
$
1,373 $
1,347
2 %
3 %
Drug Compounding
1,038
902
15 %
15 %
Total Pharmaceuticals net sales
$
2,411 $
2,249
7 %
7 %
1 Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial
Measures” for additional information about our use of that measure.
Pharmaceuticals segment net sales increased 7% for the year ended December 31, 2024, as compared to the prior
year period.
Injectables and Anesthesia net sales increased 2% for the year ended December 31, 2024, as compared to the
prior year period, primarily due to growth in our U.S. specialty injectable products, driven by strong sales volume in
our core portfolio and recent product launches, partially offset by declines for inhaled anesthetics. Foreign currency
exchange rates adversely impacted net sales by 1% for the year ended December 31, 2024, as compared to the
prior year period.
Drug Compounding net sales increased 15% for the year ended December 31, 2024, as compared to the prior year
period, driven by increased demand for our international pharmacy compounding offerings, due in part, to customer
capacity constraints that resulted in increased outsourcing of compounding activities.
Percent change
years ended December 31 (in millions)
2023
2022
At actual
currency rates
At constant
currency rates 1
Injectables and Anesthesia
$
1,347 $
1,305
3 %
4 %
Drug Compounding
902
821
10 %
12 %
Total Pharmaceuticals net sales
$
2,249 $
2,126
6 %
7 %
1 Percent change in net sales at constant currency rates is a non-GAAP financial measure. See the section entitled “Non-GAAP Financial
Measures” for additional information about our use of that measure.
Pharmaceuticals segment net sales increased 6% for the year ended December 31, 2023, as compared to the prior
year period.
Injectables and Anesthesia net sales increased 3% for the year ended December 31, 2023, as compared to the
prior year period, primarily due to growth in our U.S. injectable products, driven by our launches of Zosyn, following
the transfer of the related product rights to us in April 2023, Bendamustine and Norepinephrine, partially offset by
lower sales of inhaled anesthesia products. Foreign currency exchange rates adversely impacted net sales by 1%
for the year ended December 31, 2023, as compared to the prior year period.
Drug Compounding net sales increased 10% for the year ended December 31, 2023, as compared to the prior year
period, driven by increased demand for our international pharmacy compounding services. Foreign currency
exchange rates adversely impacted net sales by 2% for the year ended December 31, 2023, as compared to the
prior year period.
Other
During the years ended December 31, 2024, 2023 and 2022, we earned $67 million, $87 million and $177 million,
respectively, of revenues that were not attributable to our reportable segments. In the current and prior year periods,
Other sales primarily represent revenues earned by certain of our manufacturing facilities from contract
manufacturing activities. The years ended December 31, 2023 and 2022 also included royalty income under a
business development arrangement. The decrease in Other sales for the year ended December 31, 2024 as
compared to the prior year period reflects lower contract manufacturing volume. The decrease for the year ended
December 31, 2023 as compared to the prior year period was primarily driven by lower contract manufacturing
42
volume and, to a lessor extent, termination of the royalty arrangement following our acquisition of the rights to the
underlying product.
Special Items
Management believes that providing the separate impact of the following items on our results in accordance with
U.S. GAAP may provide a more complete understanding of our operations and can facilitate a fuller analysis of our
results of operations, particularly in evaluating performance from one period to another. Intangible asset
amortization expense is identified as a special item to facilitate an evaluation of current and past operating
performance and is consistent with how management and our Board of Directors assess performance. Additional
special items are identified because they are highly variable, difficult to predict and of a size that may substantially
impact our reported results of operations for the period.
43
The following table provides a summary of our special items and the related impact by line item on our consolidated
results of operations for 2024, 2023 and 2022.
years ended December 31 (in millions)
2024
2023
2022
Gross Margin
Intangible asset amortization expense
$
(419) $
(383) $
(392)
Long-lived asset impairments1
—
—
(344)
Business optimization items2
(67)
(27)
(16)
Product related items3
(15)
—
(44)
Acquisition and integration items4
(1)
(1)
(170)
European medical devices regulation5
(33)
(41)
(42)
Hurricane Helene costs6
(110)
—
—
Total Special Items
$
(645) $
(452) $
(1,008)
Impact on Gross Margin Ratio
(6.0 pts)
(4.3 pts)
(10.0 pts)
Selling, General and Administrative (SG&A) Expenses
Intangible asset amortization expense
$
206 $
207 $
287
Business optimization items2
65
137
174
Acquisition and integration items4
22
18
82
Legal matters7
17
15
—
Total Special Items
$
310 $
377 $
543
Impact on SG&A Expense Ratio
2.9 pts
3.6 pts
5.4 pts
R&D Expenses
Business optimization items2
$
30 $
10 $
3
Long-lived asset impairments1
50
—
—
Total Special Items
$
80 $
10 $
3
Impact on R&D Expense Ratio
0.7 pts
0.1 pts
0.1 pts
Goodwill Impairments
Goodwill impairments8
$
425 $
— $
2,812
Total Special Items
$
425 $
— $
2,812
Other Operating Expense (Income), Net
Acquisition and integration items4
$
— $
(19) $
(39)
Legal matters7
—
(8)
—
Loss on product divestiture arrangement9
—
—
54
Loss on subsidiary liquidation10
—
—
21
Total Special Items
$
— $
(27) $
36
Other (Income) Expense, Net
Pension curtailment11
$
— $
— $
(11)
Reclassification of cumulative translation loss to earnings12
—
—
65
Investment impairments13
—
31
—
Total Special Items
$
— $
31 $
54
Income Tax Expense (Benefit)
Tax matters14
$
80 $
65 $
25
Tax effects of special items15
(248)
(226)
(375)
Total Special Items
$
(168) $
(161) $
(350)
Impact on Effective Tax Rate
(30.3) pts
4.7 pts
(13.6) pts
1
Our results in 2024 included a long-lived asset impairment charge of $50 million to reduce the carrying amount of an IPR&D asset to its
fair value. Our results in 2022 included long-lived asset impairment charges related to assets acquired in our December 2021
acquisition of Hillrom, comprised of (i) $332 million of indefinite-lived intangible assets and (ii) $12 million of developed technology
intangible asset impairments. Refer to Notes 3 and 5 in Item 8 of this Annual Report on Form 10-K for further information regarding the
impairments. Long-lived asset impairments presented within this special item do not include impairments of long-lived assets related to
restructuring actions, which are presented within the business optimization special item described in footnote 2 below.
44
2
Our results in 2024, 2023 and 2022 were impacted by costs associated with our execution of programs to optimize our organization
and cost structure. In 2024, these restructuring and other business optimization costs included costs primarily related to initiatives to
reduce our cost structure following the sale of our Kidney Care segment, initiatives within our Healthcare Systems & Technologies
segment including the discontinuance of a product line and rationalization of certain other manufacturing and distribution facilities. In
2023 and 2022, these restructuring and other business optimization costs included actions related to our implementation of a new
operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our
commercial activities, and our ongoing integration of Hillrom. Our results in 2024 and 2023 and 2021 included business optimization
charges of $162 million, $174 million, $193 million, respectively. Refer to Note 12 in Item 8 of this Annual Report on Form 10-K for
further information regarding these charges and related liabilities.
3
Our results in 2024 included charges of $15 million, comprised of (i) $12 million related to warranty and remediation activities arising
from field corrective actions on Healthcare Systems & Technologies products and (ii) $3 million related to a revised estimate of
warranty and remediation activities arising from a field corrective action on certain of our infusion pumps initially recorded in 2022. Our
results in 2022 included charges of $44 million related to warranty and remediation activities arising from two field corrective actions on
certain of our infusion pumps.
4
Our results in 2024 included $23 million of integration costs which primarily reflected third-party consulting costs related to our
integration of Hillrom. Our results in 2023 included $19 million of integration-related costs, primarily related to our integration of Hillrom,
offset by a $19 million benefit from changes in the estimated fair values of contingent consideration liabilities. Our results in 2022
included $213 million of acquisition and integration-related items, which reflected $93 million of integration-related costs and $159
million of incremental cost of sales from the fair value step-ups on acquired Hillrom inventory that was sold in 2022, partially offset by a
$39 million benefit from changes in the estimated fair value of contingent consideration liabilities. Refer to Note 3 in Item 8 of this
Annual Report on Form 10-K for further information regarding business and asset acquisitions.
5
Our results in 2024, 2023 and 2022 included $33 million, $41 million and $42 million, respectively, of incremental costs to comply with
the European Union's medical device regulations for previously registered products, which primarily consist of contractor costs and
other direct third-party costs. We consider the adoption of these regulations to be a significant one-time regulatory charge and believe
that the costs of initial compliance for previously registered products over the implementation period are not indicative of our core
operating results.
6
Our results in 2024 included pre-tax net charges of $110 million related damages caused by Hurricane Helene. This amount consisted
of $44 million related to the write-off of damaged inventory and fixed assets, as well as $317 million of remediation, idle facility, air
freight and other costs, partially offset by $251 million of insurance recoveries. Refer to Note 1 in Item 8 of this Annual Report on Form
10-K for further information.
7
Our results in 2024 included charges of $17 million related to environmental reserves for remediation actions associated with historic
operations at certain of our facilities. Our results in 2023 included $7 million of net costs from certain legal matters. These costs
included $13 million, including related legal fees, related to matters involving alleged violations of the False Claims Act related to a
now-discontinued legacy Hillrom sales line and alleged injury from environmental exposure, partially offset by $6 million of proceeds
received, net of related legal fees, from a settlement related to an intellectual property dispute.
8
Our results in 2024 included a goodwill impairment charge of $425 million related to the Front Line Care reporting unit within our Health
Care Systems & Technologies segment. Our results in 2022 included goodwill impairment charges of $2.81 billion related to reporting
units within our Health Care Systems & Technologies segment. Refer to Notes 3 and 5 in Item 8 of this Annual Report on Form 10-K for
further information regarding these goodwill impairments.
9
Our results in 2022 included a loss of $54 million under an arrangement to divest certain product rights for an amount that is less than
our cost of those product rights, which was triggered by U.S. and European Union regulatory approvals of the related products. Refer
to Note 3 in Item 8 of this Annual Report on Form 10-K for further information about the related transactions.
10
Our results in 2022 included a loss of $21 million related to our deconsolidation of a foreign subsidiary, including the derecognition of a
related noncontrolling interest, upon its liquidation in December 2022 that was completed in connection with our legal entity
rationalization activities.
11
Our results in 2022 included a curtailment gain of $11 million related to an announced change for active non-bargaining participants in
our U.S. Hillrom pension plan. Refer to Note 13 in Item 8 of this Annual Report on Form 10-K for further information regarding this
curtailment gain.
12
Our results in 2022 included a charge of $65 million for cumulative translation adjustments (CTA) reclassified from accumulated other
comprehensive income (loss) as a result of the substantial liquidation of our operations in Argentina.
13
Our results in 2023 included $31 million of net pre-tax losses from non-marketable investments in several early-stage companies,
consisting of $34 million of noncash impairment write-downs, partially offset by a $3 million gain from the sale of an investment.
14
Our results in 2024 included a $80 million net income tax expense consisting of a $28 million valuation allowance recorded to reduce
the carrying amount of tax attribute carryforwards in the U.S., $22 million of net income tax costs on internal reorganization
transactions related to the sale of our Kidney Care segment, a $17 million income tax expense related to legislative changes under
Internal Revenue Code of 1986 (IRC) Section 987 (which is the exchange gain or loss on foreign branch remittances in the U.S.,
effective in 2024), and a $13 million net revaluation of the Swiss basis step-up deferred tax asset and related valuation allowance that
arose from Swiss tax reform legislation in 2019 that was partially offset by a decrease in such valuation allowance to reflect our current
estimate of recoverability of the basis step-up deferred tax asset. Our results in 2023 included a $14 million income tax expense from
separation related income tax costs associated with the sale of our BPS business, and a $9 million valuation allowance to reduce the
carrying amount of a deferred tax asset for a tax basis step-up related to previously enacted Swiss tax reform legislation to reflect our
current estimate of its recoverability with the remaining tax expense related to the tax effects of other special items. Our results in 2022
included a $25 million valuation allowance to reduce the carrying amount of a deferred tax asset for a tax basis step-up related to
previously enacted Swiss tax reform legislation to reflect our current estimate of its recoverability.
15
This item reflects the income tax impact of the special items identified in this table. The tax effect of each special item is based on the
jurisdiction in which the item was incurred and the tax laws in effect for each such jurisdiction.
COSTS AND EXPENSES
45
Gross Margin and Expense Ratios
2024
2023
years ended
December 31
2024
% of net
sales
2023
% of net
sales
2022
% of net
sales
$ change
% change
$ change
% change
Gross margin
$ 3,984
37.5 % $ 4,150
40.1 % $ 3,549
35.3 % $ (166)
(4.0) % $
601
16.9 %
SG&A
$ 2,967
27.9 % $ 2,953
28.5 % $ 3,097
30.8 % $
14
0.5 % $ (144)
(4.6) %
R&D
$
590
5.5 % $
518
5.0 % $
450
4.5 % $
72
13.9 % $
68
15.1 %
Gross Margin
The gross margin ratio was 37.5%, 40.1% and 35.3% for the years ended 2024, 2023 and 2022, respectively. The
special items identified earlier in this section had an unfavorable impact on gross margin ratio of 6.0, 4.3, and 10.0
percentage points in 2024. 2023, and 2022, respectively. Refer to the Special Items caption earlier in this section for
additional detail.
Excluding the impact of special items, the gross margin ratio decreased 0.9 percentage points in 2024 compared to
2023 and decreased 0.9 percentage points in 2023 compared to 2022. The decrease in 2024 was driven by an
unfavorable product mix, partially offset by initiatives to reduce our manufacturing and supply chain costs. The
decrease in 2023 was primarily due to the adverse cost impacts of raw materials inflation driving higher
manufacturing costs and higher bonus accruals under our annual employee incentive compensation plans, partially
offset by manufacturing initiatives.
SG&A
The SG&A expense ratio was 27.9%, 28.5% and 30.8% for the years ended 2024, 2023 and 2022, respectively. The
special items identified earlier in this section had an unfavorable impact on the SG&A expense ratio of 2.9, 3.6 and
5.4 percentage points in 2024, 2023 and 2022, respectively. Refer to the Special Items caption earlier in this section
for additional detail.
Excluding the impact of special items, the SG&A expense ratio increased 0.1 percentage points in 2024 compared
to 2023 and decreased 0.5 percentage points in 2023 compared to 2022. The increase in 2024 was primarily due to
higher corporate function costs and annual compensation increases, partially offset by lower accruals under our
annual employee incentive compensation plans. The decrease in 2023 was primarily due to savings from
restructuring actions implemented in recent periods, partially offset by higher bonus accruals under our annual
employee incentive compensation plans.
R&D
The R&D expense ratio was 5.5%, 5.0% and 4.5% for the years ended 2024, 2023 and 2022, respectively. The
special items identified earlier in this section had an unfavorable impact on the R&D expense ratio of 0.7 percentage
points in 2024, and 0.1 percentage points both in 2023 and 2022. Refer to the Special Items caption earlier in this
section for additional detail.
Excluding the impact of special items, the R&D expense ratio decreased 0.1 percentage points in 2024 compared to
2023 and increased 0.5 basis points in 2023 compared to 2022. The decrease in 2024 was driven by lower bonus
accruals under our annual employee incentive compensation plans. The increase in 2023 reflected higher outbound
freight costs.
Business Optimization Items
In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency.
These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and
supply chain network, employing disciplined cost management and centralizing and streamlining certain support
functions. The costs of restructuring actions consisted primarily of employee termination costs, contract termination
costs and asset impairments.
We incurred restructuring charges of $162 million, $174 million and $193 million in 2024, 2023 and 2022,
respectively. In 2024, $45 million of the restructuring charges, consisting of employee termination costs, were
related to initiatives to reduce our cost structure following the sale of our Kidney Care segment. In addition, $46
46
million of the restructuring charges were related to business optimization initiatives within our Healthcare Systems &
Technologies segment. These charges included $21 million of long-lived asset impairment charges, $9 million of
other asset write-downs related to inventory and $2 million of employee termination costs related to our decision to
discontinue a product line. Additionally, these charges included $14 million of employee termination costs related to
other business optimization initiatives within this segment. In 2023, $81 million of the restructuring charges,
consisting of employee termination costs, were related to the implementation of our new operating model intended
to streamline our operations. In 2022, $85 million restructuring charges were related to integration activities for the
Hillrom acquisition, consisting of $55 million of employee termination costs, $22 million of contract terminations and
other costs and $8 million of asset impairments.
We currently expect to incur additional pre-tax cash costs, primarily related to the implementation of business
optimization programs, of approximately $4 million through the completion of initiatives that are currently underway.
We continue to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-synergies
expected to arise as a result of the sale of our Kidney Care business, and to the extent further cost savings
opportunities are identified, we would incur additional restructuring charges and costs to implement business
optimization programs in future periods. Refer to Note 12 in Item 8 of this Annual Report on Form 10-K for additional
information regarding our business optimization programs.
Goodwill Impairments
We assess goodwill and indefinite-lived intangible assets for impairment annually during the fourth quarter or
whenever events or changes in circumstances indicate that the carrying amount of such assets may not be
recoverable. We recognize a goodwill impairment charge for the amount by which a reporting unit's carrying amount
exceeds its fair value.
In connection with our annual goodwill impairment assessment in the fourth quarter of 2024, we recorded a $425
million goodwill impairment related to our Front Line Care reporting unit within our Healthcare Systems &
Technologies segment. The reduction in value was primarily due to lower forecasted operating results and a lower
terminal growth rate utilized in valuing this reporting unit which contributed to reduced expected future cash flows,
as well as lower earnings multiples. The fair value of the Front Line Care reporting unit was determined based on a
discounted cash flow model (an income approach) and earnings multiples (a market approach) based on the
guideline public company method. Significant assumptions used in the determination of the fair values of our
reporting units generally include revenue growth rates, forecasted earnings before income, taxes, depreciation and
amortization (EBITDA) margins, discount rates, terminal growth rates and earnings multiples. The discounted cash
flow model used to determine the fair value of our Front Line Care reporting unit reflected our most recent cash flow
projections, a discount rate of 9.5% and a terminal growth rate of 3.25%. Our reporting unit fair value measurements
are classified as Level 3 in the fair value hierarchy because they involve significant unobservable inputs. As of
December 31, 2024, the carrying amount of goodwill for our Front Line Care reporting unit was $1.99 billion. No
goodwill impairments were recorded for our remaining reporting units in connection with our annual goodwill
impairment tests because the fair values of those reporting units exceeded their carrying amounts. Refer to Note 5
in Item 8 of this Annual Report on Form 10-K for additional information regarding this goodwill impairment charge.
We acquired Hillrom on December 13, 2021 and recognized $6.83 billion of goodwill and $6.03 billion of other
intangible assets, including $1.91 billion of indefinite-lived intangible assets, in connection with that acquisition.
During the third quarter of 2022, we performed trigger-based impairment tests for each of the reporting units within
our Hillrom segment (currently referred to as our Healthcare Systems & Technologies segment), as well as the
indefinite-lived intangible assets, consisting primarily of trade names, that we acquired in connection with the Hillrom
acquisition. We performed those tests as of September 30, 2022 due to (a) current macroeconomic conditions,
including the rising interest rate environment and broad declines in equity valuations, and (b) reduced earnings
forecasts for our three Hillrom reporting units, driven primarily by shortages of certain component parts used in our
products, raw materials inflation and increased supply chain costs. Those goodwill impairment tests resulted in total
pre-tax goodwill impairment charges of $2.79 billion in the third quarter of 2022. In connection with our annual
goodwill impairment assessment in the fourth quarter of 2022, we performed quantitative impairment tests for all our
reporting units and recorded an additional $27 million goodwill impairment related to our Global Surgical Solutions
reporting unit (now combined with our previous Patient Support Systems reporting unit in our Care and Connectivity
47
Solutions reporting unit). Refer to Note 3 in Item 8 of this Annual Report on Form 10-K for additional information
regarding these goodwill impairment charges.
Further adverse changes to macroeconomic conditions or our earnings forecasts could lead to additional goodwill
impairment charges in future periods and such charges could be material to our results of operations. For further
discussion, refer to Item 1A. Risk Factors of this Annual Report on Form 10-K.
Other Operating Expense (Income), Net
Other operating expense (income), net was income of $12 million in 2024, income of $28 million in 2023 and
expense of $35 million in 2022. The income in 2024 was comprised of income from transition services
arrangements related to the divestiture of our BPS business. In 2023, this amount was comprised of gains from
changes in the estimated fair value of contingent consideration arrangements and proceeds from a settlement
related to an intellectual property dispute. In 2022, we recognized a loss of $54 million under an arrangement to
divest certain product rights for an amount that was less than our cost of those product rights, which was triggered
by U.S. and European Union regulatory approvals of the related products. Refer to Note 3 in Item 8 of this Annual
Report on Form 10-K for further information about the related transactions. Additionally, we recognized a loss of $21
million related to the deconsolidation of a foreign subsidiary, including the derecognition of a related noncontrolling
interest, upon its liquidation in December 2022 that was completed in connection with our legal entity rationalization
activities. Those losses were partially offset by gains of $39 million from net decreases in the estimated fair values
of contingent consideration liabilities.
Interest Expense, Net
Interest expense, net was $341 million, $439 million and $394 million in 2024, 2023 and 2022, respectively. The
decrease in 2024 was driven by debt repayments in the fourth quarter of 2023 and, to a lesser extent, higher
interest income due to a higher average cash balance and higher interest rates during the current year period. The
increase in 2023 was driven by higher interest rates on our floating rate debt, partially offset by net repayments in
the current year periods and higher interest income in 2023.
We expect that our net interest expense will decrease in future periods as a result of debt repayments during the
fourth quarter of 2024 and debt repayments during the first quarter of 2025 using the proceeds we received from the
recent sale of our Kidney Care business. Refer to Note 6 in Item 8 of this Annual Report on Form 10-K for a
summary of the components of interest expense, net for 2024, 2023 and 2022.
Other (Income) Expense, Net
Other (income) expense, net was income of $38 million, expense of $26 million and expense of $9 million in 2024,
2023 and 2022, respectively. The net income in 2024 was primarily driven by pension and other postretirement
benefits, partially offset by foreign exchange losses. The net expense in 2023 was primarily driven by foreign
exchange losses, non-marketable investment impairments, partially offset by pension and postretirement benefits.
The net expense in 2022 was primarily due to the reclassification of a cumulative translation loss from accumulated
other comprehensive income (loss) to earnings due to the substantial liquidation of our operations in Argentina,
partially offset by pension and OPEB benefits, a pension curtailment gain and net increases in the fair value of
marketable equity securities.
Income Taxes
Our effective income tax rate was (12.8)%, 25.2% and 4.2% in 2024, 2023 and 2022, respectively. The special
items identified above impacted our effective tax rate by (30.3) percentage points, 4.7 percentage points and (13.6)
percentage points in 2024, 2023 and 2022, respectively. Refer to the Special Items caption earlier in this section for
additional detail. Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of
factors, including tax incentives, foreign rate differences, state income taxes, non-deductible expenses, non-taxable
income, increases or decreases in valuation allowances and liabilities for uncertain tax positions, excess tax
benefits or shortfalls on stock compensation awards, audit developments and legislative changes.
For the year ended December 31, 2024, the difference between our effective income tax rate and the U.S. federal
statutory rate was adversely impacted by a non-deductible impairment of goodwill, legislative changes under IRC
Section 987 (which is the exchange gain or loss on foreign branch remittances in the U.S., effective in 2024), and a
net revaluation of the Swiss basis step-up deferred tax asset and related valuation allowance that arose from Swiss
48
tax reform legislation in 2019, partially offset by a favorable geographic earnings mix, a decrease in valuation
allowance mainly related to U.S. foreign tax credit carryforward, and a tax benefit related to research and
development tax credits.
For the year ended December 31, 2023, the difference between our effective income tax rate and the U.S. federal
statutory rate was impacted favorably by geographical earnings mix, a $50 million net tax benefit after related
valuation allowances from notional interest deductions received by certain wholly-owned foreign subsidiaries that
have financed their operations with equity capital and a $17 million tax benefit related to research and development
tax credits, partially offset by tax shortfalls on stock compensation awards.
For the year ended December 31, 2022, the difference between our effective income tax rate and the U.S. federal
statutory rate was primarily attributable to non-deductible impairments of goodwill acquired in the Hillrom acquisition
and valuation allowance increases, including the increase described above related to deferred tax assets from a tax
basis step-up related to previously enacted Swiss tax legislation in 2019. Those items were partially offset by a
$47 million net tax benefit after related valuation allowances from notional interest deductions.
Our tax provisions for 2024, 2023 and 2022 did not include any significant tax charges related to either the Base
Erosion and Anti-Abuse Tax (BEAT) or Global Intangible Low Taxed Income (GILTI) provisions, except for the
inability to fully utilize foreign tax credits against such GILTI. Our accounting policy is to recognize any GILTI charge
as a period cost.
The Organization of Economic Co-operation and Development (OECD) and the G20 Inclusive Framework on Base
Erosion and Profit Shifting (the Inclusive Framework) has put forth two proposals—Pillar One and Pillar Two—that
(i) revise the existing profit allocation and nexus rules and (ii) ensure a minimal level of taxation, respectively. On
December 12, 2022, the EU member states agreed to implement the Inclusive Framework’s global corporate
minimum tax rate of 15%, and various countries both within and outside the EU have enacted new laws
implementing Pillar Two or have draft legislation proposed for adoption. The OECD continues to release additional
guidance on the two-pillar framework, with widespread implementation occurring in 2024. The impact of the Pillar
Two legislation on our income tax expense for the year ended December 31, 2024 was $11 million. We are
continuing to evaluate the potential impacts of the Inclusive Framework for 2025 and future years, pending
legislative adoption by individual countries, which could result in further adverse impacts on our income tax expense
and cash flows.
Discontinued Operations
In August 2024, we entered into a definitive agreement to sell our Kidney Care business and its results have been
presented as discontinued operations for the years ended December 31, 2024, 2023 and 2022 in the consolidated
financial statements included in Item 8 of this Annual Report on Form 10-K. On September 29, 2023, we completed
the sale of our BPS business and its results have been presented as discontinued operations for the years ended
December 31, 2023 and 2022 are reported as discontinued operations in the consolidated financial statements
included in Item 8 of this Annual Report on Form 10-K.
Income (loss) from discontinued operations, net of tax, was $(312) million, $2.48 billion and $692 million in 2024,
2023 and 2022, respectively. The decrease in the current year period was primarily driven by the $2.88 billion pre-
tax gain from the sale of the BPS business ($2.59 billion net of tax). Refer to Note 2 in Item 8 of this Annual Report
on Form 10-K for additional information.
Net Income (Loss) and Earnings (Loss) per Diluted Share
Net income (loss) for the total company, including discontinued operations, was $(638) million in 2024, $2.66 billion
in 2023 and $(2.42) billion in 2022. Diluted earnings (loss) per share for the total company, including discontinued
operations, was $(1.27) per share in 2024, $5.23 per share in 2023 and $(4.83) per share in 2022. The significant
factors and events causing the net changes from 2023 to 2024 and from 2022 to 2023 are discussed above.
Additionally, earnings (loss) per share was positively impacted by the repurchase of 0.5 million shares in 2022
through Rule 10b5-1 purchase plans. Refer to Note 9 in Item 8 of this Annual Report on Form 10-K for further
information regarding our stock repurchases.
49
SEGMENT OPERATING INCOME (LOSS)
The following is a summary of operating income (loss) for our reportable segments.
for the years ended December 31 (in millions)
2024
2023
2022
Medical Products & Therapies
$
950
$
972
$
962
% of Segment Net Sales
18.2 %
19.4 %
20.0 %
Healthcare Systems & Technologies
468
483
494
% of Segment Net Sales
15.9 %
16.0 %
16.8 %
Pharmaceuticals
313
401
391
% of Segment Net Sales
13.0 %
17.8 %
18.4 %
Total reportable segment operating income
1,731
1,856
1,847
Other
18
18
77
Unallocated corporate costs
(275)
(355)
(367)
Intangible asset amortization expense
(625)
(590)
(679)
Business optimization items
(162)
(174)
(193)
European Medical Devices Regulation
(33)
(41)
(42)
Long-lived asset impairments
(50)
—
(344)
Legal matters
(17)
(7)
—
Acquisition and integration items
(23)
—
(213)
Product-related items
(15)
—
(44)
Hurricane Helene Costs
(110)
—
—
Loss on product divestiture arrangement
—
—
(54)
Goodwill impairments
(425)
—
(2,812)
Loss on subsidiary liquidation
—
—
(21)
Total operating income (loss)
14
707
(2,845)
Interest expense, net
341
439
394
Other (income) expense, net
(38)
26
9
Income (loss) from continuing operations before income taxes
$
(289)
$
242
$ (3,248)
Medical Products & Therapies
Segment operating income was $950 million, $972 million and $962 million for the years ended 2024, 2023 and
2022, respectively. Segment operating income decreased in 2024 compared to the prior year due to increased
allocations of manufacturing and supply chain overheads, annual compensation increases and higher corporate
shared costs, partially offset by higher sales. In addition, we estimate that the North Cove flood resulting from
Hurricane Helene had an adverse impact of $60 million on segment operating income in 2024. Segment operating
income increased in 2023 compared to the prior year due to the gross profit from higher sales, partially offset by
increases in SG&A and R&D expenses.
Healthcare Systems & Technologies
Segment operating income was $468 million, $483 million and $494 million for the years ended 2024, 2023 and
2022, respectively. Segment operating income decreased in 2024 primarily due to decreased gross profit from lower
sales. Segment operating income decreased in 2023 primarily due to increased R&D expenses, particularly related
to the connected care portfolio.
Pharmaceuticals
Segment operating income was $313 million, $401 million and $391 million for the years ended 2024, 2023 and
2022, respectively. The decreases in segment operating income in 2024 were driven by lower gross margin
percentages, primarily driven by the increased cost of certain inventory manufactured by our former BPS business,
which includes a third-party mark-up following our divestiture of that business in September 2023, an unfavorable
product mix, and increased operating expenses, including marketing-related costs in connection with recent product
50
launches. Segment operating income increased in 2023 primarily due to income from recent product launches,
partially offset by a lower gross margin, primarily driven by raw materials inflation, and increased R&D expense.
Other
Other operating income, which represents operating income not attributable to our reportable segments, was $18
million for both the years ended December 31, 2024 and 2023 and $77 million for the year ended December 31,
2022. In the current and prior year periods, other operating income primarily represents income from revenues
earned by certain of our manufacturing facilities from contract manufacturing activities. Other operating income in
2022 also included royalty income under a business development arrangement. Other operating income in 2024
was flat as compared to the prior year period. The decrease in 2023 as compared to the prior year period reflects
the termination of the royalty arrangement following our acquisition of the rights to the underlying product, partially
offset by improved gross margins from contract manufacturing.
Unallocated Corporate Costs
Under our new operating model, most global functional support costs, overhead costs and other shared costs that
benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as
well as any differences between actual corporate costs and the amounts allocated to our segments, are presented
as unallocated corporate costs. With the results of our Kidney Care segment reported in discontinued operations,
corporate costs that had previously been allocated to the Kidney Care segment which will not convey with the
Kidney Care segment in the sale, are now presented as unallocated corporate costs. Additionally, intangible asset
amortization and other special items are not allocated to our segments. Prior to the implementation of our operating
model in the third quarter of 2023, more costs were maintained at corporate and were not allocated to our previous
segments. Certain of the costs that were previously maintained at corporate under our prior segment structure that
are now allocated to our segments include manufacturing variances and centrally managed supply chain costs,
certain R&D costs, product category support costs, stock compensation expense, and certain employee benefit plan
costs.
LIQUIDITY AND CAPITAL RESOURCES
years ended December 31 (in millions)
2024
2023
2022
Cash flows from operations - continuing operations
$
819 $
1,207 $
528
Cash flows from investing activities - continuing operations
(410)
(410)
(624)
Cash flows from financing activities
(1,081)
(3,489)
(1,438)
Cash Flows from Operations — Continuing Operations
In 2024, 2023 and 2022, cash provided by operating activities from continuing operations was $819 million, $1.21
billion and $528 million, respectively.
Operating cash flows from continuing operations in the current year were unfavorably impacted as compared to
2023 due to an increase in our net loss from continuing operations and higher annual payouts under our employee
incentive plans, which were determined based on our 2023 performance.
Operating cash flows from continuing operations increased in 2023 compared to 2022 primarily due to a decrease in
our net loss from continuing operations, lower annual payouts under our employee incentive compensation plans,
which were based on our 2022 results, the timing of accounts payable payments and lower increases in inventory
as compared to the prior year.
Cash Flows from Investing Activities
In 2024, cash used for investing activities from continuing operations included capital expenditures of $446 million.
In 2023, cash used for investing activities from continuing operations included capital expenditures of $432 million.
In 2022, cash used for investing activities from continuing operations included capital expenditures of $377 million
51
and payments for acquisitions and investments of $258 million, primarily related to our acquisition of the rights to
Zosyn.
Cash Flows from Financing Activities
In 2024, cash used in financing activities included debt repayments of $2.66 billion, dividend payments of $590
million, partially offset by proceeds from borrowings on our delayed draw term loan of $1.83 billion, an increase in
commercial paper borrowings of $296 million, and proceeds from stock issued under employee benefit plans of $71
million.
In 2023, cash used in financing activities included debt repayments of $2.63 billion and dividend payments of $586
million, and a decrease in commercial paper borrowings of $301 million, partially offset by proceeds from stock
issued under employee benefit plans of $95 million.
In 2022, cash used in financing activities included debt repayments of $954 million and dividend payments of
$573 million, partially offset by receipts from stock issued under employee benefit plans of $127 million and a net
increase in commercial paper borrowings of $55 million.
As authorized by the Board of Directors, we repurchase our stock depending upon our cash flows, net debt levels
and market conditions. In July 2012, the Board of Directors authorized a share repurchase program and the related
authorization was subsequently increased a number of times. We did not repurchase any shares under this
authority in 2024 and had $1.30 billion remaining available under this authorization as of December 31, 2024.
Credit Facilities, Commercial Paper Program and Access to Capital and Credit Ratings
Credit Facilities and Commercial Paper Program
As of December 31, 2024, we had a U.S. Dollar-denominated term loan credit facility, which had one tranche of
term loans outstanding, a U.S. Dollar-denominated revolving credit facility and a Euro-denominated revolving credit
facility.
As of December 31, 2024, we had $1.64 billion outstanding under our U.S. Dollar-denominated term loan credit
facility that matures in 2026. Borrowings under the term loan credit facility bear interest on the principal amount
outstanding at either Term SOFR plus an applicable margin plus a credit spread adjustment or a “base rate” plus an
applicable margin. The term loan credit facility contains various covenants, including a maximum net leverage ratio.
We have the option to prepay outstanding amounts under the term loan credit facility in whole or in part at any time.
In February 2025, we repaid $1.00 billion under our $1.64 billion five-year term loan facility maturing in 2026.
As of December 31, 2024, our U.S. Dollar-denominated revolving credit facility and Euro-denominated revolving
credit facility had a maximum capacity of $2.00 billion and €200 million, respectively, and there were no borrowings
under either of these revolving credit facilities as of December, 31, 2024 or December 31, 2023. Our commercial
paper borrowing arrangements require us to maintain undrawn borrowing capacity under our revolving credit
facilities for an amount at least equal to our outstanding commercial paper borrowings. Each of the revolving credit
facilities matures in 2026. The revolving credit facilities enable us to borrow funds on an unsecured basis at variable
interest rates, and contain various covenants, including a maximum net leverage ratio. Based on our covenant
calculations as of December 31, 2024 we have capacity to draw on the full amounts under our revolving credit
facilities, less commercial paper borrowings which were $300 million at year-end. Facility fees under the credit
facilities were 0.125% annually as of both December 31, 2024 and 2023 and are based on our credit ratings and the
total capacity of the revolving credit facility.
On July 17, 2024, we entered into a credit agreement pursuant to which a group of banks provided us with senior
unsecured term loans in an aggregate principal amount of up to $2.05 billion ("the bridge facility"). Borrowings under
the bridge facility were available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due
November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing
term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions
related to the sale of our Kidney Care business. Borrowings under the bridge facility bore interest at a rate based on
our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond
December 31, 2024 would increase by 0.25%. We also incurred a ticking fee on undrawn commitments at a rate
based on our long-term debt ratings in effect from time to time. The banks' funding commitments under the bridge
facility terminated on December 31, 2024. Outstanding borrowings under the bridge facility were scheduled to
mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we were required
52
to use the net cash proceeds from certain transactions (including from the sale of our Kidney Care business) to
repay any outstanding borrowings under the bridge facility. The bridge facility contained financial and other
covenants, including a net leverage covenant, and provided for customary events of default. In November 2024, we
reduced the bridge facility capacity from $2.05 billion to $1.83 billion. Additionally, during the fourth quarter of 2024
we drew on the bridge facility to repay our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes
due November 29, 2024 and the outstanding balance on our three-year term loan facility. There was $1.83 billion
outstanding under this bridge facility as of December 31, 2024. In January 2025, we used a portion of the
approximately $3.4 billion of net after-tax cash proceeds from the sale of our Kidney Care business to repay the
$1.83 billion outstanding under the bridge facility, at which time it was terminated.
In the first quarter of 2024, we amended the credit agreements governing our U.S. dollar-denominated term loan
credit facility and revolving credit facility and the guaranty agreement with respect to our Euro-denominated
revolving credit facility to increase the maximum net leverage ratio covenant for the six fiscal quarters ending June
30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025. In
accordance with the terms of the amendment, the capacity under our U.S dollar-denominated revolving credit facility
was reduced from $2.50 billion to $2.00 billion on September 30, 2024. As of December 31, 2024, we were in
compliance with the financial covenants in these agreements.
Based on our covenant calculations as of December 31, 2024, we have capacity to draw on the full amounts under
our revolving credit facilities, less commercial paper borrowings which were $300 million at year-end. The non-
performance of any financial institution supporting either of the revolving credit facilities would reduce the maximum
capacity of the revolving credit facilities by the institution’s respective commitment. Additionally, a deterioration in our
financial performance may reduce our ability to draw on our revolving credit facilities.
We have a commercial paper program that currently enables us to borrow efficiently at short-term interest rates.
Upon maturity of any commercial paper borrowings under this program, and to the extent old issuances are not
repaid by cash on hand, we are exposed to the rollover risk of not being able to issue new commercial paper. Our
commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our revolving
credit facilities for an amount at least equal to our outstanding commercial paper borrowings. If we were not able to
issue new commercial paper, we have the option of drawing on the revolving credit facilities; however, electing to do
so would result in higher interest expense. As of December 31, 2024, we had $300 million of commercial paper
outstanding, which were repaid in full in January 2025.
We also maintain other credit arrangements, as described in Note 6 in Item 8 of this Annual Report on Form 10-K.
Access to Capital and Credit Ratings
We intend to fund short-term and long-term obligations as they mature through cash on hand, including the
proceeds from the recently completed sale of our Kidney Care business, future cash flows from operations, or by
issuing additional debt, which could include commercial paper. We had $1.76 billion of cash and cash equivalents
as of December 31, 2024, with adequate cash available to meet operating requirements in each jurisdiction in which
we operate. We invest our excess cash in money market and other funds and diversify the concentration of cash
among different financial institutions. As of December 31, 2024, we had $13.13 billion of long-term debt and finance
lease obligations, including current maturities, and short-term debt. As of February 21, 2025, we repaid $3.13 billion
of short- and long-term indebtedness primarily with the net after-tax cash proceeds from the sale of our Kidney Care
business, and we expect to use substantially all of the remaining net after-tax proceeds to continue to repay
indebtedness through the second quarter of 2025. Subject to market conditions, we regularly evaluate opportunities
with respect to our capital structure (including with respect to the potential refinancing of our outstanding
indebtedness).
Our ability to generate cash flows from operations, issue debt, including commercial paper, or enter into other
financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand
for our products or in the solvency of our customers or suppliers, deterioration in our key financial ratios or credit
ratings or other significantly unfavorable changes in conditions. However, we believe we have sufficient financial
flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to
support our growth objectives and further reduce our debt levels as we take actions consistent with our capital
allocation priorities.
53
Our credit ratings at December 31, 2024 were as follows:
Standard &
Poor’s
Moody’s
Ratings
Senior debt
BBB
Baa2
Short-term debt
A2
P2
Outlook
Negative
Stable
In May 2024, our contract with Fitch expired. In June 2024, Fitch affirmed and withdrew ratings and coverage on us.
As a result they no longer maintain ratings on our senior debt or our short-term debt.
Contractual Obligations
As of December 31, 2024, we had contractual obligations, excluding accounts payable and accrued expenses and
other current liabilities, payable or maturing in the following periods.
(in millions)
Total
Less than
one year
More than
one year
Long-term debt and finance lease obligations, including current maturities
$ 13,180 $
2,757 $ 10,423
Interest on short- and long-term debt and finance lease obligations 1
2,348
347
2,001
Operating leases
361
93
268
Other non-current liabilities2
323
—
323
Purchase obligations3
580
159
421
Contractual obligations2
$ 16,792 $
3,356 $ 13,436
1.
Interest payments on debt and finance lease obligations are calculated for future periods using interest
rates in effect at the end of 2024. Certain of these projected interest payments may differ in the future based
on foreign currency fluctuations or other factors or events. The projected interest payments only pertain to
obligations and agreements outstanding at December 31, 2024. Refer to Note 6 and Note 7, respectively, in
Item 8 of this Annual Report on Form 10-K for further discussion regarding our debt instruments outstanding
and finance lease obligations at December 31, 2024.
2.
The primary components of other non-current liabilities in our consolidated balance sheet as of
December 31, 2024 are pension and other postretirement benefits, deferred tax liabilities, long-term tax
liabilities, and litigation and environmental reserves. We projected the timing of the related future cash
payments based on contractual maturity dates (where applicable) and estimates of the timing of payments
(for liabilities with no contractual maturity dates). The actual timing of payments could differ from our
estimates.
We contributed $46 million and $27 million to our defined benefit pension plans in 2024 and 2023,
respectively. The timing of funding in future periods is uncertain and is dependent on future movements in
interest rates, investment returns, changes in laws and regulations, and other variables. Therefore, the table
above excludes cash outflows related to our pension plans. The amount included within other non-current
liabilities (and excluded from the table above) related to our pension plan liabilities was $553 million as of
December 31, 2024. We have no obligation to fund our principal plans in the United States in 2025. We
continually reassess the amount and timing of any discretionary contributions. In 2025, we expect to make
contributions of at least $26 million to our Puerto Rico plan and $7 million to our foreign pension plans. We
expect to have net cash outflows relating to our OPEB plans of $16 million in 2025. Additionally, we have
excluded long-term tax liabilities, which include liabilities for unrecognized tax positions, and deferred tax
liabilities from the table above because we are unable to estimate the timing of the related cash outflows.
The amounts of long-term tax liabilities and deferred tax liabilities included within other non-current liabilities
(and excluded from the table above) were $94 million and $103 million, respectively, as of December 31,
2024.
3.
Includes our significant contractual unconditional purchase obligations. For cancellable agreements, any
penalty due upon cancellation is included. These commitments do not exceed our projected requirements
and are in the normal course of business. Examples include firm commitments for raw material and
component part purchases, utility agreements and service contracts.
54
Off-Balance Sheet Arrangements
We periodically enter into off-balance sheet arrangements. Certain contingencies arise in the normal course of
business and are not recorded in the consolidated balance sheets in accordance with U.S. GAAP (such as
contingent joint development and commercialization arrangement payments). Also, upon resolution of uncertainties,
we may incur charges in excess of presently established liabilities for certain matters (such as contractual
indemnifications). For a discussion of our significant off-balance sheet arrangements, refer to Note 3 and Note 8 in
Item 8 of this Annual Report on Form 10-K for information regarding joint development and commercialization
arrangements, indemnifications and legal contingencies.
FINANCIAL INSTRUMENT MARKET RISK
We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be
adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage
these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and
costs. Refer to Note 16 in Item 8 of this Annual Report on Form 10-K for further information regarding our financial
instruments and hedging strategies.
Currency Risk
We are primarily exposed to foreign exchange risk with respect to revenues generated outside of the United States
denominated in the Euro, British Pound, Australian Dollar, Canadian Dollar, Chinese Renminbi, Japanese Yen,
Mexican Peso, Indian Rupee and Swedish Krona. We manage our foreign currency exposures on a consolidated
basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative
and nonderivative financial instruments to further reduce the net exposure to foreign exchange. Gains and losses on
the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and
stockholders’ equity volatility relating to foreign exchange. However, we don't hedge our entire foreign exchange
exposure and are still subject to earnings and stockholders' equity volatility relating to foreign exchange risk.
Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.
We primarily use forward contracts to hedge the foreign exchange risk to earnings relating to forecasted
transactions and recognized assets and liabilities denominated in foreign currencies. The maximum term over which
we have cash flow hedge contracts in place related to foreign exchange risk on forecasted transactions as of
December 31, 2024 is 11 months. We also enter into derivative instruments to hedge foreign exchange risk on
certain intra-company and third-party receivables and payables and debt denominated in foreign currencies.
As part of our risk-management program, we perform sensitivity analyses to assess potential changes in the fair
value of our foreign exchange instruments relating to hypothetical and reasonably possible near-term movements in
foreign exchange rates.
A sensitivity analysis of changes in the fair value of foreign exchange contracts outstanding as of December 31,
2024, while not predictive in nature, indicated that if the U.S. Dollar uniformly weakened by 10% against all
currencies, the net pre-tax asset balance of $5 million with respect to those contracts would change by $5 million. A
similar analysis performed with respect to contracts outstanding as of December 31, 2023 indicated that, on a pre-
tax basis, the net asset balance of $40 million would change by $151 million.
The sensitivity analysis model recalculates the fair value of the foreign exchange contracts outstanding as of
December 31, 2024 by replacing the actual exchange rates as of December 31, 2024 with exchange rates that are
10% weaker compared to the actual exchange rates for each applicable currency. All other factors are held
constant. These sensitivity analyses disregard the possibility that currency exchange rates can move in opposite
directions and that gains from one currency may or may not be offset by losses from another currency. The
analyses also disregard the offsetting change in value of the underlying hedged transactions and balances.
In February 2022, the three-year cumulative inflation rate in Turkey exceeded 100 percent. As a result, on April 1,
2022, we began reporting the results of our subsidiary in that jurisdiction using highly inflationary accounting, which
requires that the functional currency of the entity be changed to the reporting currency of its parent. As of
December 31, 2024, our subsidiary in Turkey had net monetary assets of $27 million.
55
Interest Rate Risk
We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in
interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt that we believe is
appropriate at that time. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps
in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts
calculated by reference to an agreed-upon notional amount. We also periodically use forward-starting interest rate
swaps and treasury rate locks to hedge the risk to earnings associated with fluctuations in interest rates relating to
anticipated issuances of term debt. As of December 31, 2024, there were no interest rate derivative contracts
outstanding and we had $3.48 billion of outstanding floating rate debt. A 100 basis point change in interest rates
would impact our pre-tax earnings and cash flows by $35 million over a one-year period.
CHANGES IN ACCOUNTING STANDARDS
Refer to Note 1 in Item 8 of this Annual Report on Form 10-K for information on recently adopted accounting
pronouncements.
RECENT ACCOUNTING PRONOUNCEMENTS
Recently issued accounting standards not yet adopted
In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)
2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of certain
expenses on an interim and annual basis in the notes to the financial statements. This standard is effective for
annual consolidated financial statements for the year ending December 31, 2027 and for interim periods beginning
in 2028. We are currently evaluating the impact of this new standard on our consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax
Disclosures, which requires (1) disclosure of specific categories in the rate reconciliation and (2) additional
information for reconciling items that meet a quantitative threshold. Additionally, the amendment requires disclosure
of certain disaggregated information about income taxes paid, income from continuing operations before income tax
expense (benefit) and income tax expense (benefit). The standard is effective for our annual consolidated financial
statements for the year ending December 31, 2025. We are currently evaluating the impact of this standard on our
consolidated financial statements.
CRITICAL ACCOUNTING POLICIES
The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates
and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. A summary of our
significant accounting policies is included in Note 1 in Item 8 of this Annual Report on Form 10-K. Certain of our
accounting policies are considered critical, as these policies are the most important to the depiction of our financial
statements and require significant, difficult or complex judgments by us, often employing the use of estimates about
the effects of matters that are inherently uncertain. Actual results that differ from our estimates could have an
unfavorable effect on our results of operations and financial position. The following is a summary of accounting
policies that we consider critical to the consolidated financial statements.
Revenue Recognition and Related Provisions and Allowances
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of
variable consideration primarily related to rebates and distributor chargebacks. These reserves are based on
estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration
historical experience, current contractual and statutory requirements, specific known market events and trends,
industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best
estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of
variable consideration included in the net sales price is limited to the amount that is probable not to result in a
significant reversal in the amount of the cumulative revenue recognized in a future period. Additionally, our
contracts with customers often include promises to transfer multiple products and services to a customer.
56
Determining whether products and services are considered distinct performance obligations that should be
accounted for separately and determining the allocation of the transaction price may require significant judgment.
Pension and OPEB Plans
We provide pension and other postretirement benefits to certain of our employees. The service component of
employee benefit expenses is reported in the same line items in the consolidated income statements as the
applicable employee’s compensation expense. All other components of these employee benefit expenses are
reported in other (income) expense, net in our consolidated statements of income (loss). The valuation of the
funded status and net periodic benefit cost for the plans is calculated using actuarial assumptions. These
assumptions are reviewed annually and revised if appropriate. The significant assumptions include the following:
•
interest rates used to discount pension and OPEB plan liabilities;
•
the long-term rate of return on pension plan assets;
•
rates of increase in employee compensation (used in estimating liabilities);
•
anticipated future healthcare trend rates (used in estimating the OPEB plan liability); and
•
other assumptions involving demographic factors such as retirement, mortality and turnover (used
in estimating liabilities).
Selecting assumptions involves an analysis of both short-term and long-term historical trends and known economic
and market conditions at the time of the valuation (also called the measurement date). The use of different
assumptions would result in different measures of the funded status and net cost. Actual results in the future could
differ from expected results.
Our key assumptions are listed in Note 13 in Item 8 of this Annual Report on Form 10-K. The most critical
assumptions relate to the plans covering U.S. and Puerto Rico employees, because these plans are the most
significant to our consolidated financial statements.
Discount Rate Assumption
Effective for the December 31, 2024 measurement date, we utilized discount rates of 5.72% and 5.55%,
respectively, to measure the benefit obligations for our most significant pension and OPEB plans, which cover U.S.
and Puerto Rico employees. We used a broad population of approximately 200 Aa-rated corporate bonds as of
December 31, 2024 to determine the discount rate assumption. All bonds were denominated in U.S. Dollars, with a
minimum amount outstanding of $50 million. This population of bonds was narrowed from a broader universe of
approximately 700 Moody’s Aa rated, non-callable (or callable with make-whole provisions) bonds by eliminating the
top 10th percentile and bottom 40th percentile to adjust for any pricing anomalies and to represent the bonds we
would most likely select if we were to actually annuitize our pension and OPEB plan liabilities. This portfolio of
bonds was used to generate a yield curve and associated spot rate curve to discount the projected benefit
payments for the U.S. and Puerto Rico plans. The discount rate is the single level rate that produces the same
result as the spot rate curve.
For plans in Canada, Japan, the United Kingdom and other European countries, we use a method essentially the
same as that described for the U.S. and Puerto Rico plans. For our other international plans, the discount rate is
generally determined by reviewing country- and region-specific government and corporate bond interest rates.
To understand the impact of changes in discount rates on pension and OPEB plan cost, we perform a sensitivity
analysis. Holding all other assumptions constant, for each 50 basis point increase in the discount rate, global pre-
tax pension and OPEB plan cost would decrease by $3 million, and for each 50 basis point decrease in the discount
rate, global pre-tax pension and OPEB plan cost would increase by $1 million.
Return on Plan Assets Assumption
In measuring the net periodic cost for 2024, we used a long-term expected rate of return of 6.75% for our most
significant pension plans, which cover U.S. and Puerto Rico employees. This assumption will remain the same in
2025. This assumption is not applicable to our OPEB plan because it is not funded.
57
We establish the long-term asset return assumption based on a review of historical compound average asset
returns, both company-specific and relating to the broad market (based on our asset allocation), as well as an
analysis of current market and economic information and future expectations. The current asset return assumption
is supported by historical market experience for both our actual and targeted asset allocation. In calculating net
pension cost, the expected return on assets is applied to a calculated value of plan assets, which recognizes
changes in the fair value of plan assets in a systematic manner over five years. The difference between this
expected return and the actual return on plan assets is a component of the total net unrecognized gain or loss and
is subject to amortization in the future.
To understand the impact of changes in the expected asset return assumption on net cost, we perform a sensitivity
analysis. Holding all other assumptions constant, for each 50 basis point increase (decrease) in the asset return
assumption, global pre-tax pension plan cost would decrease (increase) by approximately $14 million.
Other Assumptions
For the U.S. and Puerto Rico plans, we used the Pri-2012 combined mortality table with improvements projected
using the MP-2021 projection scale adjusted to a long-term improvement of 0.8% as of December 31, 2024. For all
other pension plans, we utilized country- and region-specific mortality tables to calculate the plans’ benefit
obligations. We periodically analyze and update our assumptions concerning demographic factors such as
retirement, mortality and turnover, considering historical experience as well as anticipated future trends.
The assumptions relating to employee compensation increases and future healthcare costs are based on historical
experience, market trends, and anticipated future company actions.
Deferred Tax Asset Valuation Allowances and Reserves for Uncertain Tax Positions
We maintain valuation allowances unless it is more likely than not that all or a portion of the deferred tax asset will
be realized. Changes in valuation allowances are included in our tax provision in the period of change. In
determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history,
expected future earnings, carryback and carryforward periods, and tax strategies that could potentially enhance the
likelihood of realization of a deferred tax asset. The realizability assessments made at a given balance sheet date
are subject to change in the future, particularly if earnings of a subsidiary are significantly higher or lower than
expected, or if we take operational or tax planning actions that could impact the future taxable earnings of a
subsidiary.
In the normal course of business, we are audited by federal, state and foreign tax authorities, and are periodically
challenged regarding the amount of taxes due. These challenges relate to the timing and amount of deductions and
the allocation of income among various tax jurisdictions. We believe our tax positions comply with applicable tax law
and we intend to defend our positions. In evaluating the exposure associated with various tax filing positions, we
record reserves for uncertain tax positions in accordance with U.S. GAAP based on the technical support for the
positions, our past audit experience with similar situations, and potential interest and penalties related to the
matters. Our results of operations and effective tax rate in a given period could be impacted if, upon final resolution
with taxing authorities, we prevail in positions for which reserves have been established, or we are required to pay
amounts in excess of established reserves.
Realization of our U.S. and foreign operating loss and tax credit carryforwards depends on generating sufficient
future earnings. A valuation allowance of $536 million and $584 million was recognized as of December 31, 2024
and 2023, respectively, to reduce the deferred tax assets associated with net operating loss and tax credit
carryforwards because we do not believe it is more likely than not that these assets will be fully realized prior to
expiration. After evaluating relevant U.S. tax laws, any elections or other opportunities that may be available, and
the future expiration of certain U.S. tax provisions that will impact the utilization of our U.S. foreign tax credit
carryforwards, management expects to be able to realize some, but not all, of the U.S. foreign tax credit deferred
tax assets up to its recurring and non-recurring foreign inclusions. Therefore, a valuation allowance of $131 million
and $130 million was recognized with respect to the foreign tax credit carryforwards as of December 31, 2024 and
2023, respectively. We will continue to evaluate the need for additional valuation allowances and, as circumstances
change, the valuation allowance may change.
58
Impairment of Goodwill and Other Long-Lived Assets
Goodwill
Goodwill is initially measured as the excess of the purchase price over the fair value (or other measurement
attribute required by U.S. GAAP) of acquired assets and liabilities in a business combination. Management performs
an impairment test in the fourth quarter of each year, or whenever events or changes in circumstances indicate that
the fair value of the reporting unit is more likely than not below its carrying amount. We have the option to assess
goodwill for impairment by initially performing a qualitative assessment to determine whether it is more-likely-than-
not that the fair value of a reporting unit is less than its carrying amount. If we determine that it is not more-likely-
than-not that the fair value of a reporting unit is less than its carrying amount, then the quantitative goodwill
impairment test is not required to be performed. If we determine that it is more-likely-than-not that the fair value of a
reporting unit is less than its carrying amount, or if we do not elect the option to perform an initial qualitative
assessment, we perform a quantitative goodwill impairment test. In the quantitative impairment test, we calculate
the estimated fair value of the reporting unit. If the carrying amount of the reporting unit exceeds the estimated fair
value, an impairment charge is recorded for the amount that the reporting unit’s carrying amount, including goodwill,
exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit.
In a quantitative goodwill impairment test, the fair values of our reporting units are generally determined based on a
discounted cash flow model (an income approach) and earnings multiples (a market approach) based on the
guideline public company method. Significant assumptions used in reporting unit fair value measurements generally
include revenue growth rates, forecasted EBITDA margins, discount rates, terminal growth rates and earnings
multiples. The discounted cash flow models used to determine the fair values of our reporting units during 2024
reflected our most recent cash flow projections, discount rates ranging from 9.0% to 9.5% and terminal growth rates
ranging from 3.0% to 3.25%. Each of these inputs can significantly affect the fair values of our reporting units.
Our operating and reportable segments were changed in the third quarter of 2023 to align with our new operating
model: Medical Products & Therapies, Healthcare Systems & Technologies (formerly referred to as our Hillrom
segment) and Pharmaceuticals. As a result of this segment change, we reallocated the goodwill from our previous
Americas, EMEA and APAC segments to the reporting units within our new Medical Products & Therapies and
Pharmaceuticals segments based on the relative fair values of those reporting units. We performed impairment
tests both before and after the reporting unit change and determined that no goodwill impairment had occurred.
In connection with our annual goodwill impairment assessment in the fourth quarter of 2024, we recorded a $425
million goodwill impairment related to our Front Line Care reporting unit within our Healthcare Systems &
Technologies segment. The reduction in value was primarily due to lower forecasted operating results and a lower
terminal growth rate utilized in valuing this reporting unit which contributed to reduced expected future cash flows,
as well as lower earnings multiples. The fair value of the Front Line Care reporting unit was determined based on a
discounted cash flow model (an income approach) and earnings multiples (a market approach) based on the
guideline public company method. Significant assumptions used in the determination of the fair values of our
reporting units generally include revenue growth rates, forecasted EBITDA margins, discount rates, terminal growth
rates and earnings multiples. The discounted cash flow model used to determine the fair value of our Front Line
Care reporting unit reflected our most recent cash flow projections, a discount rate of 9.5% and a terminal growth
rate of 3.25%. In order to evaluate the sensitivity of the fair value calculations used in the Front Line Care reporting
unit goodwill impairment test, we applied a hypothetical 5% decrease to the fair value and compared that
hypothetical value to the underlying asset carrying value. The application of a hypothetical 5% decrease in fair value
would result in an additional impairment of approximately $200 million. As of December 31, 2024, the carrying
amount of goodwill for our Front Line Care reporting unit was $1.99 billion. No goodwill impairments were recorded
for our remaining reporting units in connection with our annual goodwill impairment tests because the fair values of
those reporting units exceeded their carrying amounts.
We acquired Hillrom on December 13, 2021 and recognized $6.83 billion of goodwill and $6.03 billion of other
intangible assets, including $1.91 billion of indefinite-lived intangible assets, in connection with that acquisition. In
the second half of 2022, we recognized $2.81 of goodwill impairments related to the reporting units within our
Hillrom segment (currently referred to as out Healthcare Systems & Technologies segment). As discussed below,
we also recognized impairments of indefinite-lived intangible assets related to that business, consisting primarily of
trade names.
59
Other Long-Lived Assets
Other long-lived assets are primarily comprised of property, plant and equipment and intangible assets, including
both indefinite-lived intangible assets and amortizing intangible assets.
Indefinite-Lived Intangible Assets
Indefinite-lived intangible assets, such as IPR&D acquired in business combinations and certain trade names with
indefinite lives, are subject to an impairment review annually and whenever indicators of impairment exist. We have
the option to assess indefinite-lived intangible assets for impairment by first performing qualitative assessments to
determine whether it is more-likely-than-not that the fair values of the indefinite-lived intangible assets are less than
the carrying amounts. If we determine that it is more-likely-than-not that an indefinite-lived intangible asset is
impaired, or if we elect not to perform an initial qualitative assessment, we then perform the quantitative impairment
test by comparing the fair value of the indefinite-lived intangible asset with its carrying amount. If the carrying
amount exceeds the fair value of the indefinite-lived intangible asset, we write the carrying amount down to the fair
value.
In a quantitative indefinite-lived intangible asset impairment test, fair values are generally determined based on a
discounted cash flow model. Significant assumptions used in valuations of indefinite-lived intangible assets include
the forecasted cash flows, discount rates, the assessment of the asset’s life cycle, the stage in completion (for
acquired IPR&D intangible assets), royalty rates, terminal growth rates and contributory asset charges. The relief
from royalty models used in the determination of the fair values of our trade name intangible assets during 2024
reflected our most recent revenue projections, a discount rate of 9%, a royalty rate of 5% and a terminal growth rate
of 3.0%. Each of these factors and assumptions can significantly affect the value of the intangible asset. We tested
our indefinite-lived intangible trade name intangible asset for impairment during the fourth quarter of 2024 and
determined that no impairment had occurred.
In connection with our annual IPR&D impairment assessment in the fourth quarter of 2024, we recognized a pre-tax
impairment charge of $50 million to reduce the carrying amount of an IPR&D asset to its fair value. The reduction in
value was primarily due to lower forecasted revenues and margins which contributed to reduced expected future
cash flows. The intangible asset impairment charge is classified within research and development expenses in the
accompanying consolidated statements of income (loss) for the year ended December 31, 2024. The fair value of
the IPR&D asset was determined using the multi-period excess earnings method. Significant assumptions used in
the determination of the fair value of the IPR&D asset included forecasted cash flows and the discount rate. The
multi-period excess earnings model used in our determination of the fair value of the IPR&D asset reflected our
most recent cash flow projections and a discount rate of 11%.
The total carrying amount of our indefinite-lived intangible assets was $787 million as of December 31, 2024,
comprised of a trade name intangible asset and IPR&D.
During the fourth quarter of 2023, as a result of an update to our long-term branding strategy, we reclassified two
trade name intangible assets with carrying amounts of $870 million and $21 million from indefinite-lived intangible
assets to amortizing intangible assets. The estimated useful lives assigned to those assets were 15 years and 5
years, respectively. We performed impairment tests of those intangible assets at the time of the reclassification and
determined that no impairment had occurred.
Intangible Assets with Definite Lives and Property, Plant and Equipment
We review the carrying amounts of long-lived assets used in operations, other than goodwill and intangible assets
not subject to amortization, for potential impairment when events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. In evaluating recoverability, we group assets and liabilities at
the lowest level such that the identifiable cash flows relating to the group are largely independent of the cash flows
of other assets and liabilities. We then compare the carrying amounts of the assets or asset groups with the related
estimated undiscounted future cash flows. In the event an asset (or asset group) is not recoverable, an impairment
charge is recorded as the amount by which the carrying amount of the asset (or asset group) exceeds its fair value.
However, the portion of an impairment loss allocated to an individual long-lived asset within an asset group cannot
reduce the carrying amount of that asset below its fair value if its fair value is determinable without undue cost and
effort.
60
During the third quarter of 2022, we recognized pre-tax impairment charges of $332 million to reduce the carrying
amounts of certain indefinite-lived intangible assets, which primarily related to the Hillrom and Welch Allyn trade
names acquired in the Hillrom acquisition, to their estimated fair values. Additionally, during 2022 we recognized
pre-tax impairment charges of $12 million related to developed technology intangible assets due to declines in
market expectations for the related products.
Long-Lived Assets Held for Sale
Long-lived assets are classified as held for sale when certain criteria are met, including when management has
committed to sell the asset, the asset is available for sale in its present condition and the sale is probable of being
completed within one year of the balance sheet date. Assets held for sale are no longer depreciated or amortized
and they are reported at the lower of their carrying amount or fair value less cost to sell.
Our goodwill and other long-lived asset fair value measurements are classified as Level 3 in the fair value hierarchy
because they involve significant unobservable inputs.
Further adverse changes to macroeconomic conditions or our earnings forecasts could lead to additional goodwill or
other long-lived asset impairment charges in future periods and such charges could be material to our results of
operations.
CERTAIN REGULATORY MATTERS
In July 2017, immediately prior to the closing of our acquisition of Claris Injectables Limited (Claris), FDA
commenced an inspection of the Claris’ facilities in Ahmedabad, India. FDA completed the inspection and
subsequently issued a Warning Letter based on observations identified in the 2017 inspection (2017 Warning
Letter).¹ FDA re-inspected the facilities and issued a Form FDA 483 on May 17, 2022. On September 1, 2022, FDA
notified us that the inspection had been classified as voluntary action indicated. From January 19, 2023 to January
27, 2023, FDA performed an inspection at the Ahmedabad site, concluding with the issuance of a Form FDA 483.
On April 26, 2023, FDA notified us that the inspection had been classified as official action indicated. We received a
Warning Letter on July 25, 2023 based on observations identified in the January 2023 inspection (2023 Warning
Letter)2. Since the issuance of the 2017 Warning Letter, we have implemented corrective and preventive actions to
address FDA's related observations, as well as other enhancements at the site. We have fully responded to the
2023 Warning Letter, have implemented additional corrective and preventive actions, and continue to engage with
FDA regarding the agency's observations. In addition, since the issuance of the 2017 Warning Letter, we have
secured other sites in our manufacturing network and have launched and distribute select products from those sites
in the U.S.
Refer to Item 1A. Risk Factors of this Annual Report on Form 10-K for additional discussion of regulatory matters
and how they may impact us.
1 Available online at https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm613538.htm
2 Available online at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-
letters/baxter-healthcare-corporation-654136-07252023
FORWARD-LOOKING INFORMATION
Certain statements contained in this Annual Report may constitute “forward-looking statements,” as defined in the
Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements
provide current expectations of future events based on certain assumptions and include any statement that does not
directly relate to any historical or current fact. These statements by their nature address matters that are uncertain
to different degrees. Use of the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,”
“potential,” “expects,” “plans,” “seeks,” “intends,” “evaluates,” “pursues,” “anticipates,” “continues,” “designs,”
“impacts,” “affects,” “forecasts,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the
negative of those words or other similar expressions may identify forward-looking statements, although not all
forward-looking statements contain such words. These forward-looking statements may include statements with
respect to the anticipated benefits of our recent strategic actions, our ability to successfully integrate acquisitions,
the expected growth rates for our segments, accounting estimates and assumptions (including with respect to
goodwill and other intangible asset impairments), global economic conditions, litigation-related matters, future
61
regulatory filings (or the withdrawal or resubmission of any pending submissions) and our R&D pipeline (including
anticipated product approvals or clearances), sales from new product offerings, credit exposure to foreign
governments, the adequacy of cash flows and credit facilities, potential developments with respect to credit ratings,
investment of foreign earnings, estimates of liabilities including those related to uncertain tax positions, contingent
payments, future pension plan contributions, costs, discount rates and rates of return, our exposure to financial
market volatility and foreign currency, interest rate and credit risks, our net interest expense, the impact of inflation
on our business, the impact of any significant new tariffs or changes in trade policies and treaties, the impact of
competition, future sales growth, business development activities, cost saving initiatives, future capital and R&D
expenditures, future debt issuances and refinancings, the adequacy of tax provisions and reserves, the effective
income tax rate, the impacts of severe weather events (including Hurricane Helene) and all other statements that do
not relate to historical facts.
These forward-looking statements are based on certain assumptions and analyses made in light of our experience
and perception of historical trends, current conditions, and expected future developments as well as other factors
that we believe are appropriate in the circumstances. While these statements represent our judgment on what the
future may hold, and we believe these judgments are reasonable, these statements are not guarantees of any
events or financial results. Whether actual future results and developments will conform to expectations and
predictions is subject to a number of risks and uncertainties, including the following factors, many of which are
beyond our control:
•
our ability to achieve the intended benefits of our recent strategic actions, including the sale of our Kidney
Care business, and cost saving initiatives;
•
our ability to successfully integrate acquisitions, including the acquisition of Hillrom, and the related impact
on our organization structure, senior leadership, culture, functional alignment, outsourcing and other areas,
our management of resulting related personnel capacity constraints and potential institutional knowledge
loss, and our ability to achieve anticipated performance or financial targets and maintain our reputation
following integration;
•
the impact of global economic conditions (including, among other things, changes in taxation, tariffs, trade
policies and treaties, sanctions, embargos, export control restrictions, inflation levels and interest rates,
financial market volatility, banking crises, the potential for a recession, the war in Ukraine, the conflict in the
Middle East and other geopolitical events and the potential for escalation of these conflicts, the related
economic sanctions being imposed globally in response to the conflicts and potential trade wars, global
public health crises, pandemics and epidemics, or the anticipation of any of the foregoing, on our operations
and our employees, customers, suppliers, and foreign governments in countries in which we operate;
•
failure to accurately forecast or achieve our short-and long-term financial performance and goals, market
and category growth rates, and related impacts on our liquidity;
•
our ability to execute on our capital allocation plans, including our debt repayment plans, the timing and
amount of any dividends, share repurchases and divestiture proceeds;
•
downgrades to our credit ratings or ratings outlooks, or withdrawals by rating agencies from rating us and
our indebtedness, and the related impact on our funding costs and liquidity;
•
fluctuations in foreign exchange and interest rates;
•
the impact of any goodwill, intangible asset, or other long-lived asset impairments on our operating results;
•
our ability to finance and develop new products or services, or enhancements thereto, on commercially
acceptable terms or at all;
•
product development risks, including satisfactory clinical performance and obtaining and maintaining
required regulatory approvals (including as a result of evolving regulatory requirements or the withdrawal or
resubmission of any pending applications), the ability to manufacture at appropriate scale, and the general
unpredictability associated with the product development cycle;
•
demand and market acceptance risks for, and competitive pressures related to, new and existing products
and services, challenges with accurately predicting changing customer preferences and future expenditures
and inventory levels and with being able to monetize new and existing products and services (and to
sustain any related price increases), the impact of those products and services on quality and patient safety
concerns, and the need for ongoing training and support for our products and services;
62
•
the impact of competitive products and pricing, including generic competition, drug reimportation, and
disruptive technologies;
•
regulatory agency inspections, product quality or patient safety issues leading to product recalls,
withdrawals, labeling changes, launch delays, warning letters, import bans, denial of import certifications,
sanctions, seizures, litigation, or declining sales, including the focus on evaluating product portfolios for the
potential presence or formation of nitrosamines;
•
future actions of, or failures to act or delays in acting by FDA, the European Medicines Agency, or any other
regulatory body or government authority (including the SEC, DOJ, or the Attorney General of any state) that
could delay, limit or suspend product development, manufacturing or sale or result in seizures, recalls,
injunctions, monetary sanctions or criminal or civil liabilities;
•
failures with respect to our quality, compliance or ethics programs;
•
loss of key employees, including senior management, the occurrence of labor disruptions (including as a
result of labor disagreements under bargaining agreements or national trade union agreements or disputes
with works councils) or the inability to attract, develop, retain and engage employees;
•
inability to create additional production capacity in a timely manner or the occurrence of other
manufacturing, sterilization, or supply difficulties, including as a result of natural disaster (such as Hurricane
Helene), war, terrorism, global public health crises and epidemics/pandemics, regulatory actions, or
otherwise;
•
future actions of third parties, including third-party payors and our customers and distributors (including
GPOs and IDNs);
•
the continuity, availability, and pricing of acceptable raw materials and component parts, our ability to pass
some or all of these costs to our customers through price increases or otherwise, and the related continuity
of our manufacturing and distribution and those of our suppliers;
•
breaches, including by cyber-attack, data leakage, unauthorized access or theft, or failures of or
vulnerabilities in, our information technology systems, or products;
•
ability to effectively develop, integrate or deploy artificial intelligence, machine learning and other emerging
technologies into our products, services and operations in a manner that is compliant with existing and
emerging regulations;
•
the impact of physical effects of climate change, severe storms (including Hurricane Helene) and storm-
related events, including our ability to resume production at our North Cove facility to pre-hurricane levels
and to complete the remediation;
•
changes to legislation and regulation and other governmental pressures in the United States and globally,
including the cost of compliance and potential penalties for purported noncompliance thereof, including new
or amended laws, rules and regulations as well as the impact of healthcare reform and its implementation,
suspension, repeal, replacement, amendment, modification and other similar actions undertaken by the
United States or foreign governments, including with respect to pricing, reimbursement, taxation and rebate
policies;
•
ability meet evolving and varied corporate responsibility expectations of our stakeholders, including
compliance with new and emerging sustainability regulations;
•
global regulatory, trade, and tax policies, including with respect to climate change and other sustainability
matters;
•
the ability to protect or enforce our patents or other proprietary rights (including trademarks, copyrights,
trade secrets, and know-how) or where the patents of third parties prevent or restrict our manufacture, sale,
or use of affected products or technology;
•
any changes in law concerning the taxation of income (whether with respect to current or future tax reform);
•
actions by tax authorities in connection with ongoing tax audits;
•
the outcome of pending or future litigation;
•
other factors discussed elsewhere in this Annual Report on Form 10-K, including those factors described in
Item 1A. Risk Factors, and other filings with the SEC, all of which are available on our website.
63
Actual results may differ materially from those projected in the forward-looking statements, which are more fully
discussed in Item 1A. Risk Factors and Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations and elsewhere in this Annual Report on Form 10-K. These forward-looking statements are not
exclusive and are in addition to other factors discussed elsewhere in this Annual Report on Form 10-K. Further,
other unknown or unpredictable factors could also have material adverse effects on future results. Any forward-
looking statement in this Annual Report on Form 10-K speaks only as of the date on which it is made. Except as
required by law, we assume no obligation, and expressly disclaim any obligation, to update or revise any forward-
looking statements, whether as a result of new information or future events.
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk.
Incorporated by reference to the section entitled “Financial Instrument Market Risk” in Item 7. Management’s
Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K.
64
Item 8.
Financial Statements and Supplementary Data.
CONSOLIDATED BALANCE SHEETS
as of December 31 (in millions, except share information)
2024
2023
Current assets:
Cash and cash equivalents
$
1,764 $
3,078
Accounts receivable, net of allowance of $71 in 2024 and $62 in 2023
1,679
1,719
Inventories
2,046
1,918
Prepaid expenses and other current assets
753
706
Current assets of discontinued operations
2,611
2,179
Total current assets
8,853
9,600
Property, plant and equipment, net
2,870
2,871
Goodwill
5,275
5,793
Other intangible assets, net
5,223
5,918
Operating lease right-of-use assets
306
336
Other non-current assets
755
809
Non-current assets of discontinued operations
2,500
2,949
Total assets
$
25,782 $
28,276
Current liabilities:
Short-term debt
$
2,126 $
—
Current maturities of long-term debt and finance lease obligations
626
2,667
Accounts payable
968
881
Accrued expenses and other current liabilities
1,861
1,915
Current liabilities of discontinued operations
930
1,040
Total current liabilities
6,511
6,503
Long-term debt and finance lease obligations, less current portion
10,374
11,089
Operating lease liabilities
243
265
Other non-current liabilities
1,076
1,400
Non-current liabilities of discontinued operations
554
551
Total liabilities
18,758
19,808
Commitments and contingencies
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944
shares in 2024 and 2023
683
683
Common stock in treasury, at cost, 172,567,636 shares in 2024 and 175,861,893
shares in 2023
(11,059)
(11,230)
Additional contributed capital
6,421
6,389
Retained earnings
14,929
16,114
Accumulated other comprehensive income (loss)
(4,010)
(3,554)
Total Baxter stockholders’ equity
6,964
8,402
Noncontrolling interests
60
66
Total equity
7,024
8,468
Total liabilities and equity
$
25,782 $
28,276
The accompanying notes are an integral part of these consolidated financial statements.
65
CONSOLIDATED STATEMENTS OF INCOME (LOSS)
years ended December 31 (in millions, except per share data)
2024
2023
2022
Net sales
$
10,636 $
10,360 $
10,057
Cost of sales
6,652
6,210
6,508
Gross margin
3,984
4,150
3,549
Selling, general and administrative expenses
2,967
2,953
3,097
Research and development expenses
590
518
450
Goodwill impairments
425
—
2,812
Other operating expense (income), net
(12)
(28)
35
Operating income (loss)
14
707
(2,845)
Interest expense, net
341
439
394
Other (income) expense, net
(38)
26
9
Income (loss) from continuing operations before income taxes
(289)
242
(3,248)
Income tax (benefit) expense
37
61
(135)
Income (loss) from continuing operations
(326)
181
(3,113)
Income (loss) from discontinued operations, net of tax
(312)
2,482
692
Net income (loss)
(638)
2,663
(2,421)
Less: Net income attributable to noncontrolling interests included in
continuing operations
—
—
1
Less: Net income attributable to noncontrolling interests included in
discontinued operations
11
7
11
Net income (loss) attributable to Baxter stockholders
$
(649) $
2,656 $
(2,433)
Income (loss) from continuing operations per common share
Basic
$
(0.64) $
0.36 $
(6.18)
Diluted
$
(0.64) $
0.36 $
(6.18)
Income (loss) from discontinued operations per common share
Basic
$
(0.63) $
4.89 $
1.35
Diluted
$
(0.63) $
4.87 $
1.35
Net Income (loss) per common share
Basic
$
(1.27) $
5.25 $
(4.83)
Diluted
$
(1.27) $
5.23 $
(4.83)
Weighted-average number of shares outstanding
Basic
510
506
504
Diluted
510
508
504
The accompanying notes are an integral part of these consolidated financial statements.
66
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
years ended December 31 (in millions)
2024
2023
2022
Income (loss) from continuing operations
$
(326) $
181 $ (3,113)
Other comprehensive income (loss) from continuing operations, net of tax:
Currency translation adjustments, net of tax expense (benefit) of $1 in 2024,
($26) in 2023 and $35 in 2022
(648)
301
(647)
Pension and other postretirement benefit plans, net of tax expense of $(6) in
2024, $(25) in 2023 and $10 in 2022
(19)
(92)
(39)
Hedging activities, net of tax expense (benefit) of $3 in 2024, zero in 2023
and $2 in 2022
12
(1)
7
Available-for-sale debt securities, net of tax expense of zero in 2024 and
2023 and $1 in $2 in 2022
—
—
3
Total other comprehensive income (loss) from continuing operations, net of tax
(655)
208
(676)
Comprehensive income (loss) from continuing operations
(981)
389
(3,789)
Income (loss) from discontinued operations, net of tax
(312)
2,482
692
Other comprehensive income (loss) from discontinued operations
Currency translation adjustments, net of tax expense (benefit) of $(7) in 2024,
$8 in 2023 and $6 in 2022
187
97
168
Pension and other postretirement benefit plans, net of tax expense of $3 in
2024, $(2) in 2023 and $2 in 2022
(4)
(29)
55
Total other comprehensive income from discontinued operations
183
68
223
Comprehensive income (loss) from discontinued operations
(129)
2,550
915
Comprehensive income (loss)
(1,110)
2,939
(2,874)
Less: Net income attributable to noncontrolling interests
11
7
12
Less: Other comprehensive income (loss) attributable to noncontrolling interests
(16)
(3)
(5)
Comprehensive income (loss) attributable to Baxter stockholders
$ (1,105) $
2,935 $ (2,881)
The accompanying notes are an integral part of these consolidated financial statements.
67
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
Baxter International Inc. stockholders' equity
(in millions)
Common stock
shares
Common
stock
Common stock
shares in
treasury
Common stock
in treasury
Additional
contributed
capital
Retained
earnings
Accumulated
other
comprehensive
income (loss)
Total Baxter
stockholders'
equity
Noncontrolling
interests
Total equity
Balance as of January 1, 2022
683 $
683
182 $
(11,488) $
6,197 $
17,065 $
(3,380) $
9,077 $
44 $
9,121
Net income (loss)
—
—
—
—
—
(2,433)
—
(2,433)
12
(2,421)
Other comprehensive income (loss)
—
—
—
—
—
—
(453)
(453)
(5)
(458)
Purchases of treasury stock
—
—
—
(32)
—
—
—
(32)
—
(32)
Stock issued under employee benefit plans and other
—
—
(3)
131
125
—
—
256
—
256
Dividends declared on common stock
—
—
—
—
—
(582)
—
(582)
—
(582)
Change in noncontrolling interests
—
—
—
—
—
—
—
—
11
11
Balance as of December 31, 2022
683 $
683
179 $
(11,389) $
6,322 $
14,050 $
(3,833) $
5,833 $
62 $
5,895
Net income (loss)
—
—
—
—
—
2,656
—
2,656
7
2,663
Other comprehensive income (loss)
—
—
—
—
—
—
279
279
(3)
276
Stock issued under employee benefit plans and other
—
—
(3)
159
67
—
—
226
—
226
Dividends declared on common stock
—
—
—
—
—
(592)
—
(592)
—
(592)
Balance as of December 31, 2023
683 $
683
176 $
(11,230) $
6,389 $
16,114 $
(3,554) $
8,402 $
66 $
8,468
Net income (loss)
—
—
—
—
—
(649)
—
(649)
11
(638)
Other comprehensive income (loss)
—
—
—
—
—
—
(456)
(456)
(16)
(472)
Stock issued under employee benefit plans and other
—
—
(3)
171
32
—
—
203
—
203
Dividends declared on common stock
—
—
—
—
—
(536)
—
(536)
—
(536)
Change in noncontrolling interests
—
—
—
—
—
—
—
—
(1)
(1)
Balance as of December 31, 2024
683 $
683
173 $
(11,059) $
6,421 $
14,929 $
(4,010) $
6,964 $
60 $
7,024
The accompanying notes are an integral part of these consolidated financial statements.
68
CONSOLIDATED STATEMENTS OF CASH FLOWS
years ended December 31 (in millions)
2024
2023
2022
Cash flows from operations
Net income (loss)
$
(638) $ 2,663 $ (2,421)
Less: Income (loss) from discontinued operations, net of tax
(312)
2,482
692
Income (loss) from continuing operations
(326)
181
(3,113)
Adjustments to reconcile net income (loss) to cash flows from operations:
Depreciation and amortization
997
984
1,072
Pension settlement and curtailment (gains) losses
—
1
(12)
Net periodic pension and other postretirement costs
(28)
(29)
42
Deferred income taxes
(262)
(256)
(260)
Stock compensation
114
115
140
Goodwill impairments
425
—
2,812
Intangible asset impairments
50
—
344
Other long-lived asset impairments
44
(11)
9
Loss on product divestiture arrangement
—
—
54
Reclassification of cumulative translation loss to earnings
—
—
65
Loss on subsidiary liquidation
—
—
21
Other
41
61
(40)
Changes in balance sheet items:
Accounts receivable, net
(35)
(38)
(48)
Inventories
(201)
(128)
(198)
Prepaid expenses and other current assets
(125)
(45)
(44)
Accounts payable
112
92
(67)
Accrued expenses and other current liabilities
44
293
(158)
Other
(31)
(13)
(91)
Cash flows from operations – continuing operations
819
1,207
528
Cash flows from operations – discontinued operations
200
519
683
Cash flows from operations
1,019
1,726
1,211
Cash flows from investing activities
Capital expenditures
(446)
(432)
(377)
Acquisitions of developed technology and investments
(14)
(4)
(258)
Proceeds from sale of marketable equity securities
34
—
—
Other investing activities, net
16
26
11
Cash flows from investing activities - continuing operations
(410)
(410)
(624)
Cash flows from investing activities - discontinued operations
(216)
3,623
(307)
Cash flows from investing activities
(626)
3,213
(931)
Cash flows from financing activities
Increase in short term debt
1,830
—
—
Repayments of debt
(2,657)
(2,634)
(954)
Net (decreases) increases in debt with original maturities of three months or less
296
(301)
55
Cash dividends on common stock
(590)
(586)
(573)
Proceeds from stock issued under employee benefit plans
71
95
127
Purchases of treasury stock
—
—
(32)
Other financing activities, net
(31)
(63)
(61)
Cash flows from financing activities
(1,081)
(3,489)
(1,438)
69
Effect of foreign exchange rate changes on cash, cash equivalents and restricted
cash
(96)
26
(76)
Increase (decrease) in cash, cash equivalents and restricted cash
(784)
1,476
(1,234)
Cash, cash equivalents and restricted cash at beginning of year (1)
3,198
1,722
2,956
Cash, cash equivalents and restricted cash at end of year (1)
2,414
3,198
1,722
Less cash and cash equivalents of discontinued operations
648
116
97
Cash, cash equivalents and restricted cash of continuing operations
$ 1,766 $ 3,082 $ 1,625
(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash amounts as shown in
the consolidated statement of cash flows to the amount reported in the consolidated balance sheet as of
December 31, 2024, 2023, and 2022:
As of December 31 (in millions)
2024
2023
2022
Cash and cash equivalents
$
1,764 $
3,078 $
1,621
Restricted cash included in prepaid expenses and other current assets
2
4
4
Cash, cash equivalents and restricted cash
$
1,766 $
3,082 $
1,625
The accompanying notes are an integral part of these consolidated financial statements.
70
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations
Baxter International Inc., through our subsidiaries (collectively, Baxter, we, our or us), provides a broad portfolio of
essential healthcare products, including sterile intravenous (IV) solutions; infusion systems, administrative sets;
parenteral nutrition therapies; surgical hemostat, sealant and adhesion prevention products; connected care
solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic
technologies; respiratory health devices; advanced equipment for the surgical space, including operating room
integration technologies, precision positioning devices and other accessories; injectable pharmaceuticals; inhaled
anesthetics and drug compounding services. These products are used by hospitals, nursing homes, rehabilitation
centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers and patients at home under physician
supervision. Our global footprint and the critical nature of our products and services play a key role in expanding
access to healthcare in emerging and developed countries. Our business is comprised of three reportable
segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals which are
described in Note 18.
On August 12, 2024, we entered into an Equity Purchase Agreement (EPA ) with certain affiliates of Carlyle Group
Inc. (Carlyle) to sell our Kidney Care business. That business, which is now known as Vantive Health LLC (Vantive)
is comprised of our former Kidney Care segment and provides chronic and acute dialysis therapies and services,
including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support
therapies. On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate
purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments. After
giving effect to certain adjustments, we received approximately $3.71 billion pre-tax cash proceeds at closing of the
transaction with the net after tax proceeds currently estimated to be approximately $3.4 billion, subject to certain
post-closing adjustments. We determined that our Kidney Care business met the criteria to be classified as held-for-
sale in August 2024, and we also concluded that it met the conditions to be reported as a discontinued operation at
that time. Accordingly, our Kidney Care business is reported in discontinued operations in the accompanying
consolidated financial systems, and our prior period results have been adjusted to reflect discontinued operations
presentation. See Note 2 for additional information.
Hurricane Helene
In September 2024, Hurricane Helene, which brought significant rain and extensive flooding to Western North
Carolina, caused damage to certain of our assets at our North Cove facility in Marion, N.C. and disrupted operations
at that facility. Since then, we have actively worked with our customers, regulators and other stakeholders to
manage inventory and minimize disruption to patient care as we worked towards resuming our North Cove
manufacturing operations. Our insurance policies generally cover the repair or replacement of our assets that suffer
loss or damage, less applicable deductibles and subject to any coverage limits and exclusions. Our insurance
policies also provide coverage for interruption to our business, including lost profits, and reimbursement for other
expenses and costs that have been incurred relating to the damages and losses suffered. In 2024, we recorded
$110 million of pre-tax net charges related to damages caused by Hurricane Helene. This consisted of $44 million
related to the write-off of damaged inventory and fixed assets as well as $317 million of remediation, idle facility, air
freight and other costs offset by $251 million of insurance recoveries. These amounts were recorded as a
component of cost of sales in the consolidated statement of income (loss) for the year ended December 31, 2024.
Risks and Uncertainties
Supply Constraints and Global Economic Conditions
In recent years, we have experienced significant challenges to our global supply chain, including production delays
and interruptions, increased costs and shortages of raw materials and component parts (including resins and
electromechanical devices), higher transportation costs, adverse impacts from significant weather events (including
Hurricane Helene and the flooding of our North Cove facility), elevated inflation levels and interest rates, disruptions
to certain ports of call and access to shipping lanes around the world, the war in Ukraine, the conflict in the Middle
East and other geopolitical events. While we have seen improvements in the availability of component parts and
71
improved pricing of raw materials and on transportation costs, some of these challenges (such as additional
transportation costs resulting from Hurricane Helene as we transfer product across our global network in the interest
of increasing the availability of intravenous solutions for our customers while we work to fully remediate our North
Cove facility) are expected to have a negative impact on our results of operations in the future.
We expect that the challenges caused by global economic conditions, among other factors, may continue to have
an adverse effect on our business.
Use of Estimates
The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (U.S.
GAAP) requires us to make estimates and assumptions that affect the reported amounts and related disclosures in
the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Principles of Consolidation
The consolidated financial statements include the accounts of Baxter and our majority-owned subsidiaries that we
control, after elimination of intra-company balances and transactions.
Revenue Recognition
Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or
providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the
customer and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct
performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our
contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate
the contract’s transaction price to each performance obligation using our best estimate of the standalone selling
price of each distinct good or service in the contract. Our global payment terms are typically between 30-90 days.
Our primary customers are hospitals, healthcare distribution companies and government agencies that purchase
healthcare products on behalf of providers. Most of our performance obligations are satisfied at a point in time. This
includes sales of our broad portfolio of essential healthcare products across our business segments. We earn
revenues from sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics;
generic injectable pharmaceuticals; surgical hemostat and sealant products, smart bed systems; patient monitoring
and diagnostic technologies; respiratory health devices; and advanced equipment for the surgical space. For most
of those offerings, our performance obligation is satisfied upon delivery to the customer. Shipping and handling
activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.
To a lesser extent, we enter into arrangements for which revenue may be recognized over time. For example, we
lease medical equipment to customers under operating lease arrangements and recognize the related revenues on
a monthly basis over the lease term. Our Healthcare Systems & Technologies segment includes connected care
solutions and collaboration tools that are implemented over time. We recognize revenue for these arrangements
over time or at a point in time depending on our evaluation of when the customer obtains control of the promised
goods or services. We also earn revenue from contract manufacturing activities, which is recognized over time as
the services are performed. Revenue is recognized over time when we are creating or enhancing an asset that the
customer controls as the asset is created or enhanced or our performance does not create an asset with an
alternative use and we have an enforceable right to payment for performance completed.
As of December 31, 2024, we had $5.47 billion of transaction price allocated to remaining performance obligations
related to executed contracts with an original duration of more than one year, which are primarily included in the
Medical Product and Therapies segments. Some contracts in the United States included in this amount contain
index-dependent price increases, which are not known at this time. We expect to recognize approximately 25% of
this amount as revenue in 2025, 20% in 2026, 20% in 2027, 35% in 2028 and the remainder thereafter.
Significant Judgments
Revenues from product sales are recorded at the net sales price, which includes estimates of variable
consideration, primarily related to rebates and distributor chargebacks. These reserves are based on estimates of
the amounts earned or to be claimed on the related sales and are included in accrued expenses and other current
liabilities and as reductions of accounts receivable, net on the consolidated balance sheets. Management's
estimates take into consideration historical experience, current contractual and statutory requirements, specific
known market events and trends, industry data and forecasted customer buying and payment patterns. Overall,
72
these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms
of the contract using the expected value method. The amount of variable consideration included in the net sales
price is limited to the amount for which it is probable that a significant reversal in revenue will not occur when the
related uncertainty is resolved. Revenue recognized in the years ended December 31, 2024, 2023 and 2022 related
to performance obligations satisfied in prior periods was not material. Additionally, our contracts with customers
often include promises to transfer multiple products and services to a customer. Determining whether products and
services are considered distinct performance obligations that should be accounted for separately and determining
the allocation of the transaction price may require significant judgment.
Practical Expedients
We apply a practical expedient to expense as incurred costs to obtain a contract with a customer when the
amortization period would have been one year or less. We do not disclose the value of the transaction price that is
allocated to unsatisfied performance obligations for contracts with an original expected length of less than one year.
We have elected to use the practical expedient to not adjust the promised amount of consideration for the effects of
a significant financing component if it is expected, at contract inception, that the period between when we transfer a
promised good or service to a customer and when the customer pays for that good or service will be one year or
less. Additionally, all taxes assessed by a governmental authority that are both imposed on and concurrent with a
specific revenue-producing transaction and collected from a customer are excluded from revenue.
Accounts Receivable and Allowance for Doubtful Accounts
In the normal course of business, we provide credit to our customers, perform credit evaluations of these customers
and maintain reserves for potential credit losses. In determining the amount of the allowance for doubtful accounts,
we consider, among other items, historical credit losses, the past-due status of receivables, payment histories, other
customer-specific information, current economic conditions and reasonable and supportable future forecasts.
Receivables are written off when we determine that they are uncollectible.
Shipping and Handling Costs
Shipping costs incurred to physically move product from our premises to the customer’s premises are classified as
selling, general and administrative (SG&A) expenses. Handling costs, which are costs incurred to store, move and
prepare products for shipment, are classified as cost of sales. Approximately $382 million in 2024, $358 million in
2023 and $388 million in 2022 of shipping costs were classified in SG&A expenses.
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents include cash, certificates of deposit and money market and other short-term funds with
original maturities of three months or less. Restricted cash represents cash balances restricted as to withdrawal or
use and are included in prepaid expenses and other current assets on the consolidated balance sheets.
Inventories
Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method. We
review inventories on hand at least quarterly and record provisions for estimated excess, slow-moving and obsolete
inventory, as well as inventory with a carrying value in excess of net realizable value.
Property, Plant and Equipment, Net
Property, plant and equipment are stated at cost. Depreciation expense is calculated using the straight-line method
over the estimated useful lives of the related assets, which range from 20 to 50 years for buildings and
improvements and from 3 to 15 years for machinery and equipment. Leasehold improvements are amortized over
the life of the related facility lease (including any renewal periods, if appropriate) or the asset, whichever is shorter.
We capitalize certain computer software and software development costs incurred in connection with developing or
obtaining software for internal use. Capitalized software costs are included within machinery and equipment and are
amortized on a straight-line basis over the estimated useful lives of the software, which generally range from three
to five years.
73
Research and Development
Research and development (R&D) costs, including R&D acquired in transactions that are not business
combinations, are expensed as incurred. Pre-regulatory approval contingent milestone obligations to counterparties
in collaborative arrangements, which include acquired R&D, are expensed when the milestone is probable to be
achieved. Contingent milestone payments made to such counterparties on or after regulatory approval are
capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such
payments are included in other intangible assets, net.
Acquired in-process R&D (IPR&D) is the value assigned to technology or products under development acquired in a
business combination which have not received regulatory approval and have no alternative future use. Acquired
IPR&D is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are
expensed as incurred. Upon receipt of regulatory approval of the related technology or product, the indefinite-lived
intangible asset is accounted for as a finite-lived intangible asset and amortized on a straight-line basis over the
estimated economic life of the related technology or product, subject to annual impairment reviews as discussed
below. If the R&D project is abandoned, the indefinite-lived asset is charged to expense.
Collaborative Arrangements
We periodically enter into collaborative arrangements in the normal course of business. These collaborative
arrangements take a number of forms and structures and are designed to enhance and expedite long-term sales
and profitability growth. These arrangements may provide for us to obtain commercialization rights to a product
under development, and require us to make upfront payments, contingent milestone payments, profit-sharing, and/
or royalty payments. We may be responsible for ongoing costs associated with the arrangements, including R&D
cost reimbursements to the counterparty. See the Research and Development section of this note regarding the
accounting treatment of upfront and contingent milestone payments. Any royalty and profit-sharing payments during
the commercialization phase are expensed as cost of sales when they become due and payable.
Restructuring Charges
We record liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred.
Employee termination costs are primarily recorded when actions are probable and estimable. Costs for one-time
termination benefits in which the employee is required to render service until termination in order to receive the
benefits are recognized ratably over the future service period. Refer to the discussion below regarding the
accounting for asset impairment charges.
Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill is initially measured as the excess of the purchase price over the fair value (or other measurement
attribute required by U.S. GAAP) of acquired assets and liabilities in a business combination. Management performs
an impairment test in the fourth quarter of each year, or whenever events or changes in circumstances indicate that
the fair value of the reporting unit is more likely than not below its carrying amount. We have the option to assess
goodwill for impairment by initially performing a qualitative assessment to determine whether it is more-likely-than-
not that the fair value of a reporting unit is less than its carrying amount. If we determine that it is not more-likely-
than-not that the fair value of a reporting unit is less than its carrying amount, then the quantitative goodwill
impairment test is not required to be performed. If we determine that it is more-likely-than-not that the fair value of a
reporting unit is less than its carrying amount, or if we do not elect the option to perform an initial qualitative
assessment, we perform a quantitative goodwill impairment test. In the quantitative impairment test, we calculate
the estimated fair value of the reporting unit. If the carrying amount of the reporting unit exceeds the estimated fair
value, an impairment charge is recorded for the amount that its carrying amount, including goodwill, exceeds its fair
value, limited to the total amount of goodwill allocated to that reporting unit. In a quantitative goodwill impairment
test, the fair values of our reporting units are generally determined based on a discounted cash flow model (an
income approach) and earnings multiples (a market approach). Significant assumptions in reporting unit fair value
measurements generally include revenue growth rates, forecasted earnings before interest, taxes, depreciation and
amortization (EBITDA) margins, discount rates, terminal growth rates and earnings multiples. Each of those
assumptions can significantly affect the fair values of our reporting units.
Indefinite-lived intangible assets, such as IPR&D acquired in business combinations and certain trade names with
indefinite lives, are subject to an impairment review annually in the fourth quarter and whenever indicators of
impairment exist. We have the option to assess indefinite-lived intangible assets for impairment by first performing
74
qualitative assessments to determine whether it is more-likely-than-not that the fair values of the indefinite-lived
intangible assets are less than the carrying amounts. If we determine that it is more-likely-than-not that an indefinite-
lived intangible asset is impaired, or if we elect not to perform an initial qualitative assessment, we then perform the
quantitative impairment test by comparing the fair value of the indefinite-lived intangible asset with its carrying
amount. If the carrying amount exceeds the fair value of the indefinite-lived intangible asset, we write the carrying
amount down to the fair value.
We review the carrying amounts of long-lived assets used in operations, other than goodwill and intangible assets
not subject to amortization, for potential impairment when events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. In evaluating recoverability, we group assets and liabilities at
the lowest level such that the identifiable cash flows relating to the group are largely independent of the cash flows
of other assets and liabilities. We then compare the carrying amounts of the assets or asset groups with the related
estimated undiscounted future cash flows. In the event an asset (or asset group) is not recoverable, an impairment
charge is recorded as the amount by which the carrying amount of the asset (or asset group) exceeds its fair value.
Long-lived assets are classified as held for sale when certain criteria are met, including when management has
committed to sell the asset, the asset is available for sale in its present condition and the sale is probable of being
completed within one year of the balance sheet date. Assets held for sale are no longer depreciated or amortized
and they are reported at the lower of their carrying amount or fair value less cost to sell.
See Notes 3 and 5 for further information about impairments of goodwill and intangible assets recognized in the
accompanying consolidated financial statements.
Investments in Debt and Equity Securities
Investments in debt securities classified as available-for-sale are measured at fair value with changes in fair value
reported in other comprehensive (loss) income (OCI). Investments in marketable equity securities are classified as
other non-current assets and are measured at fair value with gains and losses recognized in other (income)
expense, net. We have elected to apply the measurement alternative to equity securities without readily
determinable fair values. As such, our non-marketable equity securities are measured at cost, less any impairment,
and are adjusted for changes in fair value resulting from observable transactions for identical or similar investments
of the same issuer. Gains and losses on non-marketable equity securities are also recognized in other (income)
expense, net. Noncontrolling investments in common stock or in-substance common stock are accounted for under
the equity method if we have the ability to exercise significant influence over the operating and financial policies of
the investee. We review our investments in debt and equity securities for impairment and adjust impaired
investments to fair value through earnings, as required.
Income Taxes
Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax
reporting based on enacted tax laws and rates. We maintain valuation allowances unless it is more-likely-than-not
that the deferred tax asset will be realized. With respect to uncertain tax positions, we determine whether the
position is more-likely-than-not to be sustained upon examination based on the technical merits of the position. Any
tax position that meets the more-likely-than-not recognition threshold is measured and recognized in the
consolidated financial statements at the largest amount of benefit that is greater than 50% likely of being realized
upon ultimate settlement. The liability relating to uncertain tax positions is classified as current in the consolidated
balance sheets to the extent that we anticipate making a payment within one year. Interest and penalties associated
with income taxes are classified in the income tax expense (benefit) line in the consolidated statements of income
(loss).
Foreign Currency Translation
Cumulative translation adjustments (CTA) related to foreign operations are included in OCI. For foreign operations
in highly inflationary economies, translation gains and losses are included in other (income) expense, net, and were
not material in 2024, 2023 and 2022.
Derivatives and Hedging Activities
Derivative instruments are recognized as either assets or liabilities at fair value in the consolidated balance sheets
and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate
75
certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value or
net investment hedges.
For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the
derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged item. Cash
flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted intra-
company sales denominated in foreign currencies and forecasted interest payments on anticipated issuances of
debt, respectively.
For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the
derivative is recognized immediately to earnings, and offsets changes in fair value attributable to a particular risk,
such as changes in interest rates, of the hedged item, which are also recognized in earnings. Changes in the fair
value of hedge instruments designated as fair value hedges are classified in interest expense, net, as they hedge
the interest rate risk associated with certain of our fixed-rate debt.
We have designated certain of our Euro-denominated senior notes as hedges of our net investment in our
European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded
as a component of AOCI.
For derivative instruments that are not designated as hedges, the change in fair value is recorded directly to other
(income) expense, net.
If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we
discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges
generally continue to be deferred and are recognized consistent with the loss or income recognition of the
underlying hedged items. However, if it is probable that the hedged forecasted transactions will not occur, any gains
or losses would be immediately reclassified from AOCI to earnings. If we terminate a fair value hedge, an amount
equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings
over the remaining term of the hedged item. If we remove a net investment hedge designation, any gain or loss
recognized in AOCI are not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments
that were being hedged.
Cash flows related to the settlement of derivative instruments designated as net investment hedges of foreign
operations are classified in the consolidated statements of cash flows within investing activities. Cash flows for all
other derivatives, including those that are not designated as a hedge, are classified in the same line item as the
cash flows of the related hedged item, which is generally within operating activities.
New Accounting Standards
Recently issued accounting standards not yet adopted
In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)
2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of certain
expenses on an interim and annual basis in the notes to the financial statements. This standard is effective for
annual consolidated financial statements for the year ending December 31, 2027 and for interim periods beginning
in 2028. We are currently evaluating the impact of this new standard on our consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax
Disclosures, which requires (1) disclosure of specific categories in the rate reconciliation and (2) additional
information for reconciling items that meet a quantitative threshold. Additionally, the amendment requires disclosure
of certain disaggregated information about income taxes paid, income from continuing operations before income tax
expense (benefit) and income tax expense (benefit). The standard is effective for our annual consolidated financial
76
statements for the year ending December 31, 2025. We are currently evaluating the impact of this standard on our
consolidated financial statements.
Recently adopted accounting pronouncements
As of January 1, 2024, we adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures, which requires enhanced disclosures about segment expenses on an annual and interim
basis. This standard became effective for our annual consolidated financial statements for the year ended
December 31, 2024 and for interim periods beginning in 2025. See Note 18 for further information on our segment
disclosures.
As of January 2024, we adopted ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of
Equity Securities Subject to Contractual Sales Restrictions, which (1) clarifies the guidance in Topic 820 on the fair
value measurement of an equity security that is subject to contractual restrictions that prohibit the sale of an equity
security and (2) requires specific disclosures related to such an equity security. The standard became effective for
our annual consolidated financial statements for the year ended December 31, 2024 and for interim periods
beginning in 2025. The impact of the adoption of this ASU did not have a material effect on our consolidated
financial statements.
As of January 1, 2022, we adopted ASU 2021-05, Leases (Topic 842), which requires a lessor to classify a lease
with variable lease payments (that do not depend on an index or rate) as an operating lease if (1) the lease would
have been classified as a sales-type or direct financing lease, and (2) the lessor would have recognized a selling
loss at lease commencement. These changes are intended to avoid recognizing a day-one loss for a lease with
variable payments even though the lessor expects the arrangement will be profitable overall. The adoption of this
ASU did not have a material impact on our consolidated financial statements.
NOTE 2
DISCONTINUED OPERATIONS
A component of an entity is reported in discontinued operations after meeting the criteria for held-for-sale
classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's
operations and financial results. The consolidated financial statements reflect discontinued operations for two
strategic actions, as described below.
Discontinued Operations - Kidney Care
On August 12, 2024, we entered into an EPA to sell our Kidney Care business, subject to receipt of customary
regulatory approvals and satisfaction of other closing conditions. That business, which is comprised of our former
Kidney Care segment, provides chronic and acute dialysis therapies and services, including peritoneal dialysis,
hemodialysis, continuous renal replacement therapies, and other organ support therapies. On January 31, 2025, we
completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash,
subject to certain closing cash, working capital and debt adjustments. After giving effect to certain adjustments, we
received approximately $3.71 billion pre-tax cash proceeds at closing of the transaction with the net after tax
proceeds currently estimated to be approximately $3.4 billion, subject to certain post-closing adjustments.
We concluded that our Kidney Care business met the criteria to be classified as held-for-sale in August 2024. We
analyzed the quantitative and qualitative factors relevant to the sale of our Kidney Care business, including its
significance to our overall net income (loss), earnings (loss) per share, and net assets, and determined that those
conditions for discontinued operations presentation had been met. As such, the financial position, results of
operations and cash flows of that business are reported as discontinued operations in the accompanying
consolidated financial statements. Prior period amounts have been adjusted to reflect discontinued operations
presentation. The fair value and carrying value of assets held for sale are evaluated each period and a loss on sale
is recognized when the fair value less costs to sell are below the carrying value. There has been no loss on sale
recognized for the period ending December 31, 2024. We will recognize a gain or loss upon disposition of the
business depending on the carrying value at that date, including any tax impacts of the sale, which may be material.
Upon closing of the sale of the Kidney Care business, Baxter and Vantive entered into several agreements,
including a Manufacturing and Supply Agreement (Kidney Care MSA), a long-term Master Services Agreement, a
Distribution Agreement, a Transition Services Agreement (Kidney Care TSA), and an Intellectual Property
Agreement. Pursuant to the Kidney Care MSA, Baxter and the Kidney Care divested entities will provide each other
77
with certain dialysis-related products, other products, product components and fulfillment services for a period up to
10 years post-closing (with certain extension rights as provided therein). Pursuant to the Kidney Care TSA, Baxter
and the entities that will be divested in connection with the Kidney Care sale (the Kidney Care divested entities) will
provide each other, on an interim basis, certain transitional services for up to 30 months post-closing (with certain
extension rights as provided therein) to help ensure business continuity and help minimize disruptions to the entities'
operations post-closing. Services to be provided under the Kidney Care TSA include information technology
applications and support, supply chain and certain other corporate and administrative services. Pursuant to the
EPA, Baxter will retain (i) the manufacture and sale of saline solutions and (ii) the plastics operations of Baxter and
its subsidiaries at its Mountain Home, Arkansas facility, which is not part of the Kidney Care segment.
Discontinued Operations - BioPharma Solutions
On September 29, 2023, we sold our BPS business to Advent International and Warburg Pincus (collectively, the
buyers). Under the terms of the related Equity Purchase agreement entered into with the buyers in May 2023, we
were entitled to aggregate consideration of $4.25 billion, subject to adjustment for specified items. After giving effect
to those adjustments, we received cash proceeds of $3.96 billion. We recognized a pre-tax gain on the sale of $2.88
billion ($2.59 billion net of tax), which represents the excess of (a) the $3.91 billion in net consideration received,
consisting of (i) $3.96 billion in cash proceeds from the buyers, less (ii) $47 million in transaction costs, over (b) the
sum of (i) the $840 million net book value of the BPS business upon the closing of the transaction and (ii) BPS's
$181 million other comprehensive loss, which was reclassified to earnings.
The BPS business, which was historically reported within our former Americas segment, provided contract
manufacturing and development services, which include sterile fill-finish manufacturing and support services across
clinical and commercial applications, primarily serving customers in the pharmaceutical industry. BPS was
historically operated through our former, wholly-owned subsidiaries Baxter Pharmaceutical Solutions LLC, a
Delaware limited liability company, and Baxter Oncology GmbH, a German limited liability company (collectively, the
divested entities).
We concluded that our BPS business met the criteria to be classified as held-for-sale in May 2023. A component of
an entity is reported in discontinued operations after meeting the criteria for held-for-sale classification if the
disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial
results. We analyzed the quantitative and qualitative factors relevant to the divestiture of our BPS business,
including its significance to our overall net income (loss) and earnings (loss) per share, and determined that those
conditions for discontinued operations presentation had been met. As such, the financial position, results of
operations and cash flows of that business, including our gain from the sale of that business and the related cash
proceeds received, are reported as discontinued operations in the accompanying consolidated financial statements.
Prior period amounts have been adjusted to reflect discontinued operations presentation.
At closing of the transaction, Baxter Pharmaceutical Solutions LLC included a BPS manufacturing facility in
Bloomington Indiana and Baxter Oncology GmbH included a manufacturing facility in Halle Germany. Previously,
Baxter Oncology GmbH included an additional manufacturing site in Bielefeld Germany that was not part of the BPS
business and was transferred to another Baxter entity prior to closing of the divestiture. Accordingly, amounts
related to the Bielefeld site continue to be presented as continuing operations in the accompanying consolidated
financial statements.
At closing of the transaction, Baxter entered into a Transition Services Agreement (BPS TSA) and a Master
Commercial Manufacturing and Supply Agreement (BPS MSA) with the divested entities. Pursuant to the BPS TSA,
Baxter and the divested entities will provide to each other, on an interim basis, specific transition services for up to
24 months post-closing to help ensure business continuity and minimize disruptions. Services provided under the
BPS TSA include finance, information technology, human resources, integrated supply chain and certain other
administrative services. Pursuant to the BPS MSA, the divested entities will provide development, manufacturing,
regulatory and other related services for certain Baxter pharmaceutical products for up to 5 years post-closing (with
certain extension rights as provided therein).
78
Results of Discontinued Operations and Assets and Liabilities of Discontinued Operations
The following table summarizes the major classes of line items included in income (loss) from discontinued
operations, net of tax, for the years ended December 31, 2024, 2023 and 2022:
Kidney Care
BioPharma Solutions
Total
Year Ended December 31,
Year Ended December 31,
Year Ended December 31,
(in millions)
2024
2023
2022
2024
2023
2022
2024
2023
2022
Net sales
$ 4,513 $ 4,453 $ 4,449 $
— $ 469 $ 607 $ 4,513 $ 4,922 $ 5,056
Cost of sales
2,812 3,628 2,932
—
216
276 2,812 3,844 3,208
Gross margin
1,701
825 1,517
—
253
331 1,701 1,078 1,848
Selling, general and administrative
expenses
1,203
993
762
—
45
28 1,203 1,038
790
Research and development expenses
181
149
152
—
1
3
181
150
155
Goodwill impairments
430
—
—
—
—
—
430
—
—
Other operating expense (income), net
(1)
—
1
—
—
—
(1)
—
1
Operating income (loss)
(112) (317)
602
—
207
300 (112) (110)
902
Interest expense, net
13
3
1
—
(1)
—
13
2
1
Other (income) expense, net
10
25
3
—
1
3
10
26
6
Income (loss) from discontinued
operations before gain on disposition
and income taxes
(135) (345)
598
—
207
297 (135) (138)
895
Gain on disposition
—
—
—
— 2,882
—
— 2,882
—
Income tax expense (benefit)
177
(95)
139
—
357
64
177
262
203
Income (loss) from discontinued
operations, net of tax
(312) (250)
459
— 2,732
233 (312) 2,482
692
Less: Net income attributable to
noncontrolling interest included in
discontinued operations
11
7
11
—
—
—
11
7
11
Net income (loss) attributable to Baxter
stockholders included in discontinued
operations
$ (323) $ (257) $ 448 $
— $ 2,732 $ 233 $ (323) $ 2,475 $ 681
For the year ended December 31, 2024, SG&A expenses include $261 million of separation-related costs incurred
in connection with the sale of our Kidney Care business. For the year ended December 31, 2023, SG&A expenses
include $196 million and $17 million, respectively, of separation-related costs incurred in connection with the sale of
our Kidney Care business and the sale of BPS, respectively.
79
The following table summarizes the carrying amounts of the major classes of assets and liabilities classified as
discontinued operations in the consolidated balance sheets as of December 31, 2024 and 2023:
as of December 31 (in millions)
2024
2023
Cash and cash equivalents
$
648 $
116
Accounts receivable, net of allowances
942
971
Inventories
821
906
Prepaid expenses and other current assets
200
186
Current assets of discontinued operations
2,611
2,179
Property, plant and equipment, net
1,516
1,562
Goodwill
265
721
Other intangible assets, net
148
161
Operating lease right-of-use assets
204
188
Other non-current assets
367
317
Non-current assets of discontinued operations
2,500
2,949
Assets of discontinued operations
$
5,111 $
5,128
Current maturities of finance lease obligations
$
1 $
1
Accounts payable
344
360
Accrued expenses and other current liabilities
585
679
Current liabilities of discontinued operations
930
1,040
Long-term finance lease obligations, less current portion
37
41
Operating lease liabilities
173
173
Other non-current liabilities
344
337
Non-current liabilities of discontinued operations
554
551
Liabilities of discontinued operations
$
1,484 $
1,591
NOTE 3
ACQUISITIONS AND OTHER ARRANGEMENTS
Results of operations of acquired businesses are included in our results of operations beginning as of the respective
acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates
of their fair values (or other measurement attribute required under U.S. GAAP) at the date of the acquisition. Any
purchase price in excess of these net assets is recorded as goodwill.
Contingent consideration related to business combinations is recognized at its estimated fair value on the
acquisition date. Subsequent changes to the fair value of those contingent consideration arrangements are
recognized in earnings. Contingent consideration related to business acquisitions may consist of development,
regulatory and commercial milestone payments, and sales or earnings-based payments, and are valued using
discounted cash flow techniques. The fair value of development, regulatory and commercial milestone payments
reflects management’s expectations of the probability of payment, and increases or decreases as the probability of
payment or expectation of timing or amount of payments changes. The fair value of sales-based payments is based
upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or
expectation of timing or amount of payments changes.
Hillrom
In 2021, we completed our acquisition of all outstanding equity interests of Hillrom for a purchase price of
$10.48 billion. Hillrom was a global medical technology leader whose products and services help enable earlier
diagnosis and treatment, optimize surgical efficiency, and accelerate patient recovery while simplifying clinical
communication and shifting care closer to home. Hillrom made those outcomes possible through digital and
connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic
80
technologies, respiratory health devices, advanced equipment for the surgical space and more, delivering
actionable, real-time insights at the point of care.
Impairment of Goodwill from Our Hillrom Acquisition
During 2024, we recorded a $425 million goodwill impairment related to our Front Line Care reporting unit within our
Healthcare Systems & Technologies segment. Refer to Note 5 for additional information regarding this goodwill
impairment.
During the third quarter of 2022, we performed trigger-based impairment tests of the goodwill of each of the
reporting units within our Hillrom segment (currently referred to as our Healthcare Systems & Technologies
segment), as well as the indefinite-lived intangible assets, consisting primarily of trade names, that we
acquired in connection with the Hillrom acquisition. We performed those tests as of September 30, 2022 due to (a)
macroeconomic conditions, including the rising interest rate environment and broad declines in equity valuations,
and (b) reduced earnings forecasts for our Hillrom reporting units, driven primarily by shortages of certain
component parts used in our products, raw materials inflation and increased supply chain costs. Those impairment
tests resulted in total pre-tax goodwill impairment charges of $2.79 billion in the third quarter of 2022. In
connection with our annual goodwill impairment assessment in the fourth quarter of 2022, we performed quantitative
impairment tests for all of our reporting units and recorded an additional $27 million goodwill impairment related to
our Hillrom segment. No goodwill impairments were recorded for our remaining reporting units in connection with
our annual goodwill impairment tests because the fair values of those reporting units exceeded their carrying
amounts
The fair values of the reporting units tested for impairment during 2022 were determined based on a discounted
cash flow model (an income approach) and earnings multiples (a market approach) based on the guideline public
company method. Significant assumptions used in the determination of the fair values of our reporting units
generally include forecasted cash flows, discount rates, terminal growth rates and earnings multiples. The
discounted cash flow models used to determine the fair values of our reporting units during 2022 reflected our most
recent cash flow projections, discount rates ranging from 9% to 10% and terminal growth rates ranging from 2% to
3%. Our reporting unit fair value measurements are classified as Level 3 in the fair value hierarchy because they
involve significant unobservable inputs.
Impairment of Indefinite-Lived Intangible Assets from Our Hillrom Acquisition
In addition to the goodwill impairments discussed above, we recognized pre-tax impairment charges of $332 million
in the third quarter of 2022 to reduce the carrying amounts of certain indefinite-lived intangible assets, which
primarily related to the Hillrom and Welch Allyn trade names acquired in the Hillrom acquisition, to their estimated
fair values. Those intangible asset impairment charges are classified within cost of sales in the accompanying
consolidated statements of income (loss) for the year ended December 31, 2022.
The fair values of the trade name intangible assets were determined using the relief from royalty method. Significant
assumptions used in the determination of the fair value of the trade name intangible assets included revenue growth
rates, terminal growth rates, discount rates and royalty rates. The relief from royalty models used in the
determination of the fair values of our trade name intangible assets during 2022 reflected our most recent revenue
projections, a discount rate of 9.5%, royalty rates ranging from 3% to 5% and terminal growth rates ranging from 2%
to 3%. Our trade name intangible asset fair value measurements are classified as Level 3 in the fair value hierarchy
because they involve significant unobservable inputs.
In the fourth quarter of 2022, we recognized an impairment charge of $12 million related to developed-technology
intangible assets due to declines in market expectations for the related products. The fair values of the intangible
assets were measured using a discounted cash flow approach and the charge is classified within cost of sales in the
accompanying consolidated statements of income (loss) for the year ended December 31, 2022. We consider the
fair values of the assets to be Level 3 measurements due to the significant estimates and assumptions, including
forecasted future cash flows, that we used in establishing the estimated fair values.
Other
Total consideration transferred for other acquisitions totaled $32 million in 2022 and primarily resulted in the
recognition of goodwill and other intangible assets. These acquisitions did not materially affect our results of
operations.
81
Other Business Development Activities
Zosyn
In March 2022, we entered into an agreement with a subsidiary of Pfizer Inc. to acquire the rights to Zosyn, a
premixed frozen piperacillin-tazobactam product, in the U.S. and Canada. Zosyn is used for the treatment of intra-
abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections and
community-acquired pneumonia. Under the terms of the acquisition, we paid the acquisition price of $122 million
and received specified intellectual property, including patent rights, in the first quarter of 2022 and received
additional intellectual property, including the product rights to Zosyn, in the first quarter of 2023. Under the
arrangement, we received profit sharing payments from sales of Zosyn until the product rights transferred to us in
April 2023. The related profit sharing payments that were earned during 2023 and 2022 were not material.
The transaction has been accounted for as an asset acquisition, as substantially all of the fair value of the assets
acquired under the arrangement was concentrated in the product rights that we received, which we classify as a
developed technology intangible asset. Accordingly, the $122 million purchase price was primarily allocated to the
developed technology intangible asset class and is being amortized over an estimated useful life of 9 years.
Celerity Pharmaceuticals, LLC
In September 2013, we entered into an agreement with Celerity Pharmaceuticals, LLC (Celerity) to develop certain
acute care generic injectable premix and oncolytic products through regulatory approval. We transferred our rights
in these products to Celerity and Celerity assumed ownership and responsibility for development of the products.
We were obligated to purchase the individual product rights from Celerity if the products obtained regulatory
approval. In December 2020, we entered into an agreement with a third party to divest our rights to one of the
products that was being developed by Celerity, a generic version of liposomal doxorubicin, for less than $1 million if
that product were to receive regulatory approval in the U.S. and European Union in 2022. Liposomal doxorubicin is
a chemotherapy medicine used to treat various types of cancer and we entered into this transaction to divest our
rights to this generic version of that product after we had separately entered into a transaction to acquire the
branded version.
The related regulatory approvals were subsequently obtained for the generic version of liposomal doxorubicin and
we recognized a loss of approximately $54 million in the third quarter of 2022, representing the difference between
the amount we owed Celerity following those regulatory approvals and the proceeds that we were entitled to receive
from our divestiture of those product rights. That loss is reported within other operating expense (income), net in our
consolidated statements of income (loss) for the year ended December 31, 2022.
Other Asset Acquisitions
During 2021, we also entered into distribution license arrangements for multiple products that have not yet obtained
regulatory approval. In addition to the cash paid at acquisition, we could make additional payments of up to $17
million upon the achievement of certain development, regulatory or commercial milestones.
Other
In addition to the arrangements described above, we have entered into several other collaborative arrangements.
We could make additional payments of up to $20 million upon the achievement of certain development and
regulatory milestones, in addition to future payments related to contingent commercialization milestones, profit-
sharing and royalties.
82
NOTE 4
SUPPLEMENTAL FINANCIAL INFORMATION
Allowance for Doubtful Accounts
The following table is a summary of changes in our allowance for doubtful accounts for the years ended
December 31, 2024 and 2023.
years ended December 31
(in millions)
2024
2023
2022
Balance at beginning of period
$
62 $
50 $
52
Charged to costs and expenses
7
7
3
Write-offs
(8)
(4)
(3)
Currency translation adjustments
10
9
(2)
Balance at end of period
$
71 $
62 $
50
Inventories
as of December 31 (in millions)
2024
2023
Raw materials
$
510 $
530
Work in process
266
234
Finished goods
1,270
1,154
Inventories
$
2,046 $
1,918
Prepaid Expenses and Other Current Assets
as of December 31 (in millions)
2024
2023
Prepaid value added taxes
$
167 $
118
Prepaid income taxes
199
204
Spare parts
123
141
Contract assets
51
53
Derivative assets
8
45
Other
205
145
Prepaid expenses and other current assets
$
753 $
706
Property, Plant and Equipment, Net
as of December 31 (in millions)
2024
2023
Land and land improvements
$
115 $
119
Buildings and leasehold improvements
1,301
1,238
Machinery and equipment
5,047
4,909
Equipment on lease with customers
467
760
Construction in progress
718
624
Total property, plant and equipment, at cost
7,648
7,650
Accumulated depreciation
(4,778)
(4,779)
Property, plant and equipment, net
$
2,870 $
2,871
Depreciation expense was $372 million in 2024, $394 million in 2023 and $393 million in 2022.
83
Other Non-Current Assets
as of December 31 (in millions)
2024
2023
Deferred tax assets
$
204 $
263
Non-current receivables, net
50
42
Contract assets
82
112
Capitalized implementation costs in hosting arrangements
102
103
Pension and other postretirement benefits
56
46
Investments
109
136
Other
152
107
Other non-current assets
$
755 $
809
Accrued Expenses and Other Current Liabilities
as of December 31 (in millions)
2024
2023
Common stock dividends payable
$
87 $
147
Employee compensation and withholdings
447
477
Property, payroll and certain other taxes
96
92
Contract liabilities
131
128
Restructuring liabilities
112
81
Accrued rebates
214
240
Operating lease liabilities
80
92
Income taxes payable
121
78
Pension and other postretirement benefits
39
37
Contingent payments related to acquisitions
—
3
Other
534
540
Accrued expenses and other current liabilities
$
1,861 $
1,915
Other Non-Current Liabilities
as of December 31 (in millions)
2024
2023
Pension and other postretirement benefits
$
678 $
714
Deferred tax liabilities
103
403
Long-term tax liabilities
94
72
Contingent payments related to acquisitions
11
11
Contract liabilities
40
41
Litigation and environmental reserves
29
19
Restructuring liabilities
10
14
Other
111
126
Other non-current liabilities
$
1,076 $
1,400
Interest Expense, net
years ended December 31 (in millions)
2024
2023
2022
Interest costs
$
421 $
523 $
423
Interest costs capitalized
(13)
(15)
(10)
Interest expense
408
508
413
Interest income
(67)
(69)
(19)
Interest expense, net
$
341 $
439 $
394
84
Other (Income) Expense, net
years ended December 31 (in millions)
2024
2023
2022
Foreign exchange (gains) losses, net
$
25 $
53 $
(3)
Change in fair value of marketable equity securities
(3)
(7)
(11)
Pension settlement and curtailment (gains) losses
—
—
(12)
Pension and other postretirement benefit (gains) losses
(39)
(48)
(30)
Reclassification of cumulative translation loss to earnings
—
—
65
Non-marketable investment impairments
—
34
—
Other, net
(21)
(6)
—
Other (income) expense, net
$
(38) $
26 $
9
Following the wind down of our operations in Argentina, we determined that the net assets of the related entities
were substantially liquidated during the third quarter of 2022. As a result of that determination, we reclassified their
$65 million cumulative translation loss from accumulated other comprehensive income (loss) to other (income)
expense, net.
Supplemental Cash Flow Information
Non-Cash Investing Activities
Purchases of property, plant and equipment included in accounts payable and accrued liabilities as of December 31,
2024, 2023 and 2022 was $64 million, $58 million and $64 million, respectively.
Other Supplemental Information
year ended December 31 (in millions)
2024
2023
2022
Interest paid, net of portion capitalized
$
401 $
484 $
355
Income taxes paid
$
223 $
174 $
168
NOTE 5
GOODWILL AND OTHER INTANGIBLE ASSETS, NET
Goodwill
The following is a reconciliation of goodwill by business segment.
(in millions)
Americas
EMEA
APAC
Medical
Products &
Therapies
Healthcare
Systems &
Technologies1
Pharmaceuticals
Total
December 31, 2022
$ 1,665 $
78 $
18 $
— $
3,988 $
— $ 5,749
Currency translation and other
(19)
(3)
(2)
46
1
21
44
Reallocation of goodwill
(1,646)
(75)
(16)
1,195
—
542
—
December 31, 2023
$
— $
— $
— $
1,241 $
3,989 $
563 $ 5,793
Impairment
—
—
—
—
(425)
—
(425)
Currency translation and other
—
—
—
(56)
(14)
(23)
(93)
December 31, 2024
$
— $
— $
— $
1,185 $
3,550 $
540 $ 5,275
1Prior to the third quarter of 2023, our Healthcare Systems & Technologies segment was referred to as our Hillrom segment.
Change in Reportable Segments
Our reportable segments were previously comprised of the following geographic segments related to our legacy
Baxter business: Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia
Pacific), and a global segment for our Hillrom business. In the third quarter of 2023, we completed the
implementation of a new operating model intended to simplify and streamline our operations and better align our
85
manufacturing and supply chain to our commercial activities. Our segments were changed during the third quarter
of 2023 to align with our new operating model. Under this operating model, our business is comprised of three
reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies (formerly referred to as
our Hillrom segment) and Pharmaceuticals. As a result of this segment change, we reallocated the goodwill from our
previous Americas, EMEA and APAC segments to the reporting units within our Medical Products & Therapies and
Pharmaceuticals segments based on the relative fair values of those reporting units. We performed goodwill
impairment assessments both before and after the reporting unit change and we did not identify any goodwill
impairments.
Goodwill Impairment
In connection with our annual goodwill impairment assessment in the fourth quarter of 2024, we recorded a $425
million goodwill impairment related to our Front Line Care reporting unit within our Healthcare Systems &
Technologies segment. The reduction in value was primarily due to lower forecasted operating results and a lower
terminal growth rate utilized in valuing this reporting unit which contributed to reduced expected future cash flows,
as well as lower earnings multiples. The fair value of the Front Line Care reporting unit was determined based on a
discounted cash flow model (an income approach) and earnings multiples (a market approach) based on the
guideline public company method. Significant assumptions used in the determination of the fair values of our
reporting units generally include revenue growth rates, forecasted EBITDA margins, discount rates, terminal growth
rates and earnings multiples. The discounted cash flow model used to determine the fair value of our Front Line
Care reporting unit reflected our most recent cash flow projections, a discount rate of 9.5% and a terminal growth
rate of 3.25%. Our reporting unit fair value measurements are classified as Level 3 in the fair value hierarchy
because they involve significant unobservable inputs. As of December 31, 2024, the carrying amount of goodwill for
our Front Line Care reporting unit was $1.99 billion. No goodwill impairments were recorded for our remaining
reporting units in connection with our annual goodwill impairment tests because the fair values of those reporting
units exceeded their carrying amounts.
Other Intangible Assets, Net
The following is a summary of our other intangible assets.
Indefinite-lived intangible
assets
(in millions)
Customer
relationships
Developed
technology,
including
patents
Trade
Names
Other
amortized
intangible
assets
Trade
Names
In process
Research and
Development
Total
December 31, 2023
Gross other intangible assets
$
3,390 $
3,181 $
964 $
86 $
680 $
157 $
8,458
Accumulated amortization
(654)
(1,782)
(38)
(66)
—
— $ (2,540)
Other intangible assets, net
$
2,736 $
1,399 $
926 $
20 $
680 $
157 $
5,918
December 31, 2024
Gross other intangible assets
$
3,387 $
3,131 $
958 $
86 $
680 $
107 $
8,349
Accumulated amortization
(878)
(2,075)
(107)
(66)
—
—
(3,126)
Other intangible assets, net
$
2,509 $
1,056 $
851 $
20 $
680 $
107 $
5,223
Intangible asset amortization expense was $625 million in 2024, $590 million in 2023 and $679 million in 2022. The
anticipated annual amortization expense for definite-lived intangible assets recorded as of December 31, 2024 is
$586 million in 2025, $562 million in 2026, $412 million in 2027, $400 million in 2028 and $378 million in 2029.
During the fourth quarter of 2023, as a result of an update to our long-term branding strategy, we reclassified two
trade name intangible assets with carrying amounts of $870 million and $21 million from indefinite-lived intangible
assets to amortizing intangible assets. The estimated useful lives assigned to those assets were 15 years and 5
years, respectively. We performed impairment tests of those intangible assets at the time of the reclassification and
determined that no impairment had occurred.
86
Intangible Asset Impairments
Impairment of Indefinite-Lived Intangible Assets from Our Claris Acquisition
In connection with our annual IPR&D impairment assessment in the fourth quarter of 2024, we recognized a pre-tax
impairment charge of $50 million to reduce the carrying amount of an IPR&D asset to its fair value. The reduction in
value was primarily due to lower forecasted revenues and margins which contributed to reduced expected future
cash flows. The intangible asset impairment charge is classified within research and development expenses in the
accompanying consolidated statements of income (loss) for the year ended December 31, 2024. The fair value of
the IPR&D asset was determined using the multi-period excess earnings method. Significant assumptions used in
the determination of the fair value of the IPR&D asset included forecasted cash flows and the discount rate. The
multi-period excess earnings model used in our determination of the fair value of the IPR&D asset reflected our
most recent cash flow projections and a discount rate of 11%. Our IPR&D intangible asset fair value measurement
is classified as Level 3 in the fair value hierarchy because it involves significant unobservable inputs.
87
NOTE 6
DEBT AND CREDIT FACILITIES
Debt Outstanding
At December 31, 2024 and 2023, we had the following debt outstanding:
as of December 31 (in millions)
Effective interest
rate as of
December 31,2024¹
20241
20231
Commercial paper
4.8 % $
300
$
—
0.4% notes due 2024
— %
—
828
1.322% notes due 2024
— %
—
1,398
7.0% notes due 2024
— %
—
13
Floating-rate notes due 2024
— %
—
300
Term loan maturing 2024
— %
—
130
1.3% notes due 2025
1.5 %
625
662
Delayed draw term loan due 2025
5.7 %
1,826
—
2.6% notes due 2026
2.7 %
749
748
Term loan maturing 2026
6.7 %
1,643
1,643
7.65% debentures due 2027
7.7 %
5
5
1.915% notes due 2027
2.0 %
1,446
1,445
6.625% debentures due 2028
5.8 %
94
95
2.272% notes due 2028
2.4 %
1,245
1,244
1.3% notes due 2029
1.5 %
776
828
3.95% notes due 2030
4.1 %
497
496
1.73% notes due 2031
2.7 %
646
646
2.539% notes due 2032
2.6 %
1,541
1,540
6.25% notes due 2037
6.3 %
266
265
3.65% notes due 2042
5.4 %
6
6
4.5% notes due 2043
4.6 %
256
256
3.5% notes due 2046
3.7 %
441
440
3.132% notes due 2051
3.2 %
743
741
Finance leases and other
4.2 %
21
27
Total debt and finance lease obligations
13,126
13,756
Short-term debt
(2,126)
—
Current maturities of long-term debt and finance lease obligations
(626)
(2,667)
Long-term debt and finance lease obligations
$
10,374
$
11,089
1
Book values include any discounts, premiums and adjustments related to hedging instruments and effective interest rates reflect
amortization of those items.
Significant Debt Activity
In February 2025, we repaid $1.00 billion under our $1.64 billion five-year term loan facility maturing in 2026.
In 2024, we repaid our $13 million 7.0% notes due 2024, $809 million 0.4% notes due 2024, $1.40 billion 1.322%
notes due 2024, $300 million floating rate notes due 2024 and $130 million three-year term loan facility due 2024.
In 2023, we repaid our $800 million 0.868% notes due 2023, our $300 million floating rate notes due 2023 and
$1.54 billion under our $2.00 billion three-year term loan facility maturing in 2024.
The loss from our early extinguishments of debt in 2023 was not significant.
88
Credit Facilities
On July 17, 2024, we entered into a credit agreement pursuant to which a group of banks provided us with senior
unsecured term loans in an aggregate principal amount of up to $2.05 billion ("the bridge facility"). Borrowings under
the bridge facility were available in up to three drawings to fund (a) the refinancing of our 1.322% Senior Notes due
November 29, 2024, our Floating Rate Notes due November 29, 2024, and certain borrowings under our existing
term loan facility and (b) payment of certain U.S. tax liabilities arising from internal reorganization transactions
related to the sale of our Kidney Care business. Borrowings under the bridge facility bore interest at a rate based on
our long-term debt ratings in effect from time to time and the interest rate on any borrowings outstanding beyond
December 31, 2024 would increase by 0.25%. We also incurred a ticking fee on undrawn commitments at a rate
based on our long-term debt ratings in effect from time to time. The banks' funding commitments under the bridge
facility terminated on December 31, 2024. Outstanding borrowings under the bridge facility were scheduled to
mature on the earlier of 364 days from the first funding date and November 24, 2025. Additionally, we were required
to use the net cash proceeds from certain transactions (including from the sale of our Kidney Care business) to
repay any outstanding borrowings under the bridge facility. The bridge facility contained financial and other
covenants, including a net leverage covenant, and provided for customary events of default. In November 2024, we
reduced the bridge facility capacity from $2.05 billion to $1.83 billion. Additionally, during the fourth quarter of 2024
we drew on the bridge facility to repay our 1.322% Senior Notes due November 29, 2024, our Floating Rate Notes
due November 29, 2024 and the outstanding balance on our three-year term loan facility. There was $1.83 billion
outstanding under this bridge facility as of December 31, 2024. In January 2025, we used a portion of the
approximately $3.4 billion of net after-tax cash proceeds from the sale of our Kidney Care business to repay the
$1.83 billion outstanding under the bridge facility, at which time it was terminated.
In the first quarter of 2024, we amended the credit agreements governing our U.S. dollar-denominated term loan
credit facility and revolving credit facility and the guaranty agreement with respect to our Euro-denominated
revolving credit facility to increase the maximum net leverage ratio covenant for the six fiscal quarters ending June
30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025. In
accordance with the terms of the amendment, the capacity under our U.S dollar-denominated revolving credit facility
was reduced from $2.50 billion to $2.00 billion on September 30, 2024. As of December 31, 2024, we were in
compliance with the financial covenants in these agreements. Costs incurred in connection with the amendment
were not material. In the first quarter of 2023, we previously amended the credit agreements governing our U.S.
Dollar-denominated term loan credit facility and revolving credit facility and the guaranty agreement with respect to
our Euro-denominated revolving credit facility, in each case to amend the net leverage ratio covenant to increase
the maximum net leverage ratio for the four fiscal quarters ending March 31, 2023, June 30, 2023, September 30,
2023 and December 31, 2023.
As of December 31, 2024, we had a U.S. Dollar-denominated term loan credit facility, which had one tranche of
term loans outstanding, a U.S. Dollar-denominated revolving credit facility and a Euro-denominated revolving credit
facility.
Borrowings under the term loan credit facility bear interest on the principal amount outstanding at either Term SOFR
plus an applicable margin plus a credit spread adjustment or a “base rate” plus an applicable margin. The term loan
credit facility contains various covenants, including a maximum net leverage ratio. We have the option to prepay
outstanding amounts under the term loan credit facility in whole or in part at any time.
In addition to our U.S. dollar-denominated revolving credit facility with a current capacity of $2.00 billion, our Euro-
denominated revolving credit facility has a capacity of €200 million. Fees under the credit facilities are 0.125%
annually as of December 31, 2024 and 2023, and are based on our credit ratings and the total capacity of the
facility. There were no borrowings outstanding under these credit facilities as of December 31, 2024 or 2023. Our
commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our revolving
credit facilities for an amount at least equal to our outstanding commercial paper borrowings. Each of the revolving
credit facilities is scheduled to mature in 2026. The revolving credit facilities enable us to borrow funds on an
unsecured basis at variable interest rates and contain various covenants, including a maximum net leverage ratio.
Based on our covenant calculations as of December 31, 2024 we have capacity to draw on the full amounts under
our revolving credit facilities, less commercial paper borrowings which were $300 million at year-end.
We also maintain other credit arrangements, which totaled approximately $412 million and $238 million as of
December 31, 2024 and 2023, respectively. The increase over the prior year is due to additional credit
arrangements entered into in preparation for the sale of our Kidney Care business. There were no amounts
outstanding under these arrangements as of December 31, 2024 and 2023.
89
As of December 31, 2024, we were in compliance with the financial covenants in these agreements. The non-
performance of any financial institution supporting any of the credit facilities would reduce the maximum capacity of
these facilities by each institution’s respective commitment.
Commercial Paper
As of December 31, 2024, we had $300 million of commercial paper outstanding with a weighted-average interest
rate of 4.78% and an original term of 45 days. There was no commercial paper outstanding as of December 31,
2023. In 2025, we repaid the $300 million balance outstanding as of December 31, 2024.
Future Debt and Finance Lease Maturities
as of and for the years ended December 31 (in millions)
Debt maturities
2025
$
2,757
2026
2,398
2027
1,458
2028
1,345
2029
784
Thereafter
4,438
Total debt and finance lease maturities
13,180
Discounts, premiums, and adjustments relating to hedging instruments
(54)
Total debt and finance lease obligations
$
13,126
NOTE 7
LEASES
Lessee Activity
We have entered into operating and finance leases primarily for office, manufacturing, warehouse and R&D
facilities, vehicles and equipment. Our leases have remaining terms from 1 to 38 years and some of those leases
include options that provide us with the ability to extend the lease term for periods ranging from 1 to 10 years. Such
options are included in the lease term when it is reasonably certain that the option will be exercised.
Certain of our leases include provisions for variable lease payments which are based on, but not limited to,
maintenance, insurance, taxes, index escalations and usage-based amounts. For all asset classes, we have elected
to apply a practical expedient to account for other services within lease contracts as components of the lease. We
also have elected to apply a practical expedient for short-term leases whereby we do not recognize a lease liability
and right-of-use asset for leases with a term of less than 12 months.
We classify our leases as operating or finance at the lease commencement date. Finance leases are generally
those leases for which we will pay substantially all of the underlying asset’s fair value or will use the asset for all or a
major part of its economic life, including circumstances in which we will ultimately own the asset. All other leases are
operating leases. For finance leases, we recognize interest expense using the effective interest method and we
recognize amortization expense on the right-of-use asset over the shorter of the lease term or the useful life of the
asset. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease.
Lease liabilities and right-of-use assets are recognized at the lease commencement date based on the present
value of minimum lease payments over the lease term. We determine the present value of payments under a lease
based on our incremental borrowing rate as of the lease commencement date. The incremental borrowing rate is
equal to the rate of interest that we would have to pay to borrow on a collateralized basis over a similar term in an
amount equal to the lease payments in a similar economic environment.
90
The components of lease cost for the years ended December 31, 2024, 2023 and 2022 were:
(in millions)
2024
2023
2022
Operating lease cost
$
89
$
94
$
93
Finance lease cost
Amortization of right-of-use assets
4
3
3
Interest on lease liabilities
1
1
1
Variable lease cost
54
45
44
Lease cost
$
148
$
143
$
141
The following table contains supplemental cash flow information related to leases for the years ended December 31,
2024, 2023 and 2022:
(in millions)
2024
2023
2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases
$
100 $
115 $
108
Operating cash flows from finance leases
5
3
2
Financing cash flows from finance leases
2
1
1
Right-of-use operating lease assets obtained in exchange for lease obligations
64
66
59
Right-of-use finance lease assets obtained in exchange for lease obligations
1
15
—
Supplemental balance sheet information related to leases as of December 31, 2024 and 2023 include:
(in millions)
2024
2023
Operating leases
Operating lease right-of-use assets
$
306
$
336
Accrued expenses and other current liabilities
$
80
$
92
Operating lease liabilities
243
265
Total operating lease liabilities
$
323
$
357
Finance leases
Property, plant and equipment, at cost
$
33
$
33
Accumulated depreciation
(15)
(13)
Property, plant and equipment, net
$
18
$
20
Current maturities of long-term debt and finance lease obligations
$
2
$
2
Long-term debt and finance lease obligations
19
25
Total finance lease liabilities
$
21
$
27
91
Lease term and discount rates as of December 31, 2024 and 2023 were:
December 31, 2024
December 31, 2023
Weighted-average remaining lease term (years)
Operating leases
6
6
Finance leases
8
8
Weighted-average discount rate
Operating leases
3.1 %
3.0 %
Finance leases
4.2 %
3.9 %
Maturities of operating and finance lease liabilities as of December 31, 2024 were:
(in millions)
Finance
Leases
Operating
Leases
2025
$
4 $
93
2026
4
75
2027
4
63
2028
3
44
2029
3
24
Thereafter
10
62
Total minimum lease payments
28
361
Less: imputed interest
(7)
(38)
Present value of lease liabilities
$
21 $
323
Lessor Activity
We lease medical equipment, such as smart beds and infusion pumps, to customers, often in conjunction with
arrangements to provide consumable medical products such as intravenous (IV) fluids and inhaled anesthetics.
Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The
terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten
or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products
based on their standalone selling prices.
The components of lease revenue for the years ended December 31, 2024, 2023 and 2022 were:
(in millions)
2024
2023
2022
Sales-type lease revenue
$
10 $
7 $
8
Operating lease revenue
380
397
401
Variable lease revenue
28
21
17
Total lease revenue
$
418 $
425 $
426
The components of our net investment in sales-type leases as of December 31, 2024 and 2023 were:
(in millions)
2024
2023
Minimum lease payments
$
38 $
50
Unguaranteed residual values
(1)
—
Net investment in leases
$
37 $
50
92
Our net investment in sales-type leases is classified as follows in the accompanying consolidated balance sheets as
of December 31, 2024 and 2023:
(in millions)
2024
2023
Accounts receivable, net
$
15
$
25
Other non-current assets
22
26
Total
$
37
$
51
Our net investment in sales-type leases was $37 million as of December 31, 2024, of which $3 million originated in
2020 and prior, $10 million in 2021, $6 million in 2022, $8 million in 2023 and $10 million in 2024.
Maturities of sales-type and operating leases as of December 31, 2024 were:
(in millions)
Sales-type
Leases1
Operating
Leases
2025
$
20 $
13
2026
7
9
2027
5
3
2028
4
1
2029
1
7
Thereafter
—
—
Total minimum lease payments
$
37 $
33
1 Unamortized imputed interest on minimum lease payments was less than $1 million as of December 31, 2024.
NOTE 8
COMMITMENTS AND CONTINGENCIES
Refer to Note 3 for information regarding contingent payments associated with collaborative and other
arrangements.
Indemnifications
During the normal course of business, we make indemnities, commitments and guarantees pursuant to which we
may be required to make payments related to specific transactions. Indemnifications include: (i) intellectual property
indemnities to customers in connection with the use, sales or license of products and services; (ii) indemnities to
customers in connection with losses incurred while performing services on their premises; (iii) indemnities to
vendors and service providers pertaining to claims based on negligence or willful misconduct; (iv) indemnities
involving the representations and warranties in certain contracts; and (v) contractual indemnities for our directors
and our executive and corporate officers for services provided to or at the request of us. In addition, under our
Amended and Restated Certificate of Incorporation, and consistent with Delaware General Corporation Law, we
have agreed to indemnify our directors and officers for certain losses and expenses upon the occurrence of certain
prescribed events. The majority of these indemnities, commitments and guarantees do not provide for any limitation
on the maximum potential for future payments that we could be obligated to make. To help address some of these
risks, we maintain various insurance coverages. Based on historical experience and evaluation of the agreements,
we do not believe that any payments related to our indemnities will have a material impact on our financial condition
or results of operations.
Legal Contingencies
We are involved in product liability, patent, commercial, employment, and other legal matters that arise in the normal
course of our business. We record a liability when a loss is considered probable and the amount can be reasonably
estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better
estimate than any other amount, the minimum amount in the range is accrued. If a loss is not probable or a
probable loss cannot be reasonably estimated, no liability is recorded. As of December 31, 2024 and 2023, our total
recorded reserves with respect to legal and environmental matters were $40 million and $25 million, respectively.
93
We have established reserves for certain of the matters discussed below. We are not able to estimate the amount or
range of any loss for certain contingencies for which there is no reserve or additional loss for matters already
reserved. While our liability in connection with these claims cannot be estimated and the resolution thereof in any
reporting period could have a significant impact on our results of operations and cash flows for that period, the
outcome of these legal proceedings is not expected to have a material adverse effect on our consolidated financial
position. While we believe that we have valid defenses in the matters set forth below, litigation is inherently
uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of
claims.
In addition to the matters described below, we remain subject to the risk of future administrative and legal actions.
With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and
other restrictions on our operations (including our ability to launch new products) and monetary sanctions, including
significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation
concerning the scope of our and others’ rights. Such litigation could result in a loss of patent protection or the ability
to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of
operations.
Environmental
We are involved as a potentially responsible party (PRP) for environmental clean-up costs at six Superfund sites.
Additionally, we are a defendant in a separate matter regarding a seventh Superfund site. Under the U.S. Superfund
statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site
cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP
may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from these
Superfund cases noted above, we are involved in ongoing environmental remediations associated with historic
operations at certain of our facilities. As of December 31, 2024 and 2023, our environmental reserves, which are
measured on an undiscounted basis, were $29 million and $15 million, respectively. After considering these
reserves, the outcome of these matters is not expected to have a material adverse effect on our financial position or
results of operations.
General Litigation
In March 2020, two lawsuits were filed against us in the Northern District of Illinois by plaintiffs alleging injuries as a
result of exposure to ethylene oxide used in our manufacturing facility in Mountain Home, Arkansas to sterilize
certain of our products. The plaintiffs sought damages, including compensatory and punitive damages in an
unspecified amount, and unspecified injunctive and declaratory relief. The parties reached an agreement to settle
these lawsuits in the third quarter of 2021 for amounts that were not material to our financial results, which were
paid in the fourth quarter of 2021. We have since resolved, without litigation, additional claims of injuries from
exposure to ethylene oxide at Mountain Home for amounts within accruals previously established as of December
31, 2021. On October 20, 2022, a lawsuit was filed against us in the Western District of Arkansas alleging injury as
a result of exposure to ethylene oxide at Mountain Home. On December 16, 2022, we filed a motion to dismiss and
for a more definite statement. In response, Plaintiffs filed a First Amended Complaint on January 6, 2023. We
answered the First Amended Complaint on January 27, 2023. The parties reached an agreement to settle this
lawsuit in the third quarter of 2023 for an amount that was not material to our financial results, which was paid in the
fourth quarter of 2023. The case was dismissed on October 17, 2023. Since December 2023, 41 lawsuits (after
giving effect to the amendment referenced below) have been filed against us in the Circuit Court of Cook County,
Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including
historic use by us for sterilization at our facility in Round Lake, Illinois. The plaintiffs seek damages in an unspecified
amount. On July 16, 2024, Plaintiffs' counsel filed an omnibus motion seeking leave to add certain defendants to
hundreds of previously-filed lawsuits, including Baxter with respect to 40 cases. The motion was denied on July 25,
2024, without prejudice to refiling multiple motions each addressing smaller groupings of cases and defendants. On
September 11, 2024, the court granted leave to amend one previously-filed complaint to add Baxter as a defendant.
We acquired Hillrom on December 13, 2021. In July 2021, Hill-Rom, Inc., a wholly-owned subsidiary of Hillrom,
received a subpoena from the United States Office of Inspector General for the Department of Health and Human
Services (the DHHS) requesting documents and information related to compliance with the False Claims Act and
the Anti-Kickback Statute. The subpoena was related to a lawsuit brought under the qui tam provisions of the False
Claims Act. The allegations included in the unsealed complaint relate to conduct prior to our acquisition of Hillrom,
and the division involved is no longer operational. Hillrom voluntarily began a related internal review, and Hillrom
and Baxter cooperated fully with the DHHS and the Department of Justice (DOJ) with respect to this matter. In
94
January 2024, the parties reached an agreement to settle the allegations. We paid the settlement amounts, which
were not material to our financial results, in January 2024 and the matter was dismissed in February 2024. In
October 2022, the DOJ issued a separate Civil Investigative Demand (CID) addressed to Hillrom, requesting
documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. In
October 2024, the DOJ issued a subpoena (the 2024 Subpoena), pursuant to 18 U.S.C. 3846, to Hillrom. The 2024
Subpoena substantially overlaps with the CID and requests additional documents relating to Hillrom's respiratory
health business. Baxter is cooperating fully with the DOJ in responding to the CID and the 2024 Subpoena. The
DHHS and DOJ often issue these types of requests when investigating alleged violations of the federal health care
laws.
On December 28, 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom
Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois,
captioned Linet Americas, Inc. v. Hill-Rom Holdings, Inc.; Hill-Rom Company, Inc.; Hill-Rom Services, Inc. Linet
alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act of 1890, Section 3 of the Clayton Act,
and the Illinois Antitrust Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU
and birthing beds. Hillrom filed an answer to the complaint on January 28, 2022 and filed a motion challenging
certain aspects of plaintiff's case on May 27, 2022, which was denied on January 17, 2024, subject to further
discovery.
On June 20, 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom
Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of
Pennsylvania. The complaint alleges that Hillrom violated Sections 1 and 2 of The Sherman Antitrust Act and
Section 3 of the Clayton Act by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU
and birthing beds. The plaintiff filed the action on behalf of itself and all "direct purchasers of Standard Hospital
Beds, ICU Beds, and/or Birthing Beds from Hill-Rom during a period beginning at least as early as June 20, 2020”
and continuing past the date of filing. On September 30, 2024, the plaintiff filed a First Amended Complaint. On
November 8, 2024, Hillrom filed a Motion to Dismiss Plaintiff's Amended Complaint. Briefing was completed in
January 2025 and the motion is pending before the court.
NOTE 9
STOCKHOLDERS' EQUITY
Stock-Based Compensation
Our stock-based compensation generally includes stock options, restricted stock units (RSUs), performance share
units (PSUs) and purchases under our employee stock purchase plan. Shares issued relating to our stock-based
plans are generally issued out of treasury stock.
As of December 31, 2024, approximately 48 million authorized shares are available for future awards under our
stock-based compensation plans.
Stock Compensation Expense
Stock compensation expense was $114 million, $115 million and $140 million in 2024, 2023 and 2022, respectively.
The related tax benefit recognized was $8 million in 2024, $10 million in 2023 and $31 million in 2022. Included in
the benefit in 2024 and 2023 was tax expense for stock-based compensation shortfalls of $9 million and $11 million,
respectively. Included in the benefit in 2022 were realized excess tax benefits for stock-based compensation $5
million.
Approximately 70% of stock compensation expense is classified in SG&A expenses, with the remainder classified in
cost of sales and R&D expenses. Costs capitalized in the consolidated balance sheets at December 31, 2024 and
2023 were not material.
Stock compensation expense is based on awards expected to vest and therefore has been reduced by estimated
forfeitures.
95
Stock Options
Stock options are granted to employees and non-employee directors with exercise prices equal to 100% of the
market value on the date of grant. Stock options granted to employees generally vest in one-third increments over a
three-year period. Stock options granted to non-employee directors generally vest immediately on the grant date
and are issued with a six-month claw-back provision. Stock options typically have a contractual term of 10 years.
The grant-date fair value, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over
the substantive vesting period.
The fair value of stock options is determined using the Black-Scholes model. The weighted-average assumptions
used in estimating the fair value of stock options granted during each year, along with the weighted-average grant-
date fair values, were as follows:
years ended December 31
2023
2022
Expected volatility
27 %
24 %
Expected life (in years)
6.0
5.5
Risk-free interest rate
4.2 %
1.8 %
Dividend yield
3.0 %
1.3 %
Fair value per stock option
$
9
$
18
The following table summarizes stock option activity for the year ended December 31, 2024 and the outstanding
stock options as of December 31, 2024.
(options and aggregate intrinsic values in thousands)
Options
Weighted-
average
exercise
price
Weighted-
average
remaining
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 1, 2024
19,467 $
59.35
Granted
— $
—
Exercised
(760) $
37.43
Forfeited
(287) $
47.96
Expired
(1,039) $
65.21
Outstanding as of December 31, 2024
17,381 $
60.15
3.83 $
—
Vested or expected to vest as of December 31, 2024
17,236 $
60.31
3.80 $
—
Exercisable as of December 31, 2024
14,718 $
62.66
3.32 $
—
The aggregate intrinsic value in the table above represents the difference between the exercise price and our
closing stock price on the last trading day of the year. The total intrinsic value of options exercised in 2024, 2023
and 2022 was $1 million, $5 million and $37 million, respectively.
As of December 31, 2024, $11 million of unrecognized compensation cost related to stock options is expected to be
recognized as expense over a weighted-average period of approximately 1.1 years.
RSUs
RSUs are granted to employees and non-employee directors. RSUs granted to employees generally vest in one-
third increments over a three-year period. RSUs granted to non-employee directors generally vest immediately on
the grant date and are issued with a six-month claw-back provision. The grant-date fair value, adjusted for
estimated forfeitures, is recognized as expense on a straight-line basis over the substantive vesting period. The fair
value of RSUs is determined based on the number of shares granted and the closing price of our common stock on
the date of grant.
96
The following table summarizes nonvested RSU activity for the year ended December 31, 2024.
(share units in thousands)
Share units
Weighted-
average
grant-date
fair value
Nonvested RSUs as of January 1, 2024
4,006 $
49.77
Granted
5,179 $
42.28
Vested
(1,565) $
53.64
Forfeited
(680) $
46.32
Nonvested RSUs as of December 31, 2024
6,940 $
43.94
As of December 31, 2024, $123 million of unrecognized compensation cost related to RSUs is expected to be
recognized as expense over a weighted-average period of approximately 1.8 years. The weighted-average grant-
date fair value of RSUs granted in 2024, 2023 and 2022 was $42.37, $39.20 and $81.66, respectively. The fair
value of RSUs vested in 2024, 2023 and 2022 was $46 million, $25 million and $69 million, respectively.
PSUs
Our annual equity awards stock compensation program for senior management includes the issuance of PSUs.
PSUs awarded in 2024 (which grants were made solely to the CEO and Chief Financial Officer) were based on our
stock performance relative to our peer group over the 3-year performance period. PSUs awarded in 2020 through
2023 were based on our compound annual sales growth rate (CAGR) performance, our adjusted return on invested
capital (ROIC) performance and on our stock performance relative to our peer group. The vesting condition for
these CAGR and ROIC PSUs was set at the beginning of the 3-year performance period. Compensation cost for the
CAGR and adjusted ROIC PSUs is measured based on the fair value of the awards on the date that the specific
vesting terms for each award are established and the fair value of the awards is determined based on the quoted
price of our stock on the grant date of the award. The compensation cost for CAGR and adjusted ROIC PSUs is
adjusted at each reporting date to reflect the estimated vesting outcome.
The fair value for PSUs based on our stock performance relative to our peer group is determined using a Monte
Carlo model. The assumptions used in estimating the fair value of these PSUs granted during the period, along with
the grant-date fair values, were as follows:
years ended December 31
2024
2023
2022
Baxter volatility
29 %
27 %
27 %
Peer group volatility
20%-52%
23%-54%
24%-54%
Correlation of returns
0.12-0.51
0.23-0.48
0.21-0.61
Risk-free interest rate
4.3 %
4.6 %
1.6 %
Fair value per PSU
$
57
$
30
$
102
97
The following table summarizes nonvested PSU activity for the year ended December 31, 2024.
(share units in thousands)
Share units
Weighted-
average
grant-date
fair value
Nonvested PSUs as of January 1, 2024
729 $
57.03
Granted
186 $
57.22
Vested
(73) $
77.35
Forfeited
(240) $
87.85
Nonvested PSUs as of December 31, 2024
602 $
42.36
Unrecognized compensation cost related to all unvested PSUs of $6 million at December 31, 2024 is expected to be
recognized as expense over a weighted-average period of 2.7 years.
Employee Stock Purchase Plan
Nearly all employees are eligible to participate in our employee stock purchase plan. The employee purchase price
is 85% of the closing market price on the purchase date.
As of December 31, 2024, approximately 8 million shares of common stock were available for issuance to eligible
participants.
During each of the years ended December 31, 2024 and 2023 we issued approximately 1.4 million shares and
during the year ended December 31, 2022, we issued approximately 0.9 million shares under the employee stock
purchase plan.
Cash Dividends
Total cash dividends declared per share for 2024, 2023, and 2022 were $1.04, $1.16 and $1.15, respectively.
A quarterly dividend of $0.29 per share ($1.16 on an annualized basis) was declared in February, May and July of
2024 and was paid in April, July and October of 2024, respectively. Our Board of Directors declared a quarterly
dividend of $0.17 per share in November of 2024, which was paid in January of 2025.
Stock Repurchase Programs
As authorized by the Board of Directors, we repurchase our stock depending on our cash flows, net debt level and
market conditions. In July 2012, the Board of Directors authorized a share repurchase program and the related
authorization was subsequently increased a number of times. We did not repurchase any shares under this
authority in 2024 or 2023. We repurchased 0.5 million shares under this authority pursuant to Rule 10b5-1 plans for
$32 million in cash in 2022. We had $1.30 billion of repurchase authority available as of December 31, 2024.
Other
In addition to common stock, our authorized capital structure includes 100 million shares of preferred stock, no par
value. As of December 31, 2024 and 2023, no shares of preferred stock were outstanding.
NOTE 10
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Comprehensive income (loss) includes all changes in stockholders’ equity that do not arise from transactions with
stockholders, and consists of net income (loss), CTA, certain gains and losses from pension and other
postretirement employee benefit (OPEB) plans, certain gains and losses from hedging activities and unrealized
gains and losses on available-for-sale debt securities.
98
The following table is a net-of-tax summary of the changes in AOCI by component for the years ended
December 31, 2024, 2023, and 2022.
(in millions)
CTA
Pension and
OPEB plans
Hedging
activities
Available-for-
sale debt
securities
Total
Gains (losses)
Balance as of December 31, 2023
$
(2,985) $
(452) $
(120) $
3 $
(3,554)
Other comprehensive income (loss) before
reclassifications
(445)
(19)
10
—
(454)
Amounts reclassified from AOCI (a)
—
(4)
2
—
(2)
Net other comprehensive income (loss)
(445)
(23)
12
—
(456)
Balance as of December 31, 2024
$
(3,430) $
(475) $
(108) $
3 $
(4,010)
(in millions)
CTA
Pension and
OPEB plans
Hedging
activities
Available-for-
sale debt
securities
Total
Gains (losses)
Balance as of December 31, 2022
$
(3,386) $
(331) $
(119) $
3 $
(3,833)
Other comprehensive income (loss) before
reclassifications
216
(106)
5
—
115
Amounts reclassified from AOCI (a)
185
(15)
(6)
—
164
Net other comprehensive income (loss)
401
(121)
(1)
—
279
Balance as of December 31, 2023
$
(2,985) $
(452) $
(120) $
3 $
(3,554)
(in millions)
CTA
Pension and
OPEB plans
Hedging
activities
Available-for-
sale debt
securities
Total
Gains (losses)
Balance as of December 31, 2021
$
(2,907) $
(347) $
(126) $
— $
(3,380)
Other comprehensive income (loss) before
reclassifications
(544)
(9)
22
3
(528)
Amounts reclassified from AOCI (a)
65
25
(15)
—
75
Net other comprehensive income (loss)
(479)
16
7
3
(453)
Balance as of December 31, 2022
$
(3,386) $
(331) $
(119) $
3 $
(3,833)
(a)
See table below for details about these reclassifications.
99
The following table is a summary of the amounts reclassified from AOCI to net income (loss) during the years ended
December 31, 2024 and 2023.
Amounts reclassified from
AOCI (a)
(in millions)
2024
2023
2022
Location of impact
in income statement
CTA
Reclassification of cumulative
translation loss to earnings
$
— $
— $
(65) Other (income) expense, net
Reclassification of cumulative
translation loss to earnings from BPS
divestiture
—
(185) $
—
Income (loss) from
discontinued operations, net
of tax
—
(185)
(65)
Total before tax
Less: Tax effect
—
—
— Income tax expense (benefit)
$
— $
(185) $
(65)
Net of tax
Pension and OPEB items
Amortization of net losses and prior
service costs or credits
$
6 $
18 $
(30) Other (income) expense, net
Settlement charges
—
(2)
(1) Other (income) expense, net
Pension settlement from BPS
divestiture
—
4
—
Income (loss) from
discontinued operations, net
of tax
6
20
(31)
Total before tax
Less: Tax effect
(2)
(5)
6 Income tax expense (benefit)
$
4 $
15 $
(25)
Net of tax
Gains (losses) on hedging activities
Foreign exchange contracts
$
8 $
16 $
26
Cost of sales
Interest rate contracts
(6)
(6)
(6)
Interest expense, net
Fair value hedges
(5)
(3)
—
Other (income) expense, net
(3)
7
20
Total before tax
Less: Tax effect
1
(1)
(5) Income tax expense (benefit)
$
(2) $
6 $
15
Net of tax
Total reclassifications for the period
$
2 $
(164) $
(75)
Total net of tax
(a)
Amounts in parentheses indicate reductions to net income.
Refer to Note 4 for additional information regarding the reclassification of a cumulative translation loss to earnings,
Note 13 for additional information regarding the amortization of pension and OPEB items and Note 16 for additional
information regarding hedging activity.
NOTE 11
REVENUES
Contract Balances
The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts
receivable, unbilled receivables, contract assets, and customer advances and deposits (contract liabilities) on our
consolidated balance sheets. Net trade accounts receivable was $1.54 billion as of December 31, 2024 and 2023.
For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which
typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed
and the customers are billed. Additionally, for certain arrangements containing a performance obligation to deliver
software that can be used with medical devices, we recognize revenue upon delivery of the software, which results
in the recognition of contract assets when customers are billed over time, generally over one to five years. For
100
bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over
time, total contract revenue is allocated between the equipment and consumable medical products. In certain of
those arrangements, a contract asset is created for the difference between the amount of equipment revenue
recognized upon delivery and the amount of consideration initially receivable from the customer. In those
arrangements, the contract asset becomes a trade account receivable as consumable medical products are
provided and billed, generally over one to seven years.
The following table summarizes our contract assets:
as of December 31 (in millions)
2024
2023
Contract manufacturing services
$
2 $
4
Software sales
44
45
Bundled equipment and consumable medical products contracts
87
116
Contract assets
$
133 $
165
Contract liabilities represent deferred revenues that arise as a result of cash received from customers or where the
timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance
obligations represent the portion of the contract price for which work has not been performed and are primarily
related to our installation and service contracts. We expect to satisfy the majority of the remaining performance
obligations and recognize revenue related to installation and service contracts within the next 12 months with most
of the non-current performance obligations satisfied within 24 months.
The following table summarizes contract liability activity for the years ended December 31, 2024 and 2023. The
contract liability balance represents the transaction price allocated to the remaining performance obligations.
year ended December 31 (in millions)
2024
2023
Balance at beginning of period
$
169 $
173
New revenue deferrals
554
478
Revenue recognized upon satisfaction of performance obligations
(555)
(484)
Currency translation
3
2
Balance at end of period
$
171 $
169
In 2024 and 2023, $103 million and $117 million of revenue was recognized that was included in contract liabilities
as of December 31, 2023 and 2022, respectively. In 2022, $110 million of revenue was recognized that was
included in contract liabilities as of December 31, 2021.
The following table summarizes the classification of contract assets and contract liabilities as reported in the
consolidated balance sheet:
as of December 31 (in millions)
2024
2023
Prepaid expenses and other current assets
$
51 $
53
Other non-current assets
82
112
Contract assets
$
133 $
165
Accrued expenses and other current liabilities
$
131 $
128
Other non-current liabilities
40
41
Contract liabilities
$
171 $
169
Disaggregation of Net Sales
Refer to Note 18 for additional information on our net sales including the disaggregation of net sales within each of
our segments and net sales by geographic location.
101
NOTE 12
BUSINESS OPTIMIZATION CHARGES
In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency.
These efforts include restructuring the organization, optimizing the manufacturing footprint, R&D operations and
supply chain network, employing disciplined cost management and centralizing and streamlining certain support
functions. We currently expect to incur additional pre-tax cash costs, primarily related to the implementation of
business optimization programs, of approximately $4 million through the completion of initiatives that are currently
underway. We continue to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-
synergies expected to arise as a result of the sale of our Kidney Care business, and to the extent further cost
savings opportunities are identified, we would incur additional restructuring charges and costs to implement
business optimization programs in future periods. For segment reporting, business optimization charges are
unallocated expenses.
We recorded the following charges related to business optimization programs in 2024, 2023 and 2022:
years ended December 31 (in millions)
2024
2023
2022
Restructuring charges
$
146 $
141 $
144
Costs to implement business optimization programs1
16
33
49
Total business optimization charges
$
162 $
174 $
193
1 Costs to implement business optimization programs for the years ended December 31, 2024, 2023 and 2022, respectively, consisted primarily
of external consulting and transition costs, including employee compensation and related costs. The costs were primarily included within cost of
sales and SG&A expenses.
The costs of restructuring actions consisted primarily of employee termination costs, contract termination costs and
asset impairments. During the years ended December 31, 2024, 2023 and 2022, we recorded the following
restructuring charges:
2024
(in millions)
COGS
SG&A
R&D
Total
Employee termination costs
$
20 $
48 $
30 $
98
Contract termination and other costs
3
6
—
9
Asset impairments
39
—
—
39
Total restructuring charges
$
62 $
54 $
30 $
146
2023
(in millions)
COGS
SG&A
R&D
Total
Employee termination costs
$
20 $
91 $
10 $
121
Contract termination and other costs
(1)
3
—
2
Asset impairments
11
7
—
18
Total restructuring charges
$
30 $
101 $
10 $
141
2022
(in millions)
COGS
SG&A
R&D
Total
Employee termination costs
$
15 $
94 $
3 $
112
Contract termination and other costs
—
22
—
22
Asset impairments
—
10
—
10
Total restructuring charges
$
15 $
126 $
3 $
144
For the year ended December 31, 2024, $45 million of the restructuring charges reflected above, consisting of
employee termination costs, were related to initiatives to reduce our cost structure following the sale of our Kidney
Care segment. For the year ended December 31, 2024, $46 million of the restructuring charges reflected in the
table above were related to business optimization initiatives within our Healthcare Systems & Technologies
segment. These charges included $21 million of long-lived asset impairment charges, $9 million of other asset write-
downs related to inventory and $2 million of employee termination costs related to our decision to discontinue a
product line. Additionally, these charges included $14 million of employee termination costs related to other
business optimization initiatives within this segment.
102
For the year ended December 31, 2023, $81 million of the restructuring charges reflected above, consisting of
employee termination costs, were related to the implementation of our new operating model intended to streamline
our operations.
For the year ended December 31, 2022, $85 million restructuring charges reflected in the table above were related
to integration activities for the Hillrom acquisition, consisting of $55 million of employee termination costs, $22
million of contract terminations and other costs and $8 million of asset impairments.
The following table summarizes activity in the liability related to our restructuring initiatives.
(in millions)
Liability balance as of December 31, 2021
$
75
Charges
152
Payments
(118)
Reserve adjustments
(18)
Currency translation
(5)
Liability balance as of December 31, 2022
86
Charges
146
Payments
(101)
Reserve adjustments
(23)
Currency translation
(13)
Liability balance as of December 31, 2023
95
Charges
116
Payments
(80)
Reserve adjustments
(9)
Currency translation
—
Liability balance as of December 31, 2024
$
122
Reserve adjustments primarily relate to employee termination cost reserves established in prior periods.
Substantially all of our restructuring liabilities as of December 31, 2024 relate to employee termination costs, with
the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those
liabilities are expected to be disbursed by the end of 2024.
NOTE 13
PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS
We sponsor a number of qualified and nonqualified pension plans for eligible employees. We also sponsor certain
unfunded contributory healthcare and life insurance benefits for substantially all domestic retired employees. Newly
hired employees in the United States and Puerto Rico are not eligible to participate in the pension plans but receive
a higher level of company contributions in our defined contribution plans.
103
Reconciliation of Pension and Other Postretirement Benefit Plan Obligations, Assets and Funded Status
The benefit plan information in the table below pertains to all of our pension and OPEB plans, both in the United
States and in other countries.
Pension benefits
OPEB
as of and for the years ended December 31 (in millions)
2024
2023
2024
2023
Benefit obligations
Beginning of period
$
2,901 $
2,665 $
154 $
160
Service cost
11
19
—
—
Interest cost
136
148
8
8
Participant contributions
3
4
—
—
Actuarial (gain) loss
(129)
169
(3)
5
Benefit payments
(133)
(133)
(15)
(19)
Settlements
(8)
(14)
—
—
Acquisitions
—
2
—
—
Plan Amendments
—
3
(2)
—
Foreign exchange and other
(33)
38
(1)
—
End of period
2,748
2,901
141
154
Fair value of plan assets
Beginning of period
2,350
2,161
—
—
Actual return on plan assets
(4)
268
—
—
Employer contributions
46
27
15
19
Participant contributions
3
4
—
—
Benefit payments
(133)
(133)
(15)
(19)
Settlements
(8)
(14)
—
—
Foreign exchange and other
(26)
37
—
—
End of period
2,228
2,350
—
—
Funded status at December 31
$
(520) $
(551) $
(141) $
(154)
Amounts recognized in the consolidated balance sheets
Noncurrent asset
$
56 $
46 $
— $
—
Current liability
(23)
(20)
(16)
(17)
Noncurrent liability
(553)
(577)
(125)
(137)
Net liability recognized at December 31
$
(520) $
(551) $
(141) $
(154)
Actuarial gains and losses result from changes in actuarial assumptions (such as changes in the discount rate and
revised mortality rates). Actuarial gains in 2024 and losses in 2023 related to plan benefit obligations were primarily
the result of changes in discount rates.
The pension obligation information in the table above represents the projected benefit obligation (PBO). The PBO
incorporates assumptions relating to future compensation levels. The accumulated benefit obligation (ABO) is the
same as the PBO except that it includes no assumptions relating to future compensation levels. The ABO for all of
our pension plans was $2.71 billion and $3.06 billion at the 2024 and 2023 measurement dates, respectively.
104
The information in the funded status table above represents the totals for all of our pension plans. The following
table is information relating to the individual plans in the funded status table above that have an ABO in excess of
plan assets.
as of December 31 (in millions)
2024
2023
ABO
$
2,403 $
2,502
Fair value of plan assets
$
1,843 $
1,919
The following table presents information relating to the individual plans in the funded status table above that have a
PBO in excess of plan assets (many of which also have an ABO in excess of assets and are therefore also included
in the table directly above).
as of December 31 (in millions)
2024
2023
PBO
$
2,419 $
2,561
Fair value of plan assets
$
1,843 $
1,961
Expected Net Pension and OPEB Plan Payments for the Next 10 Years
(in millions)
Pension
benefits
OPEB
2025
$
156 $
17
2026
160
15
2027
172
14
2028
179
14
2029
183
13
2030 through 2034
973
55
Total expected net benefit payments for next 10 years
$
1,823 $
128
The expected net benefit payments above reflect the total net benefits expected to be paid from the plans’ assets
(for funded plans) or from our assets (for unfunded plans). The federal subsidies relating to the Medicare
Prescription Drug, Improvement and Modernization Act are not expected to be significant.
Amounts Recognized in AOCI
The pension and OPEB plans’ gains or losses, prior service costs or credits, and transition assets or obligations not
yet recognized in net periodic benefit cost are recognized on a net-of-tax basis in AOCI and will be amortized from
AOCI to net periodic benefit cost in the future. For active employees, we utilize the average future working lifetime
as the amortization period for prior service. For inactive employees, we utilize the average remaining life expectancy
as the amortization period for prior service.
The following table is a summary of the pre-tax losses (gains) included in AOCI at December 31, 2024 and 2023.
(in millions)
Pension
benefits
OPEB
Actuarial loss (gain)
$
642 $
(42)
Prior service credit and transition obligation
11
(10)
Total pre-tax loss (gain) recognized in AOCI at December 31, 2024
$
653 $
(52)
Actuarial loss (gain)
$
615 $
(50)
Prior service credit and transition obligation
11
(16)
Total pre-tax loss (gain) recognized in AOCI at December 31, 2023
$
626 $
(66)
105
Refer to Note 10 for the net-of-tax balances included in AOCI as of each of the year-end dates. The following table
is a summary of the net-of-tax amounts recorded in OCI relating to pension and OPEB plans.
Year ended December 31 (in millions)
2024
2023
2022
Gain (loss) arising during the year, net of tax of $(6) in 2024, $31 in 2023 and
$4 in 2022
$
(15) $
(103) $
(61)
Amortization of gain (loss) to earnings, net of tax of zero in 2024, $(5) in
2023 and $6 in 2022
(4)
13
21
Settlement charges, net of tax of zero in 2024, $(1) in 2023 and zero 2022
—
(2)
1
Pension and other employee benefits
$
(19) $
(92) $
(39)
In 2024, 2023 and 2022, OCI activity for pension and OPEB plans was primarily related to actuarial gains and
losses.
Net Periodic Benefit Cost
Year ended December 31 (in millions)
2024
2023
2022
Pension benefits
Service cost
$
11 $
19 $
71
Interest cost
136
148
94
Expected return on plan assets
(179)
(187)
(156)
Amortization of net losses and other deferred amounts
15
6
41
Curtailment gain
—
—
(12)
Settlement charges
—
1
—
Other
—
1
1
Net periodic pension benefit cost
$
(17) $
(12) $
39
OPEB
Service cost
$
— $
— $
1
Interest cost
8
8
4
Amortization of net losses and prior service credit
(19)
(24)
(14)
Curtailment gain
—
(1)
—
Net periodic OPEB cost
$
(11) $
(17) $
(9)
Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date
Pension benefits
OPEB
2024
2023
2024
2023
Discount rate
U.S. and Puerto Rico plans
5.71 %
5.20 %
5.54 %
5.11 %
International plans
3.67 %
1.76 %
n/a
n/a
Rate of compensation increase
U.S. and Puerto Rico plans
3.00 %
2.60 %
n/a
n/a
International plans
3.07 %
2.59 %
n/a
n/a
Annual rate of increase in the per-capita cost
n/a
n/a
6.75 %
6.25 %
Rate decreased to
n/a
n/a
5.00 %
5.00 %
by the year ended
n/a
n/a
2032
2029
The assumptions above, which were used in calculating the December 31, 2024 measurement date benefit
obligations, will be used in the calculation of net periodic benefit cost in 2025.
106
Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost
Pension benefits
OPEB
2024
2023
2022
2024
2023
2022
Discount rate
U.S. and Puerto Rico plans
5.20 %
5.55 %
3.01 %
5.11 %
5.46 %
2.76 %
International plans
3.41 %
4.11 %
1.55 %
n/a
n/a
n/a
Expected return on plan assets
U.S. and Puerto Rico plans
6.65 %
6.43 %
5.00 %
n/a
n/a
n/a
International plans
4.86 %
4.93 %
3.89 %
n/a
n/a
n/a
Rate of compensation increase
U.S. and Puerto Rico plans
2.60 %
2.93 %
3.68 %
n/a
n/a
n/a
International plans
3.32 %
3.43 %
3.17 %
n/a
n/a
n/a
Annual rate of increase in the per-capita
cost
n/a
n/a
n/a
6.75 %
6.25 %
6.50 %
Rate decreased to
n/a
n/a
n/a
5.00 %
5.00 %
5.00 %
by the year ended
n/a
n/a
n/a
2032
2029
2029
We established the expected return on plan assets assumption primarily based on a review of historical compound
average asset returns, both company-specific and relating to the broad market (based on our asset allocation), as
well as an analysis of current market and economic information and future expectations. We plan to use a 6.65%
assumption for our U.S. and Puerto Rico plans for 2025.
Pension Plan Assets
An investment committee of members of senior management is responsible for supervising, monitoring and
evaluating the invested assets of our funded pension plans. The investment committee, which meets at least
quarterly, abides by documented policies and procedures relating to investment goals, targeted asset allocations,
risk management practices, allowable and prohibited investment holdings, diversification, use of derivatives, the
relationship between plan assets and benefit obligations, and other relevant factors and considerations.
The investment committee’s policies and procedures include the following:
•
Ability to pay all benefits when due;
•
Targeted long-term performance expectations relative to applicable market indices, such as
Russell, MSCI EAFE, and other indices;
•
Targeted asset allocation percentage ranges (summarized below), and periodic reviews of these
allocations;
•
Diversification of assets among third-party investment managers, and by geography, industry, stage
of business cycle and other measures;
•
Specified investment holding and transaction prohibitions (for example, private placements or other
restricted securities, securities that are not traded in a sufficiently active market, short sales, certain
derivatives, commodities and margin transactions);
•
Specified portfolio percentage limits on holdings in a single corporate or other entity (generally 5%
at time of purchase, except for holdings in U.S. government or agency securities);
•
Specified average credit quality for the fixed-income securities portfolio (at least A- by Standard &
Poor’s or A3 by Moody’s);
•
Specified portfolio percentage limits on foreign holdings; and
•
Periodic monitoring of investment manager performance and adherence to the investment
committee’s policies.
Plan assets are invested using a total return investment approach whereby a mix of equity securities, debt securities
and other investments are used to preserve asset values, diversify risk and exceed the planned benchmark
107
investment return. Investment strategies and asset allocations are based on consideration of plan liabilities, the
plans’ funded status and other factors, such as the plans’ demographics and liability durations. Investment
performance is reviewed by the investment committee on a quarterly basis and asset allocations are reviewed at
least annually.
Plan assets are managed in a balanced portfolio comprised of two major components: return-seeking investments
and liability hedging investments. The target allocations for plan assets are 50% in return-seeking investments and
50% in liability hedging investments and other holdings. The documented policy includes an allocation range based
on each individual investment type within the major components that allows for a variance from the target
allocations depending on the investment type. Return-seeking investments primarily include common stock of U.S.
and international companies, common/collective trust funds, mutual funds, hedge funds, and partnership
investments. Liability hedging investments and other holdings primarily include cash, money market funds with an
original maturity of three months or less, U.S. and foreign government and governmental agency issues, corporate
bonds, municipal securities, derivative contracts and asset-backed securities.
While the investment committee provides oversight over plan assets for U.S. and international plans, the summary
above is specific to the plans in the United States. The plan assets for international plans are managed and
allocated by the entities in each country, with input and oversight provided by the investment committee. The plan
assets for the U.S. and international plans are included in the table below.
The following tables summarize our pension plan financial instruments that are measured at fair value on a
recurring basis.
Basis of fair value measurement
(in millions)
Balance at
December 31,
2024
Quoted prices
in active
markets for
identical assets
(Level 1)
Significant
other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Measured at
NAV (a)
Assets
Cash
$
52
Fixed income securities
Cash equivalents
$
179 $
— $
179 $
— $
—
U.S. government and government
agency issues
135
—
135
—
—
Corporate bonds
357
—
357
—
—
Equity securities
Common stock
353
353
—
—
—
Mutual funds
199
199
—
—
—
Common/collective trust funds
540
—
—
—
540
Partnership investments
198
—
—
—
198
Other holdings
215
9
79
127
—
Fair value of pension plan assets
$
2,228 $
561 $
750 $
127 $
738
(a) Certain assets that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been classified in the
fair value hierarchy.
108
Basis of fair value measurement
(in millions)
Balance at
December 31,
2023
Quoted prices
in active
markets for
identical assets
(Level 1)
Significant
other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Measured at
NAV (a)
Assets
Cash
$
60
Fixed income securities
Cash equivalents
$
399 $
— $
399 $
— $
—
U.S. government and government
agency issues
95
—
95
—
—
Corporate bonds
265
—
265
—
—
Equity securities
Common stock
344
344
—
—
—
Mutual funds
192
192
—
—
—
Common/collective trust funds
540
—
—
—
540
Partnership investments
216
—
—
—
216
Other holdings
239
12
72
155
—
Fair value of pension plan assets
$
2,350 $
548 $
831 $
155 $
756
(a) Certain assets that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been classified in the
fair value hierarchy.
The following table is a reconciliation of changes in fair value measurements that used significant unobservable
inputs (Level 3).
(in millions)
Other
holdings
Balance at December 31, 2022
$
7
Purchases1
148
Balance at December 31, 2023
155
Unrealized gains (losses)
(24)
Sales
(7)
Purchases
3
Balance at December 31, 2024
$
127
1 Purchases in 2023 included $148 million for an insurance contract buy-in related to our pension plan in the United Kingdom.
109
The assets and liabilities of our pension plans are valued using the following valuation methods:
Investment category
Valuation methodology
Cash equivalents
These largely consist of a short-term investment fund, U.S. Dollars and
foreign currency. The fair value of the short-term investment fund is based on
the net asset value.
U.S. government and government
agency issues
Values are based on reputable pricing vendors, who typically use pricing
matrices or models that use observable inputs.
Corporate bonds
Values are based on reputable pricing vendors, who typically use pricing
matrices or models that use observable inputs.
Common stock
Values are based on the closing prices on the valuation date in an active
market on national and international stock exchanges.
Mutual funds
Values are based on the net asset value of the units held in the respective
fund which are obtained from national and international exchanges or based
on the net asset value of the underlying assets of the fund provided by the
fund manager.
Common/collective trust funds
Values are based on the net asset value of the units held at year end.
Partnership investments
Values are based on the net asset value of the participation by us in the
investment as determined by the general partner or investment manager of
the respective partnership.
Other holdings
Other holdings includes assets valued by pricing vendors using pricing
matrices or models that use observable inputs and an insurance contract held
by our pension plan in the United Kingdom, which is measured using a
discounted cash flow model. In addition to observable market inputs such as
interest rates, the fair value measurement of the insurance contract also
reflects unobservable inputs, such as qualitative judgments about pricing of
similar contracts in the insurance market.
Expected Pension and OPEB Plan Funding
Our funding policy for our pension plans is to contribute amounts sufficient to meet legal funding requirements, plus
any additional amounts that we may determine to be appropriate considering the funded status of the plans, tax
deductibility, the cash flows generated by us, and other factors. Volatility in the global financial markets could have
an unfavorable impact on future funding requirements. In 2025, we have no obligation to fund our principal plans in
the United States, but we regularly reassess the amount and timing of any discretionary contributions. Conversely,
we do expect to make contributions of at least $26 million to our Puerto Rico plan and $7 million to our foreign
pension plans in 2025. Additionally, we expect to have net cash outflows relating to our OPEB plans of
approximately $16 million in 2025.
The following table details the funded status percentage of our pension plans as of December 31, 2024, including
certain plans that are unfunded in accordance with the guidelines of our funding policy outlined above.
United States and Puerto Rico
International
as of December 31, 2024 (in millions)
Qualified
plans
Nonqualified
plan
Funded
plans
Unfunded
plans
Total
Fair value of plan assets
$
1,763
$ n/a
$
465
$ n/a $
2,228
PBO
2,015
183
518
33
2,749
Funded status percentage
87 %
n/a
90 %
n/a
81 %
Pension Plan Amendments
In May 2022, we announced that the pay and service amounts used to calculate pension benefits for active non-
bargaining participants in our U.S. Hillrom pension plan would freeze as of December 31, 2022. Years of additional
service earned and eligible compensation received after December 31, 2022 will not be included in the
determination of the benefits payable to those participants. This change resulted in an $11 million decline in the
110
projected benefit obligation (PBO) with an offsetting curtailment gain included within other (income) expense, net on
the consolidated statements of income (loss) for the year ended December 31, 2022.
U.S. Defined Contribution Plan
Most U.S. employees are eligible to participate in a qualified defined contribution plan. We recognized expense of
$119 million in 2024, $116 million in 2023 and $96 million in 2022 related to contributions to this plan.
NOTE 14
INCOME TAXES
Income (Loss) Before Income Tax Expense (Benefit) by Category
years ended December 31 (in millions)
2024
2023
2022
United States
$
(1,499) $
(1,057) $
(3,858)
International
1,210
1,299
610
Income (loss) from continuing operations before income taxes
$
(289) $
242 $
(3,248)
Income Tax Expense (Benefit)
years ended December 31 (in millions)
2024
2023
2022
Current
United States
Federal
$
19 $
1 $
9
State and local
21
9
—
International
259
307
116
Current income tax expense (benefit)
299
317
125
Deferred
United States
Federal
(197)
(123)
(264)
State and local
(21)
(25)
(49)
International
(44)
(108)
53
Deferred income tax expense (benefit)
(262)
(256)
(260)
Income tax expense (benefit)
$
37 $
61 $
(135)
111
Deferred Tax Assets and Liabilities
as of December 31 (in millions)
2024
2023
Deferred tax assets
Accrued liabilities and other
$
310 $
282
Pension and other postretirement benefits
131
135
Tax credit and net operating loss carryforwards
750
723
Swiss tax reform net asset basis step-up
92
157
Operating lease liabilities
139
140
Valuation allowances
(536)
(584)
Total deferred tax assets
886
853
Deferred tax liabilities
Subsidiaries’ unremitted earnings
21
81
Long-lived assets and other
632
783
Operating lease right-of-use assets
132
131
Total deferred tax liabilities
785
995
Net deferred tax asset (liability)
$
101 $
(142)
At December 31, 2024, we had U.S. state operating loss carryforwards totaling $58 million, U.S. federal operating
loss carryforwards totaling $13 million and tax credit carryforwards totaling $282 million, which includes a U.S.
foreign tax credit carryforward of $184 million. The U.S. federal and state operating loss and tax credit carryforwards
expire between 2025 and 2044, with $14 million of the operating loss carryforwards having no expiration date.
At December 31, 2024, with respect to our operations outside the U.S., we had foreign operating loss carryforwards
totaling $74 million and foreign tax credit carryforwards totaling $14 million. The foreign operating loss carryforwards
expire between 2025 and 2041 with $50 million having no expiration date. All of the foreign tax credit carryforwards
have no expiration date.
Realization of the U.S. and foreign operating loss and tax credit carryforwards depends on generating sufficient
future earnings. A valuation allowance of $536 million and $584 million was recognized as of December 31, 2024
and 2023, respectively, to reduce the deferred tax assets associated with net operating loss and tax credit
carryforwards because we do not believe it is more likely than not that these assets will be fully realized prior to
expiration.
After evaluating relevant U.S. tax laws, any elections or other opportunities that may be available and the future
expiration of certain U.S. tax provisions that will impact the utilization of our U.S. foreign tax credit carryforwards,
management expects to be able to realize some, but not all, of the U.S. foreign tax credit deferred tax assets up to
its recurring and non-recurring foreign inclusions. Therefore, a valuation allowance of $131 million and $130 million
was recognized with respect to the foreign tax credit carryforwards as of December 31, 2024 and 2023,
respectively. We will continue to evaluate the need for additional valuation allowances and, as circumstances
change, the valuation allowance may change.
As a result of Swiss tax reform legislation enacted during 2019, we recognized an $863 million net asset tax basis
step-up that is amortizable as a tax deduction ratably over tax years 2025 through 2029. A deferred tax asset of
$92 million and $157 million for the tax basis step-up was recognized as of December 31, 2024 and 2023,
respectively. We expect to realize some, but not all, of the Swiss deferred tax assets for that tax basis step-up
based on expected future earnings generated by our Swiss subsidiary during the period in which the tax basis will
be amortized. Therefore, a valuation allowance of $42 million and $90 million was recognized on the Swiss deferred
tax assets for the tax basis step-up as of December 31, 2024 and 2023, respectively. For the year ended
December 31, 2024, we recorded an adjustment to the tax rate originally applied to the Swiss net asset tax basis
step-up, and as a result recorded a net tax expense of $25 million to decrease the deferred tax asset by $59 million
and the related valuation allowance by $34 million as of December 31, 2024. We evaluated the impact on prior
periods and determined the impact was immaterial.
112
The following table is a summary of changes in our deferred tax valuation allowance for the years ended
December 31, 2024, 2023 and 2022.
years ended December 31 (in millions)
2024
2023
2022
Balance at beginning of period
$
584 $
631 $
326
Charged to income tax expense
48
87
313
Deductions
(73)
(139)
(1)
Currency translation adjustments
(23)
5
(7)
Balance at end of period
$
536 $
584 $
631
Income Tax Expense (Benefit) Reconciliation
years ended December 31 (in millions)
2024
2023
2022
Income tax expense (benefit) at U.S. statutory rate
$
(61) $
51 $
(682)
Tax incentives
(176)
(200)
(156)
State and local taxes, net of federal benefit
(9)
(2)
(27)
Impact of foreign taxes
137
190
78
Non-deductible goodwill impairments
86
—
591
Notional interest deduction expense (benefit)
(37)
31
(306)
Valuation allowances
(25)
(51)
312
Stock compensation (windfall) shortfall tax expense (benefit)
9
10
(4)
Research and development tax credits
(19)
(17)
(8)
Uncertain tax positions
9
6
(7)
Unutilized foreign tax credits
15
32
32
Subpart F income
18
26
11
Foreign tax credits
(5)
(7)
4
Pillar Two taxes
11
—
—
Revaluation of Swiss basis step-up deferred tax asset
58
—
—
Tax law changes on Section 987
17
—
—
Other, net
9
(8)
27
Income tax expense (benefit)
$
37 $
61 $
(135)
Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors,
including tax incentives, foreign rate differences, state income taxes, non-deductible expenses, non-taxable income,
increases or decreases in valuation allowances and liabilities for uncertain tax positions, excess tax benefits or
shortfalls on stock compensation awards, audit developments and legislative changes.
In 2024, the difference between our effective income tax rate and the U.S. federal statutory rate was adversely
impacted by a non-deductible impairment of goodwill and legislative changes under IRC Section 987 (which is the
exchange gain or loss on foreign branch remittances in the U.S., effective in 2024), and a net revaluation of the
Swiss basis step-up deferred tax asset and related valuation allowance that arose from Swiss tax reform legislation
in 2019, partially offset by a favorable geographic earnings mix, a decrease in valuation allowance mainly related to
U.S. foreign tax credit carryforward, and a tax benefit related to research and development tax credits.
In 2023, our effective income tax rate was impacted favorably by geographic earnings mix, a $50 million net tax
benefit after related valuation allowances from notional interest deductions that are received by certain wholly-
owned foreign subsidiaries that have financed their operations with equity capital and a $17 million tax benefit
related to research and development tax credits, partially offset by tax shortfalls on stock compensation awards.
In 2022, our effective income tax rate was adversely impacted by non-deductible impairments of goodwill acquired
in the Hillrom acquisition and valuation allowance increases, including the increase described above related to
113
deferred tax assets from a tax basis step-up that arose from Swiss tax reform legislation in 2019. Those items were
partially offset by a $47 million net tax benefit after related valuation allowances from notional interest deductions.
We plan to repatriate our foreign earnings with the exception of approximately $607 million of accumulated earnings
that are indefinitely reinvested as of December 31, 2024 related to three of our foreign operations. Additional
withholding and capital gain taxes of $70 million would be incurred if such earnings were remitted currently.
Our tax provisions for 2024, 2023 and 2022 do not include any significant tax charges related to either the Base
Erosion and Anti-Abuse Tax (BEAT) or Global Intangible Low Taxed Income (GILTI) provisions, except for the
inability to fully utilize foreign tax credits against such GILTI. Our accounting policy is to recognize any GILTI charge
as a period cost.
Unrecognized Tax Benefits
We classify interest and penalties associated with income taxes in income tax expense (benefit) within the
consolidated statements of income (loss). Net interest and penalties recognized were not significant during 2024,
2023 and 2022. The liability recognized related to interest and penalties was $21 million and $17 million as of
December 31, 2024 and 2023, respectively. The total amount of gross unrecognized tax benefits that, if recognized,
would impact the effective tax rate are $51 million, $47 million and $31 million as of December 31, 2024, 2023 and
2022, respectively. We believe that it is reasonably possible that our gross unrecognized tax benefits will be reduced
within the next 12 months by $13 million.
The following table is a reconciliation of our unrecognized tax benefits for the years ended December 31, 2024,
2023 and 2022.
as of and for the years ended (in millions)
2024
2023
2022
Balance at beginning of the year
$
89 $
87 $
106
Increase associated with tax positions taken during the current year
10
9
11
Increase (decrease) associated with tax positions taken during a prior year
5
3
14
Settlements
(1)
(2)
(7)
Decrease associated with lapses in statutes of limitations
(7)
(8)
(37)
Balance at end of the year
$
96 $
89 $
87
Of the gross unrecognized tax benefits, $39 million and $33 million were recognized as liabilities in the consolidated
balance sheets as of December 31, 2024 and 2023, respectively.
Tax Incentives
We have received tax incentives in Puerto Rico, Switzerland, Dominican Republic, and Costa Rica. The financial
impact of the reductions as compared to the statutory tax rates is indicated in the income tax expense (benefit)
reconciliation table above. The tax reductions as compared to the local statutory rate favorably impacted earnings
(loss) per diluted share by $0.34 in 2024, $0.39 in 2023 and $0.31 in 2022. The above grants provide that our
manufacturing operations are and will be partially exempt from local taxes with varying expirations from 2024 to
2034.
Examinations of Tax Returns
As of December 31, 2024, we had ongoing audits in the United States, Germany, Italy and other jurisdictions.
During 2022, we closed U.S. tax years 2017-2018 with the IRS with no material adjustments to our financial
statements. Tax years 2019 and 2020 remain under examination by the IRS, including with respect to transfer
pricing matters, and tax years 2012 and forward remain under examination by various foreign taxing authorities.
While the final outcome of these matters is inherently uncertain, we believe we have made adequate tax provisions
for all years subject to examination.
114
NOTE 15
EARNINGS (LOSS) PER SHARE
The numerator for both basic and diluted earnings (loss) per share (EPS) is net income (loss) attributable to Baxter
stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the
period. The dilutive effect of outstanding stock options, RSUs and PSUs is reflected in the denominator for diluted
EPS using the treasury stock method.
The following table is a reconciliation of net income (loss) attributable to Baxter stockholders.
years ended December 31(in millions)
2024
2023
2022
Income (loss) from continuing operations
$
(326) $
181 $
(3,113)
Less: Net income attributable to noncontrolling interests included in
continuing operations
—
—
1
Income (loss) from continuing operations attributable to Baxter stockholders
(326)
181
(3,114)
Income (loss) from discontinued operations
(312)
2,482
692
Less: Net income attributable to noncontrolling interests included in
discontinued operations
11
7
11
Income (loss) from discontinued operations attributable to Baxter
stockholders
(323)
2,475
681
Net income (loss) attributable to Baxter stockholders
$
(649) $
2,656 $
(2,433)
The following table is a reconciliation of basic shares to diluted shares.
years ended December 31(in millions)
2024
2023
2022
Basic shares
510
506
504
Effect of dilutive securities
—
2
—
Diluted shares
510
508
504
Basic and diluted shares are the same for the years ended December 31, 2024 and 2022 due to our loss from
continuing operations attributable to Baxter stockholders. The effect of dilutive securities includes unexercised stock
options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS
excludes 25 million, 19 million, and 22 million equity awards in 2024, 2023 and 2022, respectively, because their
inclusion would have had an anti-dilutive effect on diluted EPS. Refer to Note 9 for additional information regarding
items impacting basic shares.
NOTE 16
DERIVATIVES AND HEDGING ACTIVITIES
Concentrations of Credit Risk
We invest excess cash in certificates of deposit or money market or other funds and diversify the concentration of
cash among different financial institutions. With respect to financial instruments, where appropriate, we have
diversified our selection of counterparties, and have arranged collateralization and master-netting agreements to
minimize the risk of loss.
Global economic conditions and liquidity issues in certain countries have resulted, and may continue to result, in
delays in the collection of receivables and credit losses. Global economic conditions, governmental actions and
customer-specific factors may require us to re-evaluate the collectability of our receivables and we could potentially
incur additional credit losses.
Foreign Currency and Interest Rate Risk Management
We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be
adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage
these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and
costs.
115
We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted
transactions and net assets denominated in the Euro, British Pound, Australian Dollar, Canadian Dollar, Chinese
Renminbi, Japanese Yen, Mexican Peso, Indian Rupee and Swedish Krona. We manage our foreign currency
exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In
addition, we use derivative and nonderivative instruments to further reduce the net exposure to foreign exchange
risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce
the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency
volatility may limit our ability to cost-effectively hedge these exposures.
We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in
interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt that we believe is
appropriate at that time. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps
in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts
calculated by reference to an agreed-upon notional amount.
We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain
credit-risk-related contingent features.
Cash Flow Hedges
We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the
foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We
periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates
relating to anticipated issuances of debt.
The notional amounts of foreign exchange contracts designated as cash flow hedges were $99 million and $340
million as of December 31, 2024 and 2023, respectively. The maximum term over which we have cash flow hedge
contracts in place related to forecasted transactions at December 31, 2024 is 11 months for foreign exchange
contracts. There were no outstanding interest rate contracts designated as cash flow hedges as of December 31,
2024 and 2023.
Fair Value Hedges
We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These
instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated
benchmark interest rate.
There were no outstanding interest rate contracts designated as fair value hedges as of December 31, 2024 and
2023.
In October 2023, we entered into a foreign currency forward contract with a notional amount of $798 million and
designated that derivative as a fair value hedge of our €750 million of 0.40% senior notes due May 2024. This
forward contract matured in May 2024.
Net Investment Hedges
In May 2017, we issued €600 million of 1.3% senior notes due May 2025. In May 2019, we issued €750 million of
1.3% senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in
our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances are
recorded as a component of AOCI.
In May 2019, we issued €750 million of 0.40% senior notes due May 2024, which we repaid in full on their maturity
date. We had designated these debt obligations as hedges of our investment in our European operations and, as a
result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of
AOCI. In October 2023, we dedesignated this previously designated net investment hedge and concurrently entered
into a fair value hedging relationship as discussed in the “Fair Value Hedges” section above.
As of December 31, 2024, we had an accumulated pre-tax unrealized translation gain in AOCI of $124 million
related to the Euro-denominated senior notes.
116
Dedesignations
If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we
discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges
generally continue to be deferred and are recognized consistent with the loss or income recognition of the
underlying hedged items. However, if it is probable that hedged forecasted transactions will not occur, any gains or
losses would be immediately reclassified from AOCI to earnings. There were no cash flow hedge dedesignations in
2024, 2023 or 2022 resulting from changes in our assessment of the probability that the hedged forecasted
transactions would occur. The losses relating to these terminations continue to be deferred and are being
recognized consistent with the underlying hedged item, interest expense on the issuance of debt.
If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at
the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair
value hedges terminated in 2024, 2023 or 2022.
If we remove a net investment hedge designation, any gain or loss recognized in AOCI is not reclassified to
earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. In October 2023,
we dedesignated one of our net investment hedges as discussed in the "Net Investment Hedges" section above.
There were no net investment hedges terminated in 2024 or 2022.
Undesignated Derivative Instruments
We use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-
company and third-party receivables and payables denominated in a foreign currency. These derivative instruments
are generally not formally designated as hedges and the terms of these instruments generally do not exceed one
month.
The total notional amount of undesignated derivative instruments was $389 million and $305 million as of
December 31, 2024 and 2023, respectively.
Gains and Losses on Hedging Instruments and Undesignated Derivative Instruments
The following tables summarize the gains and losses on our hedging instruments and the classification of those
gains and losses within our consolidated financial statements for the years ended December 31, 2024, 2023 and
2022.
(in millions)
Gain (loss)
recognized in OCI
Location of gain
(loss) in
income statement
Gain (loss) reclassified from
AOCI into income
2024
2023
2022
2024
2023
2022
Cash flow hedges
Interest rate contracts
$
— $
— $
—
Interest expense, net $
(6) $
(6) $
(6)
Foreign exchange contracts
17
15
28
Cost of sales
8
15
26
Fair value hedges
Foreign exchange contracts
(3)
(4)
— Other (income) expense, net
(5)
(3)
—
Net investment hedges
87
(58)
141 Other (income) expense, net
—
—
—
Total
$
101 $
(47) $
169
$
(3) $
6 $
20
Location of gain (loss) in
income statement
Gain (loss) recognized
in income
(in millions)
2024
2023
2022
Fair value hedges
Foreign exchange contracts
Other (income) expense, net
$
(24) $
38 $
—
Undesignated derivative instruments
Foreign exchange contracts
Other (income) expense, net
(13)
2
(16)
Total
$
(37) $
40 $
(16)
117
The following table summarizes net-of-tax activity in AOCI, a component of stockholders’ equity, related to our cash
flow hedges.
as of and for the year ended December 31 (in millions)
2024
2023
2022
Accumulated other comprehensive income (loss) balance at beginning of
year
$
(120) $
(119) $
(126)
(Loss) gain in fair value of derivatives during the year
10
5
22
Amount reclassified to earnings during the year
2
(6)
(15)
Accumulated other comprehensive income (loss) balance at end of year
$
(108) $
(120) $
(119)
As of December 31, 2024, $1 million of deferred, net after-tax gains on derivative instruments included in AOCI are
expected to be recognized in earnings during the next 11 months, coinciding with when the hedged items are
expected to impact earnings.
Derivative Assets and Liabilities
The following table summarizes the classification and fair values of derivative instruments reported in the
consolidated balance sheet as of December 31, 2024.
Derivatives in asset positions
Derivatives in liability positions
(in millions)
Balance sheet location
Fair value
Balance sheet location
Fair value
Derivative instruments
designated as hedges
Foreign exchange contracts
Prepaid expenses and
other current assets $
6
Accrued expenses and
other current liabilities $
—
Undesignated derivative
instruments
Foreign exchange contracts
Prepaid expenses and
other current assets
1
Accrued expenses and
other current liabilities
2
Total derivative instruments
$
7
$
2
The following table summarizes the classification and fair values of derivative instruments reported in the
consolidated balance sheet as of December 31, 2023.
Derivatives in asset positions
Derivatives in liability positions
(in millions)
Balance sheet location
Fair value
Balance sheet location
Fair value
Derivative instruments
designated as hedges
Foreign exchange contracts
Prepaid expenses and
other current assets $
41
Accrued expenses and
other current liabilities $
—
Undesignated derivative
instruments
Foreign exchange contracts
Prepaid expenses and
other current assets
4
Accrued expenses and
other current liabilities
5
Total derivative instruments
$
45
$
5
While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities
related to derivative instruments on a gross basis within the consolidated balance sheets. Additionally, we are not
required to post collateral for any of our outstanding derivatives.
118
The following table provides information on our derivative positions as if they were presented on a net basis,
allowing for the right of offset by counterparty.
December 31, 2024
December 31, 2023
(in millions)
Asset
Liability
Asset
Liability
Gross amounts recognized in the consolidated balance
sheets
$
7 $
2 $
45 $
5
Gross amount subject to offset in master netting
arrangements not offset in the consolidated balance
sheets
(1)
(1)
(4)
(4)
Total
$
6 $
1 $
41 $
1
The following table presents the amounts recorded on the consolidated balance sheets related to fair value hedges:
Carrying amount of hedged items
Cumulative amount of fair value hedging
adjustment included in the carrying amount
of the hedged items (a)
(in millions)
Balance as of
December 31, 2024
Balance as of
December 31, 2023
Balance as of
December 31, 2024
Balance as of
December 31, 2023
Long-term debt
$
99 $
100 $
2 $
3
(a) These fair value hedges were terminated in 2018 and earlier periods.
NOTE 17
FAIR VALUE MEASUREMENTS
The fair value hierarchy consists of the following three levels:
•
Level 1 — Quoted prices in active markets that we have the ability to access for identical assets or
liabilities;
•
Level 2 — Quoted prices for similar instruments in active markets, quoted prices for identical or
similar instruments in markets that are not active, and model-based valuations in which all
significant inputs are observable in the market; and
•
Level 3 — Valuations using significant inputs that are unobservable in the market and include the
use of judgment by management about the assumptions market participants would use in pricing
the asset or liability.
The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.
Basis of fair value measurement
(in millions)
Balance as of
December 31,
2024
Quoted prices
in active
markets for
identical assets
(Level 1)
Significant
other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Assets
Foreign exchange contracts
$
7 $
— $
7 $
—
Available-for-sale debt securities
1
—
—
1
Marketable equity securities
13
13
—
—
Total
$
21 $
13 $
7 $
1
Liabilities
Foreign exchange contracts
$
2 $
— $
2 $
—
Contingent payments related to acquisitions
12
—
—
12
Total
$
14 $
— $
2 $
12
119
Basis of fair value measurement
(in millions)
Balance as of
December 31,
2023
Quoted prices
in active
markets for
identical assets
(Level 1)
Significant
other
observable
inputs
(Level 2)
Significant
unobservable
inputs
(Level 3)
Assets
Foreign exchange contracts
$
45 $
— $
45 $
—
Available-for-sale debt securities
1
—
—
1
Marketable equity securities
44
44
—
—
Total
$
90 $
44 $
45 $
1
Liabilities
Foreign exchange contracts
$
5 $
— $
5 $
—
Contingent payments related to acquisitions
14
—
—
14
Total
$
19 $
— $
5 $
14
As of December 31, 2024 and 2023, cash and cash equivalents of $1.76 billion and $3.08 billion, respectively,
included money market and other short-term funds of approximately $583 million and $1.63 billion, respectively, that
are considered Level 2 in the fair value hierarchy.
For assets that are measured using quoted prices in active markets, the fair value is the published market price per
unit multiplied by the number of units held, without consideration of transaction costs. A majority of the derivatives
entered into by us are valued using internal valuation techniques as no quoted market prices exist for such
instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes
models. The key inputs, which are considered observable and vary depending on the type of derivative, include
contractual terms, interest rate yield curves, foreign exchange rates and volatility.
Available-for-sale debt securities, which consist of convertible debt and convertible redeemable preferred shares
issued by nonpublic entities, are measured using discounted cash flow and option pricing models. Those available-
for-sale debt securities are classified as Level 3 fair value measurements when there are no observable
transactions near the balance sheet date due to the lack of observable data over certain fair value inputs such as
equity volatility. The fair values of available-for-sale debt securities increase when interest rates decrease, equity
volatility increases, or the fair values of the equity shares underlying the conversion options increase.
Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are
valued using discounted cash flow techniques incorporating management's expectations of future outcomes. The
fair value of milestone payments increases as the estimated probability of payment increases or the expected timing
of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future
120
revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios
increases or the expected timing of payment is accelerated.
The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs
(Level 3), which consist of contingent payments related to acquisitions and available-for-sale debt securities.
2024
2023
as of and for the years ended December 31 (in millions)
Contingent payments
related to acquisitions
Available-for-sale
debt securities
Contingent payments
related to acquisitions
Available-for-sale
debt securities
Fair value at beginning of period
$
14 $
1 $
84 $
27
Change in fair value recognized in earnings
—
—
(19)
(21)
Payments
(2)
—
(51)
—
Transfers out of Level 3
—
—
—
(5)
Fair value at end of period
$
12 $
1 $
14 $
1
During the year ended December 31, 2023, available-for-sale debt securities were reclassified from Level 3, upon
conversion to marketable equity securities, which are classified as Level 1 in the fair value hierarchy, upon initial
public offerings of the investees.
Financial Instruments Not Measured at Fair Value
In addition to the financial instruments that we are required to recognize at fair value in the consolidated balance
sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair
value. For these financial instruments, the following table provides the values recognized in the consolidated
balance sheets and the estimated fair values.
Book values
Fair values(a)
as of December 31 (in millions)
2024
2023
2024
2023
Liabilities
Short-term debt
$
2,126 $
— $
2,126 $
—
Current maturities of long-term debt and finance lease
obligations
626
2,667
619
2,621
Long-term debt and finance lease obligations
10,374
11,089
9,295
10,026
(a)
These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.
The carrying value of short-term debt approximates its fair value due to the short-term maturities of the obligations.
The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount
of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and
yield curves commensurate with our credit risk. The carrying values of other financial instruments not presented in
the table above, such as accounts receivable and accounts payable, approximate their fair values due to the short-
term maturities of most of those assets and liabilities.
The carrying values of equity investments without readily determinable fair values that we measure at cost, less
impairment were $37 million and $33 million at December 31, 2024 and 2023, respectively. When applicable, we
also adjust the measurement of such equity investments for observable prices in orderly transactions for an identical
or similar investment of the same issuer. These investments are included in Other non-current assets on our
consolidated balance sheets.
121
NOTE 18
SEGMENT AND GEOGRAPHIC INFORMATION
Our business is comprised of three reportable segments: Medical Products & Therapies, Healthcare Systems &
Technologies, and Pharmaceuticals. The Medical Products & Therapies segment includes sales of our sterile IV
solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and
adhesion prevention products. The Healthcare Systems & Technologies segment includes sales of our connected
care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic
technologies, respiratory health devices and advanced equipment for the surgical space, including operating room
integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment
includes sales of specialty injectable pharmaceuticals, inhaled anesthetics and drug compounding services. Other
sales not allocated to a segment primarily include sales of products and services provided directly through certain of
our manufacturing facilities and royalty income under a business development arrangement that ended in early
2023 when we acquired the related product rights.
Disaggregation of Net Sales
The following tables present our U.S. and International disaggregated net sales.
for the years ended
December 31
2024
2023
2022
(in millions)
U.S.
International
Total
U.S.
International
Total
U.S.
International
Total
Infusion Therapies &
Technologies
$ 2,279 $
1,824 $ 4,103 $ 2,227 $
1,733 $ 3,960 $ 2,241 $
1,576 $ 3,817
Advanced Surgery
603
501 1,104
582
469
1,051
574
424
998
Medical Products &
Therapies
2,882
2,325 5,207 2,809
2,202
5,011 2,815
2,000 4,815
Care and Connectivity
Solutions
1,311
503 1,814 1,263
537
1,800 1,295
496 1,791
Front Line Care
843
294 1,137
905
308
1,213
840
308 1,148
Healthcare Systems &
Technologies
2,154
797 2,951 2,168
845
3,013 2,135
804 2,939
Injectables and
Anesthesia
780
593 1,373
759
588
1,347
682
623 1,305
Drug Compounding
—
1,038 1,038
—
902
902
—
821
821
Pharmaceuticals
780
1,631 2,411
759
1,490
2,249
682
1,444 2,126
Other1
34
33
67
66
21
87
137
40
177
Total Baxter
$ 5,850 $
4,786 $ 10,636 $ 5,802 $
4,558 $ 10,360 $ 5,769 $
4,288 $ 10,057
1 In connection with the reclassification of our BPS business to discontinued operations during the second quarter of 2023, we reclassified
$2 million of contract manufacturing revenues from the first quarter of 2023 and $37 million of sales for the year ended December 31, 2022 from
BPS to Other (within continuing operations), as the related manufacturing facility was not part of that divestiture transaction.
122
Geographic Information
Our net sales are attributed to the following geographic regions based on the location of the customer.
for the years ended December 31 (in millions)
2024
2023
2022
Net sales:
United States
$
5,850 $
5,802 $
5,769
Emerging markets1
1,350
1,343
1,253
Rest of world 2
3,436
3,215
3,035
Total net sales
$
10,636 $
10,360 $
10,057
1 Emerging markets include sales from our operations in Eastern Europe, the Middle East, Africa, Latin America and Asia (except for Japan).
2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia and New Zealand.
Our property, plant and equipment and operating lease right-of-use assets, net are attributed to the following
geographic regions.
as of December 31 (in millions)
2024
2023
Property, plant and equipment and operating lease right-of-use assets, net:
United States
$
1,654 $
1,615
Emerging markets
793
829
Rest of world
729
763
Total property, plant and equipment and operating lease right-of-use assets, net
$
3,176 $
3,207
Segment Information
Our chief operating decision maker who has been identified as our Chair, President and Chief Executive Officer,
reviews the financial information presented for purposes of evaluating the performance of our segments and to
make resource allocation decisions.
Segment operating income is the measure of segment profitability and represents income before income taxes,
interest and other non-operating income or expense, unallocated corporate costs, intangible asset amortization and
other special items. Special items, which are presented below in our reconciliations of segment operating income to
income (loss) from continuing operations before income taxes, are excluded from segment operating income
because they are highly variable, difficult to predict and of a size that may substantially impact our reported results
of operations for the period.
Corporate costs, inclusive of global functional support costs, overhead costs and other shared costs that benefit our
segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any
differences between actual corporate costs and the amounts allocated to our segments, are presented as
unallocated corporate costs. With the results of our former Kidney Care segment reported in discontinued
operations, corporate costs that had previously been allocated to the Kidney Care segment which did not convey
with the Kidney Care segment in the completed sale are now presented as unallocated corporate costs.
Segment results include net sales, cost of sales, selling general and administrative expenses, research and
development expenses, and other segment items which are directly allocated to each segment. Beginning in 2024
123
annual reporting, we adopted ASU 2023-07 retrospectively. The following tables present our segment information of
net sales, significant expenses and operating income during the periods presented.
For the year ended December 31, 2024
(in millions)
Medical
Products &
Therapies
Healthcare
Systems &
Technologies
Pharmaceuticals
Net sales
$
5,207 $
2,951 $
2,411
Cost of sales
2,867
1,464
1,612
Selling, general and administrative expenses
1,176
836
396
Research and development expenses
216
184
91
Other segment items
(2)
(1)
(1)
Segment operating income
$
950 $
468 $
313
For the year ended December 31, 2023
(in millions)
Medical
Products &
Therapies
Healthcare
Systems &
Technologies
Pharmaceuticals
Net sales
$
5,011 $
3,013 $
2,249
Cost of sales
2,720
1,532
1,400
Selling, general and administrative expenses
1,097
822
363
Research and development expenses
222
176
86
Other segment items
—
—
(1)
Segment operating income
$
972 $
483 $
401
For the year ended December 31, 2022
(in millions)
Medical
Products &
Therapies
Healthcare
Systems &
Technologies
Pharmaceuticals
Net sales
$
4,815 $
2,939 $
2,126
Cost of sales
2,584
1,463
1,293
Selling, general and administrative expenses
1,069
827
361
Research and development expenses
202
155
81
Other segment items
(2)
—
—
Segment operating income
$
962 $
494 $
391
124
The following table presents our reportable segment operating income and reconciliations of reportable segment
operating income to income (loss) from continuing operations before income taxes.
for the years ended December 31 (in millions)
2024
2023
2022
Medical Products & Therapies
$
950 $
972 $
962
Healthcare Systems & Technologies
468
483
494
Pharmaceuticals
313
401
391
Total reportable segment operating income
1,731
1,856
1,847
Other
18
18
77
Unallocated corporate costs
(275)
(355)
(367)
Intangible asset amortization expense
(625)
(590)
(679)
Business optimization items
(162)
(174)
(193)
European Medical Devices Regulation
(33)
(41)
(42)
Long-lived asset impairments
(50)
—
(344)
Legal matters
(17)
(7)
—
Acquisition and integration items
(23)
—
(213)
Product-related items
(15)
—
(44)
Hurricane Helene Costs
(110)
—
—
Loss on product divestiture arrangement
—
—
(54)
Goodwill impairments
(425)
—
(2,812)
Loss on subsidiary liquidation
—
—
(21)
Total operating income (loss)
14
707
(2,845)
Interest expense, net
341
439
394
Other (income) expense, net
(38)
26
9
Income (loss) from continuing operations before income taxes
$
(289) $
242 $
(3,248)
Additional financial information for our segments is as follows:
for the years ended December 31 (in millions)
2024
2023
2022
Depreciation Expense1:
Medical Products & Therapies
$
201 $
232 $
217
Healthcare Systems & Technologies
109
108
117
Pharmaceuticals
62
54
59
Total depreciation expense
$
372 $
394 $
393
1 Depreciation expense related to Corporate property, plant and equipment has been fully allocated to our segments and those allocations are
reflected in the depreciation amounts presented herein.
Our chief operating decision maker does not receive asset or capital expenditure information by segment and,
accordingly, we do not report that information for our segments.
NOTE 19
QUARTERLY FINANCIAL DATA (UNAUDITED)
The following table represents data from our unaudited consolidated statements of income (loss) for the most recent
eight quarters. This quarterly information has been prepared on the same basis as the consolidated financial
statements and includes all normal recurring adjustments necessary to fairly state the information for the periods
125
presented. The results of operations of any quarter are not necessarily indicative of the results that may be
expected for any future period.
2024
(in millions, except per share data)
First
Quarter
Second
Quarter2
Third
Quarter
Fourth
Quarter3
Full Year 1
Net sales
$
2,490 $
2,694 $
2,699 $
2,753 $ 10,636
Gross margin
961
1,031
1,033
959
3,984
Income (loss) from continuing operations
6
95
61
(488)
(326)
Income (loss) from discontinued operations
33
(406)
83
(22)
(312)
Net income (loss)
39
(311)
144
(510)
(638)
Net income (loss) attributable to Baxter stockholders
37
(314)
140
(512)
(649)
Income (loss) from continuing operations per common
share
Basic
$
0.01 $
0.19 $
0.12 $
(0.95) $
(0.64)
Diluted
$
0.01 $
0.19 $
0.12 $
(0.95) $
(0.64)
Income (loss) from discontinued operations per
common share
Basic
$
0.06 $
(0.81) $
0.15 $
(0.05) $
(0.63)
Diluted
$
0.06 $
(0.81) $
0.15 $
(0.05) $
(0.63)
Net Income (loss) per common share
Basic
$
0.07 $
(0.62) $
0.27 $
(1.00) $
(1.27)
Diluted
$
0.07 $
(0.62) $
0.27 $
(1.00) $
(1.27)
2023
(in millions, except per share data)
First
Quarter
Second
Quarter4
Third
Quarter5
Fourth
Quarter
Full Year 1
Net sales
$
2,441 $
2,591 $
2,599 $
2,729 $ 10,360
Gross margin
964
1,030
1,056
1,100
4,150
Income (loss) from continuing operations
(48)
(27)
37
219
181
Income from discontinued operations
93
(112)
2,474
27
2,482
Net income (loss)
45
(139)
2,511
246
2,663
Net income (loss) attributable to Baxter stockholders
44
(141)
2,508
245
2,656
Income (loss) from continuing operations per common
share
Basic
$
(0.10) $
(0.05) $
0.07 $
0.43 $
0.36
Diluted
$
(0.10) $
(0.05) $
0.07 $
0.43 $
0.36
Income from discontinued operations per common
share
Basic
$
0.19 $
(0.23) $
4.88 $
0.05 $
4.89
Diluted
$
0.19 $
(0.23) $
4.86 $
0.05 $
4.87
Net Income (loss) per common share
Basic
$
0.09 $
(0.28) $
4.95 $
0.48 $
5.25
Diluted
$
0.09 $
(0.28) $
4.93 $
0.48 $
5.23
1
The sum of per share amounts for quarterly periods may not equal full year amounts due to rounding.
2
Our results from discontinued operations for the quarter ended June 30, 2024 included a $430 million charge related to a goodwill
impairment of our Chronic Therapies reporting unit within our Kidney Care segment.
126
3
Our results from continuing operations for the fourth quarter ended December 31, 2024 included a $425 million charge related to a
goodwill impairment of our Front Line Care reporting unit within our Healthcare Systems & Technologies segment.
4
Our results from discontinued operations for the quarter ended June 30, 2023 included $243 million of long-lived asset impairment
charges resulting from our decision to cease production at one of our dialyzer manufacturing facilities.
5
Our results from discontinued operations for the quarter ended September 30, 2023 included a gain of $2.88 billion from the sale of our
BPS business, partially offset by $267 million of long-lived asset impairment charges related to our the hemodialysis business of our
former Kidney Care segment.
127
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Baxter International Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Baxter International Inc. and its subsidiaries
(the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of income (loss), of
comprehensive income (loss), of changes in equity and of cash flows for each of the three years in the period ended
December 31, 2024, including the related notes (collectively referred to as the “consolidated financial statements”).
We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on
criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the
financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash
flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles
generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material
respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in
Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective
internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial
reporting, included in Management’s Assessment of Internal Control Over Financial Reporting appearing under Item
9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the
Company's internal control over financial reporting based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan
and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free
of material misstatement, whether due to error or fraud, and whether effective internal control over financial
reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material
misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts
and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of
the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an
understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and
testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our
audits also included performing such other procedures as we considered necessary in the circumstances. We
believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. A company’s internal control over financial reporting
includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
128
with generally accepted accounting principles, and that receipts and expenditures of the company are being made
only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s
assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may
become inadequate because of changes in conditions, or that the degree of compliance with the policies or
procedures may deteriorate.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated
financial statements that was communicated or required to be communicated to the audit committee and that (i)
relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our
especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter
in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by
communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the
accounts or disclosures to which it relates.
Goodwill Impairment Assessment – Front Line Care Reporting Unit
As described in Notes 1 and 5 to the consolidated financial statements, the Company’s consolidated goodwill
balance as of December 31, 2024 was $5.3 billion, and the goodwill associated with the Front Line Care reporting
unit was $1.99 billion. Management performs an impairment test in the fourth quarter of each year, or whenever
events or changes in circumstances indicate that the fair value of the reporting unit is more likely than not below its
carrying amount. If management determines that it is more-likely-than-not that the fair value of a reporting unit is
less than its carrying amount, or they do not elect the option to perform an initial qualitative assessment, they
perform a quantitative goodwill impairment test. In the quantitative impairment test, management calculates the
estimated fair value of the reporting unit, and if the carrying amount of the reporting unit exceeds the estimated fair
value, an impairment charge is recorded. The fair values of the Company’s reporting units are generally determined
based on a discounted cash flow model (an income approach) and earnings multiples (a market approach) based
on the guideline public company method. Significant assumptions in reporting unit fair value measurements
generally include revenue growth rates, forecasted earnings before interest, taxes, depreciation, and amortization
(EBITDA) margins, discount rates, terminal growth rates and earnings multiples. In connection with the annual
goodwill impairment assessment, management recorded a $425 million goodwill impairment related to the Front
Line Care reporting unit.
The principal considerations for our determination that performing procedures relating to the goodwill impairment
assessment of the Front Line Care reporting unit is a critical audit matter are (i) the significant judgment by
management when developing the fair value estimate of the reporting unit; (ii) a high degree of auditor judgment,
subjectivity, and effort in performing procedures and evaluating management’s significant assumptions related to the
revenue growth rate, forecasted EBITDA margin, discount rate, and terminal growth rate used in the discounted
cash flow model and earnings multiples used in the earnings multiples approach; and (iii) the audit effort involved
the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our
overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of
controls relating to management’s goodwill impairment assessments, including controls over the valuation of the
Front Line Care reporting unit. These procedures also included, among others, (i) testing management’s process for
developing the fair value estimate of the Front Line Care reporting unit; (ii) evaluating the appropriateness of the
discounted cash flow model and the earnings multiples approach used by management; (iii) testing the
completeness and accuracy of underlying data used in the discounted cash flow model and the earnings multiples
approach; (iv) and evaluating the reasonableness of the significant assumptions used by management related to the
revenue growth rate, forecasted EBITDA margin, discount rate, terminal growth rate and earnings multiples.
Evaluating management’s significant assumptions related to the revenue growth rate and forecasted EBITDA
margin involved evaluating whether the assumptions used by management were reasonable considering (i) the
current and past performance of the Front Line Care reporting unit; (ii) the consistency with external market and
industry data; and (iii) whether the assumption was consistent with evidence obtained in other areas of the audit.
Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the
129
discounted cash flow model and the earnings multiples approach and (ii) the reasonableness of the discount rate,
terminal growth rate and earnings multiples assumptions.
/s/ PricewaterhouseCoopers LLP
Chicago, Illinois
February 21, 2025
We have served as the Company’s auditor since 1985.
130
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial
Disclosure.
None.
Item 9A.
Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We have established disclosure controls and procedures that are designed to ensure that information required to be
disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 (the Exchange Act) is
recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC,
and that such information is communicated to our management, including our Interim Chief Executive Officer and
Chief Financial Officer, to allow timely decisions regarding required disclosure. Our management, with the
participation of our Interim Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of
December 31, 2024. Based on that evaluation, our Interim Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures were effective as of December 31, 2024.
Management’s Assessment of Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting,
as defined in Rule 13a-15(f) of the Exchange Act. Our internal control over financial reporting is designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with accounting principles generally accepted in the United States of America
(U.S. GAAP).
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may
become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures
may deteriorate.
Management performed an assessment of the effectiveness of our internal control over financial reporting as of
December 31, 2024. In making this assessment, management used the framework in Internal Control-Integrated
Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on
that assessment under the framework in Internal Control-Integrated Framework (2013), management concluded
that our internal control over financial reporting was effective as of December 31, 2024.
The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by
PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which
appears herein.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting (as such term is defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2024 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 9B.
Other Information.
Certain of our officers and directors have made elections to participate in, and are participating in, our employee
stock purchase plan or have made, and may from time to time make, elections to have shares withheld to cover
withholding taxes or pay the exercise price of options, which may constitute non-Rule 10b5-1 trading arrangements
(as defined in Item 408(c) of Regulation S-K).
Item 9C.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not Applicable.
131
PART III
Item 10.
Directors, Executive Officers and Corporate Governance.
Refer to information under the captions entitled “Corporate Governance at Baxter International Inc. — Proposal
1 — Election of Directors,” “— Board of Directors — Nomination of Directors,” “— Committees of the Board — Audit
Committee,” “— Board Responsibilities — Code of Conduct,” “Ownership of Baxter Stock — Delinquent Section
16(a) Reports” and "Compensation Discussion and Analysis — Additional Compensation Governance —
Prohibitions on Trading; No-Hedging" in Baxter’s definitive proxy statement to be filed with the Securities and
Exchange Commission and delivered to stockholders in connection with the Annual Meeting of Stockholders
expected to be held on May 6, 2025 (the Proxy Statement), all of which information is incorporated herein by
reference. Also refer to information regarding executive officers of Baxter under the caption entitled “Information
about our Executive Officers” in Part I of this Annual Report on Form 10-K.
Item 11.
Executive Compensation.
Refer to information under the captions entitled “Executive Compensation,” "—Compensation and Human Capital
Committee Report," “Corporate Governance at Baxter International Inc.—Director Compensation,” and “—
Committees of the Board — CHC Committee Interlocks and Insider Participation” in the Proxy Statement, all of
which information is incorporated herein by reference.
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters.
The following table provides information relating to shares of common stock that may be issued under our existing
equity compensation plans as of December 31, 2024.
Plan Category
Number of Shares
to be Issued upon
Exercise of
Outstanding
Options,
Warrants and
Rights(a)
Weighted-Average
Exercise Price of
Outstanding
Options, Warrants
and Rights(b)
Number of Shares
Remaining
Available for
Future Issuance
Under Equity
Compensation Plans
(Excluding
Shares Reflected in
Column(a)(b))
Equity Compensation Plans Approved by
Stockholders
25,169,949
(1) $
60.15
(2)
55,869,497
(3)
Equity Compensation Plans Not Approved by
Stockholders
—
$
—
—
Total
25,169,949
(4) $
60.15
(2)
55,869,497
(1)
Excludes purchase rights under the Employee Stock Purchase Plan. Under the Employee Stock Purchase
Plan, eligible employees may purchase shares of common stock through payroll deductions of up to 15
percent of base pay at a purchase price equal to 85 percent of the closing market price on the purchase
date (as defined by the Employee Stock Purchase Plan). A participating employee may not purchase more
than $25,000 in fair market value of common stock under the Employee Stock Purchase Plan in any
calendar year and may withdraw from the Employee Stock Purchase Plan at any time.
(2)
Restricted stock units (RSUs) and performance share units (PSUs) are excluded when determining the
weighted-average exercise price of outstanding options.
(3)
Includes (i) 7,676,283 shares of common stock available for purchase under the Employee Stock Purchase
Plan and (ii) 48,191,214 shares of common stock available under the 2021 Incentive Plan.
(4)
Includes outstanding awards of 17,381,375 stock options, which have a weighted-average exercise price of
60.15 and a weighted-average remaining term of 3.83 years, 6,940,259 shares of common stock issuable
upon vesting of RSUs, and 602,107 shares of common stock reserved for issuance in connection with PSU
grants.
Refer to information under the captions entitled “Ownership of Baxter Stock — Security Ownership by Directors and
Executive Officers” and “— Security Ownership by Certain Beneficial Owners” in the Proxy Statement, all of which
information is incorporated herein by reference.
132
Item 13.
Certain Relationships and Related Transactions, and Director Independence.
Refer to the information under the caption entitled “Corporate Governance at Baxter International Inc.—Board of
Directors—Director Independence,” “— Proposal 1 — Election of Directors,” “— Committees of the Board,” and “—
Board Responsibilities—Certain Relationships and Related Person Transactions” in the Proxy Statement, all of
which information is incorporated herein by reference.
Item 14.
Principal Accountant Fees and Services.
Refer to the information under the caption entitled “Audit Matters—Audit and Non-Audit Fees” and “—Pre-Approval
of Audit and Permissible Non-Audit Fees” in the Proxy Statement, all of which information is incorporated herein by
reference.
PART IV
Item 15.
Exhibits and Financial Statement Schedules
The following documents are filed as a part of this report:
Page
Number
(1)
Financial Statements:
Consolidated Balance Sheets
48
Consolidated Statements of Income (Loss)
49
Consolidated Statements of Comprehensive Income (Loss)
50
Consolidated Statements of Changes in Equity
51
Consolidated Statements of Cash Flows
52
Notes to Consolidated Financial Statements
54
Report of Independent Registered Public Accounting Firm (PCAOB ID 238)
105
(2)
Schedules required by Article 12 of Regulation S-X:
All schedules have been omitted because they are not applicable or not required.
(3)
Exhibits required by Item 601 of Regulation S-K are listed in the Exhibit Index, which is
incorporated herein by reference. Exhibits in the Exhibit Index marked with a “C” in the left
margin constitute management contracts or compensatory plans or arrangements
contemplated by Item 15(b) of Form 10-K.
Item 16.
Form 10-K Summary.
Not applicable.
133
EXHIBIT INDEX
2.1
Agreement and Plan of Merger, dated September 1, 2021, among Hill-Rom Holdings, Inc., the
Company and Bel Air Subsidiary, Inc. (incorporated by reference to Exhibit 2.1 to Baxter International
Inc.’s Current Report on Form 8-K, filed on September 2, 2021).
2.2
Equity Purchase Agreement, dated May 8, 2023, by and among Baxter International Inc., Baxter
Healthcare Corporation, Baxter Deutschland Holding GmbH, Gambro Dialysatoren GmbH, Bamboo
US BidCo LLC and Blitz 23-317 GmbH (incorporated by reference to Exhibit 2.1 to Baxter
International Inc.'s Current Report on Form 8-K, filed on May 9, 2023).
2.3
Equity Purchase Agreement, dated August 12, 2024, by and among Baxter International Inc., Spruce
Bidco I, Inc., Spruce Bidco II, Inc., Spruce Bidco I Limited and CP Spruce Holdings, S.C.Sp.
(incorporated by reference to Exhibit 2.1 to Baxter International Inc.'s Current Report on Form 8-K,
filed on August 13, 2024).
3.1*
Amended and Restated Certificate of Incorporation of Baxter International Inc., dated May 7, 2024
3.2*
Amended and Restated Bylaws of Baxter International Inc., dated November 26, 2024.
4.1(P)
Form of Common Stock Certificate of the Company (incorporated by reference to Exhibit(a) to the
Company’s Registration Statement on Form S-16 (Registration No. 02-65269), filed on August 17,
1979).
4.2*
Description of Securities Registered Under Section 12 of the Exchange Act.
4.3
Indenture, dated August 8, 2006, between the Company and J.P. Morgan Trust Company, National
Association, as Trustee (incorporated by reference to Exhibit 4.1 to Baxter International Inc.’s Current
Report on Form 8-K, filed on August 9, 2006).
4.4
Second Supplemental Indenture, dated December 7, 2007, between the Company and The Bank of
New York Trust Company, N.A. (as successor in interest to J.P. Morgan Trust Company, National
Association), as Trustee (including form of 6.250% Senior Note due 2037) (incorporated by reference
to Exhibit 4.1 to Baxter International Inc.’s Current Report on Form 8-K, filed on December 7, 2007).
4.5
Eighth Supplemental Indenture, dated August 13, 2012, between the Company and The Bank of
New York Mellon Trust Company, N.A. (as successor in interest to J.P. Morgan Trust Company,
National Association), as Trustee (including form of 3.650% Senior Notes due 2042) (incorporated by
reference to Exhibit 4.1 to Baxter International Inc.’s Current Report on Form 8-K, filed on August 13,
2012).
4.6
Ninth Supplemental Indenture, dated June 11, 2013, between the Company and The Bank of New
York Mellon Trust Company, N.A. (as successor in interest to J.P. Morgan Trust Company, National
Association), as Trustee (including form of 4.500% Senior Notes due 2043) (incorporated by
reference to Exhibit 4.1 to Baxter International Inc.’s Current Report on Form 8-K, filed on June 11,
2013).
4.7
Tenth Supplemental Indenture, dated August 13, 2016, between the Company and The Bank of New
York Mellon Trust Company, N.A., as Trustee (including forms of 2.600% Senior Notes due 2026 and
3.500% Senior Notes due 2046) (incorporated by reference to Exhibit 4.2 to Baxter International
Inc.’s Current Report on Form 8-K, filed on August 15, 2016).
4.8
Eleventh Supplemental Indenture, dated as of May 30, 2017, by and between the Company and The
Bank of New York Mellon Trust Company, N.A., as Trustee (including form of 1.300% Senior Notes
due 2025) (incorporated by reference to Exhibit 4.2 to Baxter International Inc.’s Current Report on
Form 8-K, filed on May 30, 2017).
4.9
Twelfth Supplemental Indenture, dated as of May 15, 2019, by and between the Company and The
Bank of New York Mellon Trust Company, N.A., as Trustee (including form of 1.300% Senior Notes
due 2029) (incorporated by reference to Exhibit 4.2 of Baxter International Inc.’s Current Report on
Form 8-K, filed on May 15, 2019).
4.10
Indenture, dated as of March 26, 2020, between the Company and The Bank of New York Mellon
Trust Company, N.A., as Trustee (incorporated by reference to Exhibit 4.1 to Baxter International
Inc.’s Current Report on Form 8-K, filed on March 27, 2020).
4.11
First Supplemental Indenture, dated as of March 26, 2020, to the Indenture, dated as of March 26,
2020, between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee
(including form of form of 3.950% Senior Notes due 2030) (incorporated by reference to Exhibit 4.2
to Baxter International Inc.’s Current Report on Form 8-K, filed on March 27, 2020).
Number and Description of Exhibit
134
4.12
Second Supplemental Indenture, dated as of November 2, 2020, to the Indenture, dated as of March
26, 2020, between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee
(including form of 1.730% Senior Notes due 2031) (incorporated by reference to Exhibit 4.1 to Baxter
International Inc.’s Current Report on Form 8-K, filed on November 6, 2020).
4.13
Indenture, dated as of July 29, 2021, between the Company, as Issuer, and U.S. Bank National
Association, as Trustee (incorporated by reference to Exhibit 4.1 to Baxter International Inc.’s
Registration Statement on Form S-3, filed on July 29, 2021).
4.14
Indenture, dated as of December 1, 2021, between the Company, as Issuer, and U.S. Bank National
Association, as Trustee (incorporated by reference to Exhibit 4.1 to Baxter International Inc.’s Current
Report on Form 8-K, filed on December 2, 2021).
4.15
First Supplemental Indenture, dated as of December 1, 2021, to the Indenture, dated as of
December 1, 2021, between the Company and U.S. Bank National Association, as Trustee (including
forms of 1.915% Senior Notes due 2027, 2.272% Senior Notes due 2028, 2.539% Senior Notes due
2032 and 3.132% Senior Notes due 2051) (incorporated by reference to Exhibit 4.2 to Baxter
International Inc.’s Current Report on Form 8-K, filed on December 2, 2021).
10.1
Credit Agreement, dated as of December 20, 2019, among Baxter Healthcare SA and Baxter World
Trade SPRL, as Borrowers, J.P. Morgan Europe Limited, as Administrative Agent and certain other
financial institutions named therein (incorporated by reference to Exhibit 10.2 to Baxter International
Inc.’s Current Report on Form 8-K, filed on December 20, 2019).
10.2
First Amendment, dated as of October 1, 2021, to the Credit Agreement, dated as of December 20,
2019, among Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers, the Company, the
several banks party thereto, J.P. Morgan AG, as Administrative Agent and each other party thereto
(incorporated by reference to Exhibit 10.3 to Baxter International Inc.’s Current Report on Form 8-K,
filed on October 4, 2021).
10.3
Second Amendment, dated as of September 28, 2022, to the Credit Agreement, dated as of
December 20, 2019, as amended by the First Amendment, dated as of October 1, 2021, among
Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers, JPMorgan SE, as Administrative
Agent and certain other financial institutions named therein (incorporated by reference to Exhibit 10.5
to Baxter International Inc.'s Current Report on Form 8-K, filed on September 30, 2022).
10.4
Credit Agreement, dated as of September 30, 2021, among the Company, as Borrower, the financial
institutions named therein, as Banks, JPMorgan Chase Bank, N.A., as Administrative Agent, and
Citibank, N.A., as Syndication Agent (incorporated by reference to Exhibit 10.1 to Baxter International
Inc.’s Current Report on Form 8-K, filed on October 4, 2021).
10.5
First Amendment, dated as of September 28, 2022, to the Credit Agreement, dated as of September
30, 2021, among Baxter International Inc., as Borrower, JPMorgan Chase Bank, National
Association, as Administrative Agent and certain other financial institutions named therein
(incorporated by reference to Exhibit 10.1 to Baxter International Inc.'s Current Report on Form 8-K,
filed on September 30, 2022).
10.6
Second Amendment, dated as of September 28, 2022, to the Credit Agreement, dated as of
September 30, 2021, as amended by the First Amendment, dated as of September 28, 2022, amount
Baxter International Inc., as Borrower, JPMorgan Chase Bank, National Association, as
Administrative Agent and certain other financial institutions named therein (incorporated by reference
to Exhibit 10.2 to Baxter International Inc.'s Current Report on Form 8-K, filed on September 30,
2022).
10.7
Third Amendment, dated as of March 13, 2023, to the Credit Agreement, dated as of September 30,
2021, as amended by that certain First Amendment, dated as of September 28, 2022, and that
certain Second Amendment, dated as of September 28, 2022, among Baxter International Inc. as
Borrower, JPMorgan Chase Bank, National Association, as Administrative Agent and certain other
financial institutions named therein (incorporated by reference to Exhibit 10.1 to Baxter International
Inc.'s Current Report on Form 8-K, filed on March 13, 2023).
10.8
Fourth Amendment, dated as of March 21, 2024, to the Credit Agreement, dated as of September 30,
2021, as amended by that certain First Amendment, dated as of September 28, 2022, and that
certain Second Amendment, dated as of September 28, 2022, and that certain Third Amendment,
dated as of March 13, 2023, among Baxter International Inc. as Borrower, JPMorgan Chase Bank,
National Association, as Administrative Agent and certain other financial institutions named therein
(incorporated by reference to Exhibit 10.1 to Baxter International Inc.'s Current Report on Form 8-K,
filed on March 21, 2024).
Number and Description of Exhibit
135
10.9
Credit Agreement, dated as of July 17, 2024, among Baxter International Inc., as Borrower,
JPMorgan Chase Bank, National Association, as Administrative Agent, and certain other financial
institutions named therein (incorporated by reference to Exhibit 10.1 to Baxter International Inc.’s
Current Report on Form 8-K, filed on July 18, 2024).
10.10
Five-Year Credit Agreement, dated as of September 30, 2021, among the Company, as Borrower,
the financial institutions named therein, as Banks, JPMorgan Chase Bank, N.A., as Administrative
Agent, and Bank of America, N.A. and Citibank, N.A., as Syndication Agents (incorporated by
reference to Exhibit 10.2 to Baxter International Inc.’s Current Report on Form 8-K, filed on October
4, 2021).
10.11
First Amendment, dated as of September 28, 2022, to the Five-Year Credit Agreement, dated as of
September 30, 2021, among Baxter International Inc., as Borrower, JPMorgan Chase Bank, National
Association, as Administrative Agent and certain other financial institutions named therein
(incorporated by reference to Exhibit 10.3 to Baxter International Inc.'s Current Report on Form 8-K,
filed on September 30, 2022).
10.12
Second Amendment, dated as of September 28, 2022, to the Five-Year Credit Agreement, dated as
of September 30, 2021, among Baxter International Inc., as Borrower, JPMorgan Chase Bank,
National Association, as Administrative Agent and certain other financial institutions named therein
(incorporated by reference to Exhibit 10.4 to Baxter International Inc.'s Current Report on Form 8-K,
filed on September 30, 2022).
10.13
Third Amendment, dated as of March 13, 2023, to the Five-Year Credit Agreement, dated as of
September 30, 2021, as amended by that certain First Amendment, dated as of September 28, 2022,
and that certain Second Amendment, dated as of September 28, 2022, among Baxter International
Inc. as Borrower, JPMorgan Chase Bank, National Association, as Administrative Agent and certain
other financial institutions named therein (incorporated by reference to Exhibit 10.2 to Baxter
International Inc.’s Current Report on Form 8-K, filed on March 13, 2023).
10.14
Fourth Amendment, dated as of March 21, 2024, to the Five-Year Credit Agreement, dated as of
September 30, 2021, as amended by that certain First Amendment, dated as of September 28, 2022,
that certain Second Amendment, dated as of September 28, 2022, and that certain Third
Amendment, dated as of March 13, 2023, among Baxter International Inc. as Borrower, JPMorgan
Chase Bank, National Association, as Administrative Agent and certain other financial institutions
named therein (incorporated by reference to Exhibit 10.2 to Baxter International Inc.’s Current Report
on Form 8-K, filed on March 21, 2024).
10.15
Second Guaranty Amendment, dated as of March 13, 2023, to the Amended and Restated Guaranty,
dated as of October 1, 2021, as amended by that certain Second Amendment, dated as of
September 28, 2022, among Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers, J.P.
Morgan SE, as Administrative Agent and certain other financial institutions named therein
(incorporated by reference to Exhibit 10.3 to Baxter International Inc.'s Current Report on Form 8-K,
filed on March 13, 2023)
10.16
Third Guaranty Amendment, dated as of March 21, 2024, to the Amended and Restated Guaranty,
dated as of October 1, 2021, as amended by that certain Second Amendment, dated as of
September 28, 2022, and that certain Second Guaranty Amendment, dated as of March 13, 2023,
among Baxter Healthcare SA and Baxter World Trade SRL, as Borrowers, J.P. Morgan SE, as
Administrative Agent and certain other financial institutions named therein (incorporated by reference
to Exhibit 10.3 to Baxter International Inc.'s Current Report on Form 8-K, filed on March 21, 2024)
10.17
Tax Matters Agreement, dated as of June 30, 2015, by and between Baxter International Inc. and
Baxalta Incorporated (incorporated by reference to Exhibit 10.2 to Baxter International Inc.’s Current
Report on Form 8-K, filed on July 7, 2015).
C 10.18
Form of Indemnification Agreement entered into with directors and officers (incorporated by reference
to Exhibit 10.8 to Baxter International Inc.'s Annual Report on Form 10-K, filed on February 21,
2019).
C 10.19
Baxter International Inc. 2007 Incentive Plan (incorporated by reference to Appendix A to the
Company’s Definitive Proxy Statement on Schedule 14A, filed on March 20, 2007).
C 10.20
Baxter International Inc. Equity Plan for the 2007 Incentive Plan (incorporated by reference to Exhibit
10.1 to the Company’s Current Report on Form 8-K, filed on March 16, 2007).
C 10.21
Baxter International Inc. 2011 Incentive Plan (incorporated by reference to Appendix B to Baxter
International Inc.’s Definitive Proxy Statement on Schedule 14A, filed on March 18, 2011).
C 10.22
Baxter International Inc. Equity Plan for the 2011 Incentive Plan (incorporated by reference to Exhibit
10.1 to Baxter International Inc.’s Quarterly Report on Form 10-Q, filed on May 3, 2011).
Number and Description of Exhibit
136
C 10.23
Baxter International Inc. 2015 Incentive Plan (incorporated by reference to Appendix A to Baxter
International Inc.’s Definitive Proxy Statement on Schedule 14A, filed on March 25, 2015).
C 10.24
Baxter International Inc. Equity Plan for the 2015 Incentive Plan (incorporated by reference to Exhibit
10.6 to Baxter International Inc.’s Current Report on Form 8-K, filed on July 7, 2015).
C 10.25
Baxter International Inc. Equity Plan for José E. Almeida under the 2015 Incentive Plan (incorporated
by reference to Exhibit 10.2 to Baxter International Inc.’s Current Report on Form 8-K, filed on
October 29, 2015).
C 10.26
Baxter International Inc. 2017 Equity Plan, effective as of March 2, 2017 (incorporated by reference
to Exhibit 10.2 to Baxter International Inc.’s Current Report on Form 8-K, filed on March 3, 2017).
C 10.27
Baxter International Inc. 2020 Equity Plan, effective as of March 16, 2020 (incorporated by reference
to Exhibit 10.22 to Baxter International Inc.’s Annual Report on Form 10-K, filed on March 17, 2020).
C 10.28
Baxter International Inc. Amended and Restated 2021 Incentive Plan (incorporated by reference to
Appendix A to Baxter International Inc.’s Definitive Proxy Statement on Schedule 14A, filed on March
25, 2024).
C 10.29
Form of Performance Stock Unit Grant Agreement under Baxter International Inc. 2021 Incentive
Plan (incorporated by reference to Exhibit 10.1 to Baxter International Inc.'s Quarterly Report on
Form 10-Q, filed on April 28, 2022).
C 10.30
Form of Restricted Stock Unit Grant Agreement under Baxter International Inc. 2021 Incentive Plan
(incorporated by reference to Exhibit 10.2 to Baxter International Inc.'s Quarterly Report on Form 10-
Q, filed on April 28, 2022).
C 10.31
Form of Stock Option Grant Agreement under Baxter International Inc. 2021 Incentive Plan
(incorporated by reference to Exhibit 10.3 to Baxter International Inc.'s Quarterly Report on Form 10-
Q, filed on April 28, 2022).
C 10.32
Baxter International Inc. Directors' Deferred Compensation Plan (amended and restated effective
January 31, 2024) (incorporated by reference to Baxter International Inc.’s Annual Report on Form
10-K, filed on February 8, 2024.
C 10.33
Amended Offer Letter between the Company and José E. Almeida, dated as of July 25, 2023
(incorporated by reference to Exhibit 10.1 to Baxter International Inc.’s Quarterly Report on Form 10-
Q, filed on July 27, 2023).
C 10.34
Offer Letter, dated September 26, 2023, by and between the Company and Joel Grade (incorporated
by reference to Exhibit 10.1 to Baxter International Inc.’s Current Report on Form 8-K, filed on
October 3, 2023).
C 10.35
Offer Letter, dated April 22, 2023, by and between the Company and Christopher Toth (incorporated
by reference to Baxter International Inc.’s Annual Report on Form 10-K, filed on February 8, 2024.
C 10.36
Letter Agreement, dated February 1, 2025, by and between José E. Almeida and the Company
(incorporated by reference to Baxter International Inc’s Current Report on Form 8-K, filed on
February 3, 2025).
C 10.37
Letter Agreement, dated February 1, 2025, by and between Brent Shafer and the Company
(incorporated by reference to Baxter International Inc’s Current Report on Form 8-K, filed on
February 3, 2025).
C 10.38
Form of Severance Agreement entered into with executive officers (incorporated by reference to
Exhibit 10.11 to Baxter International Inc.’s Annual Report on Form 10-K, filed on February 21, 2014).
C 10.39
Baxter International Inc. Executive Officer Cash Severance Policy, effective February 13, 2023
(incorporated by reference to Exhibit 10.1 to Baxter International Inc.’s Current Report on Form 8-K,
filed on February 14, 2023).
C 10.40
Baxter International Inc. Employee Stock Purchase Plan, as amended and restated effective July 1,
2011 (incorporated by reference to Appendix A to Baxter International Inc.’s Definitive Proxy
Statement on Schedule 14A, filed on March 18, 2011).
Number and Description of Exhibit
137
C 10.41
First Amendment to Baxter International Inc. Employee Stock Purchase Plan, dated as of July 15,
2016 (incorporated by reference to Exhibit 10.27 to Baxter International Inc.’s Annual Report on
Form 10-K, filed on February 23, 2017).
C 10.42
Baxter International Inc. Non-Employee Director Compensation Plan, as amended and restated
effective January 1, 2025 (incorporated by reference to Exhibit 10.2 to Baxter International Inc.'s
Quarterly Report on Form 10-Q, , filed on November 2, 2024).
C 10.43
Form of Non-Competition, Non-Solicitation and Confidentiality Agreement (incorporated by reference
to Exhibit 10.1 to Baxter International Inc.’s Current Report on Form 8-K, filed on April 14, 2017).
C 10.44R
Commitment Agreement, dated as of October 4, 2019, by and among the Company, The Prudential
Insurance Company of America and State Street Global Advisors Trust Company, acting solely in its
capacity as the independent fiduciary of the Baxter International Inc. and Subsidiaries Pension Plan
(incorporated by reference to Exhibit 10.32 to Baxter International Inc.’s Annual Report on Form 10-
K, filed on March 17, 2020).
C 10.45
Baxter International Inc. and Subsidiaries Pension Plan, as amended and restated effective January
5, 2018 (incorporated by reference to Exhibit 10.1 to Baxter International Inc.’s Current Report on
Form 8-K, filed on January 8, 2018).
C 10.46
First Amendment to the Baxter International Inc. and Subsidiaries Pension Plan (incorporated by
reference to Exhibit 10.34 to Baxter International Inc.’s Annual Report on Form 10-K, filed on March
17, 2020).
C 10.47
Second Amendment to the Baxter International Inc. and Subsidiaries Pension Plan (incorporated by
reference to Exhibit 10.35 to Baxter International Inc.’s Annual Report on Form 10-K, filed on March
17, 2020).
C 10.48
Baxter International Inc. and Subsidiaries Pension Plan II, as amended and restated effective
January 1, 2019 (incorporated by reference to Exhibit 10.36 to Baxter International Inc.’s Annual
Report on Form 10-K, filed on March 17, 2020).
C 10.49
Baxter International Inc. and Subsidiaries Supplemental Pension Plan, as amended and restated
effective January 5, 2018 (incorporated by reference to Exhibit 10.3 to Baxter International Inc.’s
Current Report on Form 8-K, filed on January 8, 2018).
C 10.50
Baxter International Inc. and Subsidiaries Deferred Compensation Plan, as amended and restated
effective January 1, 2021 (incorporated by reference to Exhibit 10.31 to Baxter International Inc.'s
Annual Report on Form 10-K, filed on February 11, 2021).
C 10.51
Baxter International Inc. Management Incentive Compensation Program – 2020 Program Document
(incorporated by reference to Exhibit 10.1 to Baxter International Inc.’s Quarterly Report on Form 10-
Q, filed on July 30, 2020).
C 10.52
New Change-in-Control Agreement, dated as of September 24, 2020, between the Company and
José E. Almeida (incorporated by reference to Exhibit 10.1 to Baxter International Inc.’s Current
Report on Form 8-K, filed on September 25, 2020).
C 10.53
Form of Amended Grandfathered Change-in-Control Agreement (incorporated by reference to Exhibit
10.2 to Baxter International Inc.’s Current Report on Form 8-K, filed on September 25, 2020).
C 10.54
Change in Control Agreement between the Company and Christopher Toth, dated as of June 15,
2023 (incorporated by reference to Exhibit 10.2 to Baxter International Inc.’s Quarterly Report on
Form 10-Q filed on July 27, 2023).
C 10.55
Form of Change-in-Control Agreement (incorporated by reference to Exhibit 10.4 to Baxter
International Inc.’s Quarterly Report on Form 10-Q, filed on October 29, 2020).
C 10.56
Baxter International Inc. Executive Severance Plan, as amended and restated effective July 15,
2024) (incorporated by reference to Exhibit 10.3 to Baxter International Inc.’s Quarterly Report on
Form 10-Q, filed on November 2, 2024).
19*
Baxter International Inc. Securities Trading Policy
21*
Subsidiaries of Baxter International Inc.
23*
Consent of PricewaterhouseCoopers LLP.
Number and Description of Exhibit
138
31.1*
Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities
Exchange Act of 1934, as amended.
31.2*
Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) and 15d-14(a) of
the Securities Exchange Act of 1934, as amended.
32.1**
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
97.1
Baxter International Inc. Mandatory Clawback Policy (incorporated by reference to Exhibit 97.1 to
Baxter International Inc.’s Annual Report on Form 10-K, filed on February 8, 2024).
101.INS*
XBRL Instance Document
101.SCH*
XBRL Taxonomy Extension Schema Document
101.CAL*
XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*
XBRL Taxonomy Extension Label Linkbase Document
101.PRE*
XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*
XBRL Taxonomy Extension Definition Linkbase Document
Number and Description of Exhibit
______________________________________
*
Filed herewith.
*
Furnished herewith. This exhibit shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, or otherwise subject to the liability of that Section. Such exhibit
shall not be deemed incorporated into any filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934.
R
Includes redactions.
C
Management contract or compensatory plan or arrangement.
(P)
Paper exhibit
139
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BAXTER INTERNATIONAL INC.
By:
/s/ Brent Shafer
Brent Shafer
Chair and Interim Chief Executive Officer
DATE: February 21, 2025
140
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by
the following persons on behalf of the registrant and in the capacities indicated on February 21, 2025.
Signature
Title
/s/ Brent Shafer
Chair and Interim Chief Executive Officer
Brent Shafer
(principal executive officer)
/s/ Joel T. Grade
Executive Vice President, Chief Financial Officer and Interim
Chief Accounting Officer
Joel T. Grade
(principal financial officer and principal accounting officer)
/s/ William A. Ampofo II
Director
William A. Ampofo II
/s/ Jeffrey A. Craig
Director
Jeffery A. Craig
/s/ Patricia B. Morrison
Director
Patricia B. Morrison
/s/ Stephen N. Oesterle, M.D.
Director
Stephen N. Oesterle, M.D.
/s/ Stephen H. Rusckowski
Director
Stephen H. Rusckowski
/s/ Nancy M. Schlichting
Director
Nancy M. Schlichting
/s/ Cathy R. Smith
Director
Cathy R. Smith
/s/ Amy A. Wendell
Director
Amy A. Wendell
/s/ David S. Wilkes, M.D.
Director
David S. Wilkes, M.D.
141
[THIS PAGE INTENTIONALLY LEFT BLANK]